CA2241531A1 - Use of inhibitors of the cellular na+/h+ exchanger (nhe) for the preparation of a drug for respiratory stimulation - Google Patents

Use of inhibitors of the cellular na+/h+ exchanger (nhe) for the preparation of a drug for respiratory stimulation Download PDF

Info

Publication number
CA2241531A1
CA2241531A1 CA002241531A CA2241531A CA2241531A1 CA 2241531 A1 CA2241531 A1 CA 2241531A1 CA 002241531 A CA002241531 A CA 002241531A CA 2241531 A CA2241531 A CA 2241531A CA 2241531 A1 CA2241531 A1 CA 2241531A1
Authority
CA
Canada
Prior art keywords
alkyl
substituted
hydrogen
group
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002241531A
Other languages
French (fr)
Inventor
Klaus Writh
Wolfgang Scholz
Hans-Willi Jansen
Hans Jochen Lang
Joachim Brendel
Heinz-Werner Kleemann
Jan-Robert Schwark
Andreas Weichert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2241531A1 publication Critical patent/CA2241531A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B60VEHICLES IN GENERAL
    • B60LPROPULSION OF ELECTRICALLY-PROPELLED VEHICLES; SUPPLYING ELECTRIC POWER FOR AUXILIARY EQUIPMENT OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRODYNAMIC BRAKE SYSTEMS FOR VEHICLES IN GENERAL; MAGNETIC SUSPENSION OR LEVITATION FOR VEHICLES; MONITORING OPERATING VARIABLES OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRIC SAFETY DEVICES FOR ELECTRICALLY-PROPELLED VEHICLES
    • B60L50/00Electric propulsion with power supplied within the vehicle
    • B60L50/50Electric propulsion with power supplied within the vehicle using propulsion power supplied by batteries or fuel cells
    • B60L50/60Electric propulsion with power supplied within the vehicle using propulsion power supplied by batteries or fuel cells using power supplied by batteries
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B60VEHICLES IN GENERAL
    • B60LPROPULSION OF ELECTRICALLY-PROPELLED VEHICLES; SUPPLYING ELECTRIC POWER FOR AUXILIARY EQUIPMENT OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRODYNAMIC BRAKE SYSTEMS FOR VEHICLES IN GENERAL; MAGNETIC SUSPENSION OR LEVITATION FOR VEHICLES; MONITORING OPERATING VARIABLES OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRIC SAFETY DEVICES FOR ELECTRICALLY-PROPELLED VEHICLES
    • B60L7/00Electrodynamic brake systems for vehicles in general
    • B60L7/10Dynamic electric regenerative braking
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B60VEHICLES IN GENERAL
    • B60LPROPULSION OF ELECTRICALLY-PROPELLED VEHICLES; SUPPLYING ELECTRIC POWER FOR AUXILIARY EQUIPMENT OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRODYNAMIC BRAKE SYSTEMS FOR VEHICLES IN GENERAL; MAGNETIC SUSPENSION OR LEVITATION FOR VEHICLES; MONITORING OPERATING VARIABLES OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRIC SAFETY DEVICES FOR ELECTRICALLY-PROPELLED VEHICLES
    • B60L7/00Electrodynamic brake systems for vehicles in general
    • B60L7/10Dynamic electric regenerative braking
    • B60L7/16Dynamic electric regenerative braking for vehicles comprising converters between the power source and the motor
    • EFIXED CONSTRUCTIONS
    • E01CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01CCONSTRUCTION OF, OR SURFACES FOR, ROADS, SPORTS GROUNDS, OR THE LIKE; MACHINES OR AUXILIARY TOOLS FOR CONSTRUCTION OR REPAIR
    • E01C19/00Machines, tools or auxiliary devices for preparing or distributing paving materials, for working the placed materials, or for forming, consolidating, or finishing the paving
    • E01C19/22Machines, tools or auxiliary devices for preparing or distributing paving materials, for working the placed materials, or for forming, consolidating, or finishing the paving for consolidating or finishing laid-down unset materials
    • E01C19/23Rollers therefor; Such rollers usable also for compacting soil
    • E01C19/26Rollers therefor; Such rollers usable also for compacting soil self-propelled or fitted to road vehicles
    • EFIXED CONSTRUCTIONS
    • E01CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01CCONSTRUCTION OF, OR SURFACES FOR, ROADS, SPORTS GROUNDS, OR THE LIKE; MACHINES OR AUXILIARY TOOLS FOR CONSTRUCTION OR REPAIR
    • E01C19/00Machines, tools or auxiliary devices for preparing or distributing paving materials, for working the placed materials, or for forming, consolidating, or finishing the paving
    • E01C19/22Machines, tools or auxiliary devices for preparing or distributing paving materials, for working the placed materials, or for forming, consolidating, or finishing the paving for consolidating or finishing laid-down unset materials
    • E01C19/23Rollers therefor; Such rollers usable also for compacting soil
    • E01C19/28Vibrated rollers or rollers subjected to impacts, e.g. hammering blows

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Transportation (AREA)
  • Power Engineering (AREA)
  • Civil Engineering (AREA)
  • Architecture (AREA)
  • Structural Engineering (AREA)
  • Sustainable Energy (AREA)
  • Sustainable Development (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The active ingredients identified as NHE inhibitors are particularly suitable for the preparation of a drug for respiratory stimulation. They are particularly good for treating sleep apnea or other respiratory disorders.

Description

CA 02241S31 1998-06-2~

Description 5 Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for respiratory stimulation The invention relates to the use of NHE inhibitors for the production of a medicament for respiratory stimulation.
The active compounds which are known and identified as NHE inhibitors are guanidine derivatives, preferably acylguanidines, inter alia such as described in the following publications and patent disclosures: Edward J.
Cragoe, Jr., "DIURETICS, Chemistry, Pharmacology and Medicine", J. WILEY & Sons (1983), 303 - 341, additionally compounds of the following formulae:
I. (HOE 89/F 288 - US 5 292 755) a) benzoylguanidines of the formula I
R(1)~ R(5) R~2~N~N~ R
HN~ R~3) in which:
R(1) or R(2) is R(6)-S(O)n- or R(7)R(8)N-O2S-;
and the other substituent R(1) or R(2) in each case is H, F, Cl, Br, (C1-C4)-alkyl, (C1-C4)-alkoxy or phenoxy, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of fluorine, chorine, methyl and methoxy;
or the other substituent R(1) or R(2) in each case is R(6)-S(O)n or R(7)R(8)N-;
n is zero,1 or 2;
R(6) is (C1-C6)-alkyl, (C5-C7)-cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl, CA 02241531 1998-06-2~

which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy;
R(7) and R(8) identically or differently are H or (C1-C6)-alkyl;
or R(7) is phenYI~(cH2)m;
m is 1-4;
or R(7) is phenyl, which is unsubstituted or substituted by 1 - 2 substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy;
or R(7) and R(8) together are a straight-chain or branched (C4-C7)-chain, where the chain can additionally be interrupted by O, S or NR(9);
R(9) is H or methyl;
or R(7) and R(8) together with the nitrogen atom to which they are bonded, are a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system;
R(3), R(4) and R(5) independently of one another are H or (C1-C2)-alkyl, or R(3) and R(4) together are a (C2-C4)-alkylene chain;
or R(4) and R(5) together are a (C4-C7)-alkylene chain;
and their pharmaceutically tolerable salts;
(HOE 92/F 34 - US 5 373 924) CA 02241~31 1998-06-2~

b) benzoylguanidines of the formula I
R ( 2 )~, R ( 3 ,,,J~,1~N~, N H 2 ( I ) ~ NH2 in which:
R(1 ) is R(4)-SOm or R(5)R(6)N-SO2-;
m iszero, 1 or2;
R(4) and R(5) are C1-C8-alkyl, C3-C6-alkenyl or-CnH2n-R(7);
n is zero, 1, 2, 3 or 4;
R(7) is C5-C7-cycloalkyl or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(8)R(9);
R(8) and R(9) are H or C1-C4-alkyl;
or R(5) is H;
R(6) is H or C1-C4-alkyl, or R(5) and R(6) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by an O, S, NH, N-CH3 or N-benzyl;
R(2) is hydrogen, F, Cl, Br, (C1-C4)-alkYI-, O~(CH2)mCpF2P+1 or-X R(10);
m is zero or 1;
p is1,2Or3;
X is O, S or NR(11 );
R(10) is H, C1-C6-alkyl, C5-C7-cycloalkyl, cyclohexylmethyl, cyclopentylmethyl or-CnH2n-R(12);
n is zero, 1, 2, 3 or 4;
R(12) is phenyl, which is unsubstituted or substituted by 1 - 3 CA 02241~31 1998-06-2~

substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy und NR(8)R(9);
R(8) and R(9) are H or C1-C4-alkyl;
R(11) ishydrogenorC1-C3-alkyl;
or R(10) and R(11) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by O, S, NH, N-CH3 or N-benzyl;
R(3) is defined as R(1), or is C1-C6-alkyl, nitro, cyano, trifluoromethyl, F, Cl, Br, l or-X-R(10);
X is O, S or NR(11);
R(10) is H, C1-C6-alkyl, C5-C7-cycloalkyl, cyclohexylmethyl, cyclopentylmethyl or -CnH2n-R(12);
n iszeroto4;
R(12) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy und NR(8)R(9);
R(8) and R(9) are H or C1-C4-alkyl;
R(11) is C1-C3-alkyl, or R(10) and R(11) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by O, S, NH, N-CH3 or N-benzyl;
and their pharmaceutically tolerable salts;
(HOE 92/F 035 EP- Offenlegungsschrift 556 673) CA 02241~31 1998-06-2~

c) ortho-substituted benzoylguanidines of the formula I
R ( 2 ) R(~ ~ R( 1 ) R ( ~,~N~,N H2 o NH2 R ( S ) in which:
R(1 ) is F, Cl, Br, I, C1-C6-alkyl or -X-R(6);
X is O, S, NR(7) or Y-ZO;
Y is O or NR(7);
Z is C or SO;
R(6) is H, C1-C6-alkyl, C5-C7-cycloalkyl, cyclohexylmethyl, cyclopentylmethyl~-(cH2)mcpF2p+1 0r~CnH2n~R(8);
m iszeroor 1;
p is 1 - 3;
n iszeroto4;
R(8) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of the groups F, Cl, CF3, methyl, methoxy and NR(9)R(1 0);
R(9) and R(10) are H or C1-C4-alkyl;
R(7) is H orC1-C3-alkyl;
or R(6) and R(7) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by O, S, NH, N-CH3 or N-benzyl;
R(3) is H or -X-R(6);
X is O, S, NR(7) or Y-ZO;
R(7) is H or C1-C3-alkyl;
Y is O or NR(7);
where Y is bonded to the phenyl radical of the CA 02241~31 1998-06-2~

formula 1, Z is C or SO;
R(6) is H, C1-C6-alkyl, C5-C7-cycloalkyl, cyclohexylmethyl, cyclopentylmethyl~-(CH2)mCpF2p+1 0r~CnH2n~R(8);
m is zero or 1;
p is 1-3;
n iszeroto4;
R(8) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H or C1-C4-alkyl;
or R(6) and R(7) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by O, S, NH, N-CH3 or N-benzyl;
R(2) and R(4) identically or differently are R(11 )~SOq~ or R(1 2)R(1 3)N-SO2-;
q is zero - 2;
R(11) isC1-C4-alkyl, which is unsubstituted or carries phenyl as a substituent, where phenyl is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H or C1-C4-alkyl;
R(12) and R(13) are defined as R(6) and R(7);
or one of the two radicals R(2) or R(4) is hydrogen or is defined as R(1 );
R(5) is H, methyl, F, Cl or methoxy, and their pharmaceutically tolerable salts.
(HOE 92/F 036 - US 5 364 868) CA 02241~31 1998-06-2~

d) benzoylguanidines of the formula I
R ( 1 ) ~,~

R ( 2 )/~V~N~'NH2 ( I ) ~ NH2 in which:
R(1 ) or R(2) is an amino group -NR(3)R(4);
R(3) and R(4) identically or differently are H, C1-C6-alkyl or C3-C7-cycloalkyl;
or R(3) is phenyl-(CH2)p-;
p isO, 1, 2, 30r4;
or R(3) is phenyl, where the phenyl in each case is unsubstituted or carries one to two substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy;
or R(3) and R(4) together can be a straight-chain or branched C4-C7-methylene chain, where one -CH2- member of the methylene chain can be replaced by oxygen, S or NR(5);
R(5) is H or lower alkyl;
the other substituent R(1 ) or R(2) in each case is H F, Cl, C~-C4-alkyl, C~-C4-alkoxy~ CF3, CmF2m+1~CH2~~ benzyl or phenoxy, where the respective phenyl radical is unsubstituted or carries one to two substituents selected from the group consisting of methyl, methoxy, fluorine and chlorine;
m is1,20r3;
and their pharmaceutically tolerable salts;

CA 02241~31 1998-06-2~

(92/F 197 K - NZ 248 013) e) benzoylguanidines of the formula I
R( l ) N H z ~ NH2 in which:
R(1) is R(4)-SOm or R(5)R(6)N-SO2-;
m is zero,1 or 2;
R(4) and R(5) are C1-C8-alkyl, C3-C6-alkenyl or-CnH2n-R(7);
n iszero,1,2,3Or4;
R(7) is C5-C7-cycloalkyl or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(8)R(9);
R(8) and R(9) are H or C1-C4-alkyl;
or R(5) is H;
R(6) is H or C1-C4-alkyl;
or R(5) and R(6) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by an O, S, NH, N-CH3 or N-benzyl;
R(2) is hydrogen, straight-chain or branched (C5-C8)-alkyl, -CR(13)=CHR(12) or -C-CR(12);
R(12) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and N R(14)R(15);

CA 02241~31 1998-06-2S

R(14) and R(15) are H or (C1-C4)-alkyl;
or R(12) is(C1-Cg)-heteroaryl, which is unsubstituted or substituted as phenyl, or R(12) is (C1-C6)-alkyl, which is unsubstituted or substituted by 1 - 3 OH, or R(12) is (C3-C8)-cycloalkyl;
R(13) ishydrogenormethyl, or R(12) is (C3-C8)-cycloalkyl, (C3-C8)-cycloalkyl-(C1-C4)-alkyl, phenyl, C6H5-(C1-C4)-alkyl, naphthyl, biphenylyl,1,1-diphenyl-(C1-C4)-alkyl, cyclopentadienyl, pyridyl, pyrrolyl, furanyl, thienyl, thiazolyl, oxazolyl, indenyl, quinolyl, indolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indazolyl, isoquinolyl, phthalazinyl, quinoxalinyl, quinazolinyl or cinnolinyl;
R(3) is defined as R(2);
and where the aromatic substituents R(2) and R(3) are unsubstituted or substituted by 1 - 3 substituents from the groups F, Cl, CF3, (C1-C4)-alkyl or -alkoxy, or NR(10)R(11) with R(10) and R(11) being H or (C1-C4)-alkyl;
and their pharmaceutically tolerable salts.
(HOE 92/F 303 K - EP- Offenlegungsschrift 589 336, NZ 248 703) f) benzoylguanidines of the formula I

R( 1 )~C''C~C ~NH2 ,C~C,C\ ~N C~
R ( 2 ) C NH2 Il in which: ~

CA 02241~31 1998-06-2~

R(1 ) or R(2) is R(3)-S(O)n- or R ( 4 )\

/N -~2 S -R ( 5 ) the other substituent R(1 ) or R(2) in each case is H, OH, F, Cl, Br, I, C1-C4-alkyl, C1-C4-alkoxy, benzyloxy or phenoxy, which is unsubstituted or carries one to three substituents selected from the group consisting of fluorine, chlorine, methyl, methoxy, hydroxyl or benzyloxy, R(3)-S(O)n, -NR4)R(5) or 3,4-dehydropiperidine R(3) is C1-C6-alkyl, C5-CTcycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl, which is unsubstituted or substituted by one to three substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy;
R(4) and R(5) identically or differently, are H or C1-C6-alkyl;
or R(4) is phenYl-(cH2)m-;
m is 1, 2, 30r4;
or R(4) is phenyl, which is unsubstituted or carries one to two substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy;
or R(4) and R(5) together are a straight-chain or branched C4-C7-chain, where the chain can additionally be interrupted by 0, S or NR(6), R(6) is H or methyl;
or CA 02241~31 1998-06-2~

R(4) and R(5) together with the nitrogen atom to which they are bonded, are a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system;
n is zero, 1 or 2;
and their pharmaceutically tolerable salts.
(92/F 304 - US 5 416 094) g) isoquinolines of the formula I
X ( 1 ) X ( 4 {~ R ( 2 ) X ( 2 ) COG
15 in which:
R(1) is hydrogen, alkyl, cycloalkyl, arylalkyl, alkenyl, substituted aminoalkyl or an aryl or heteroaryl ring;
where the rings are unsubstituted or substituted by 1 - 3 groups selected from the group consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl, trifluoromethyl, R(2) is hydrogen, halogen, alkyl or aryl;
which is unsubstituted or substituted by 1 - 3 groups selected from the group consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl, G is /R ( 3 ) /N R(4) V l I
\N~ ( ) ~ R(6) CA 02241~31 1998-06-2~

X(2), X(3) and X(4) independently of one another are hydrogen, halogen, nitro, amino, alkyl, sulfonamide, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, benzyloxy, hydroxyl;
5 X(1 ) is hydrogen, oxygen, sulfur or NR(7);
R(7) is hydrogen, alkyl, cycloalkyl, arylalkyl, alkenyl, substituted aminoalkyl or an aryl or a heteroaryl ring;
which rings are unsubstituted or substituted by 1 - 3 groups selected from the group consisting of halogen, nitro, amino, mono(loweralkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl and trifluoromethyl;
in which substituents each alkyl chain or alkenyl chain can be interrupted by oxygen, sulfur or NR(8);
R(8) is hydrogen, alkyl, cycloalkyl, arylalkyl, alkenyl, substituted aminoalkyl or an aryl or heteroaryl ring, which rings are unsubstituted or substituted by 1 - 3 groups selected from the group consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl and trifluoromethyl;
and their pharmaceutically acceptable salts;
(92/F 404 - EP 602 522, NZ 250 438) h) compounds of the formula I
R(l ) R(2) \~ (I) ~ Nq/ N H 2 R ( 3 ) in which:

CA 02241~31 1998-06-2~

R(1) is hydrogen, F, Cl, Br, l, -NO2, -C-N, -CF3, R(4)-SOm or R(5)R(6)N-S02-;
m is zero,1 or 2;
R(4) and R(5) are (C1-C8)-alkyl, (C3-C6)-alkenyl, -CnH2n-R(7) or CF3;
n iszero,1, 2, 30r4;
R(7) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(8)R(9);
R(8) and R(9) are H or C1-C4-alkyl;
or R(5) is H;
R(6) is H or (C1-C4)-alkyl;
or R(5) and R(6) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(2) is -SR(10), -OR(10), -N H R(10), -N R(10)R(11), -CH R(10)R(12), -[CR(12)R(13)0R(13')], -{C-[CH2-OR(13')]R(12) (R(13)} or -[CR(18)R(17)]p-(CO)-[CR(19)R(20)]q-R(14);
R(10), R(11) identically or differently are -[CHR(16)]s-(cH2)p-(cHoH)q-(cH2)r-(cHoH)t-R(21) or ~(CH2)p~0~(CH2~CH20)q~R(21 )~
R(21) is hydrogen, methyl, p, q, r identically or differently are zero,1, 2, 3 or 4;
s is zero or 1;
t is 1, 2, 3 or 4;
R(12) and R(13) identically or differently are hydrogen, (C1-C6)-alkyl or, together with the carbon atom carrying them, are a CA 02241531 1998-06-2~

(C3-C8)-cycloalkyl, R(13') is hydrogen or (C1 -C4)-alkyl;
R(14) is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or-CaH2a-R(15);
a iszero,1,2,3Or4;
R(15) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(8)R(9);
R(8) and R(9) are H or (C1-C4)-alkyl;
or R(15) is(C1-Cg)-heteroaryl, which is unsubstituted or substituted as phenyl, or R(15) is (C1-C6)-alkyl, which is unsubstituted or substituted by 1 - 3 OH;
R(16), R(17), R(18), R(19) and R(20) are hydrogen or (C1-C3)-alkyl;
R(3) is defined as R(1), or R(3) is (C1-C6)-alkyl or-X-R(22);
X is oxygen, S or NR(16);
R(16) is H or (C1-C3)-alkyl;
or R(22) and R(16) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(22) is defined as R(14);
and their pharmaceutically tolerable salts.
(HOE 92/F 405 - EP 602 523, NZ 250 437) CA 02241531 1998-06-2~

i) benzoylguanidines of the formula I
R(l ) in which:
R(1) is hydrogen, F, Cl, Br, I, -N02, -C-N, R(16)~CpH2p~0q~ R(4)-SOm or 1 0 R(5)R(6)N-S02-;
m is zero, 1 or 2;
p iszeroor1;
q is zero, 1, 2 or 3;
R(16) is CrF2r+1;
r is1,20r3;
R(4) and R(5) are (C1-C8)-alkyl, (C3-C6)-alkenyl, -CnH2n-R(7) or CF3;
n iszero,1,2,30r4;
R(7) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(8)R(9);
R(8) and R(9) are H or C1-C4-alkyl;
or R(5) is H;
R(6) is H or (C1-C4)-alkyl;
or R(5) and R(6) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl, R(2) is (C1-Cg)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group CA 02241~31 1998-06-2~

consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(2) is -SR(10), -OR(10), -N R(10)R(11), -CR(10)R(11)R(12);
R(10) is-CaH2a-(C1-Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
a iszero,1 or2;
R(11) and R(12) independently of one another are defined as R(10) or are hydrogen or (C1-C4)-alkyl;
R(3) is defned as R(1), or is (C1-C6)-alkyl or-X-R(13);
X is oxygen, S, or NR(14);
R(14) is H or (C1-C3)-alkyl;
R(13) is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or-CbH2b-R(15);
b is zero,1, 2, 3 or 4;
or R(13)and R(14) together are 4 or 5 methylene groups, of which [lacuna] CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(15) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(8)R(9);
R(8) and R(9) are H or (C1-C4)-alkyl;
and their pharmaceutically tolerable salts;
(HOE 92/F 411 - NZ 250 450, EP 603 650) CA 02241~31 1998-06-2~

k) benzoylguanidines of the formula I
R(l ) R ( 2 )~

R ( 3 )J~N~NH2 ( I ) R ( 4 ) ~ NH2 in which:
one of the substituents R(~ ), R(2), R(3) or R(4):
~R ( S ) is an amino group - N
CnH2n-R ( 6 ) R(5) is hydrogen or C(~ alkyl;
n iszero,1,2,3Or4;
R(6) is H or C(14)-alkyl;
in which one CH2 group can be replaced by 1 sulfur atom or a group NR(7);
R(7) is hydrogen, methyl or ethyl;
or R(6) is C(3 8)-cycloalkyl or phenyl, which is unsubstituted or carries 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, methyl, methoxy, -NR(8)R(9);
R(8) and R(9) are H, methyl or ethyl;
or R(5) and R(6) together with the nitrogen atom are a 5-, 6- or 7-membered ring, in which 1 carbon atom can be replaced by oxygen, S or NR(1 0);
R(10) is H, C(1 3)-alkyl or benzyl;

CA 02241~31 1998-06-2~

and the other substituents R(1), R(2), R(3), R(4) in each case are:
hydrogen, F, Cl, Br, l, CN, CF3, NO2, CF3-O-, CmF2m+1~CH2~~~ or R(11)~CqH2q~Xp~;
m is 1, 2 or 3;
q iszero,1, 2, 3 or4;
p is zero or 1;
X is oxygen or NR(12);
R(12) is H or C(1 3)-alkyl;
R(11) is hydrogen, C(1 6)-alkyl, C(3 8)-cycloalkyl or phenyl, which is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, CH3, CH3-O- and NR(13)R(14);
R(13), R(14) are H, methyl or ethyl;
15 and their pharmaceutically tolerable salts.
(HOE 92/F 422 - EP 604 852) I) benzoylguanidines of the formula I
R(2)~R(3) 0 ¦ ll H
( )\N~S~N~N H 2 H ~ O NH
in which R(1) is R(4)R(5)N-C(X)-;
X is oxygen, S or N-R(6);
R(4) and R(5) identically or differently, are H, (C1-C8)-alkyl, (C3-C6)-alkenyl or -CnH2n-R(7);
n is zero,1, 2, 3 or 4;
R(7) is (C5-C7)-cycloalkyl or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methoxy and (C1-C4)-alkyl;
or R(4) and R(5) CA 02241~31 1998-06-2~

together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(6) is defined as R(4) or is amidine;
R(2) is H, F, Cl, Br, l, (C1-C8)-alkyl,1-alkenyl or 1-alkynyl, (C3-C8)-cycloalkyl, (C3-C8)-cycloalkyl-(C1-C4)-alkyl, phenyl, C6H5-(C1-C4)-alkyl, naphthyl, biphenylyl,1,1-diphenyl-(C1-C4)-alkyl, cyclopentadienyl, pyridyl, thiopyridyl, pyrrolyl, furanyl, thienyl, thiazolyl, oxazolyl, indenyl, quinolyl, indolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl or-W-R(8);
W is oxygen, S or NR(9);
R(8) is H, (C1-C6)-alkyl, (C5-C7)-cycloalkyl, cyclohexylmethyl, cyclopentylmethyl, -(CH2)mCpF2p+
or ~CqH2q~R(10);
m is zero or 1;
p is1,20r3;
q iszero,1,2,30r4;
R(10) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(11)R(12);
R(11) and R(12) are H or (C1-C4)-alkyl;
R(9) is H or (C1-C3)-alkyl;
or R(8) and R(9) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(3) is H, F, Cl, Br, l, (C1-C6)-alkyl or-W-R(8) as defined for R(2), and their pharmaceutically acceptable salts;
(93/F 054 - NZ 250 919, EP- Offenlegungsschrift 612 723) CA 02241~31 1998-06-2~

m) benzoylguanidines of the formula I
R(l ) R ( 2 ~

R(3)/~Nq/NH2 ( I ) ~ NH2 in which:
10 R(1), R(2), R(3) are hydrogen, F, Cl, Br, I or (C1-C12)-alkyl;
one of the substituents R(1), R(2) or R(3) is N3, CN, OH or (C1-C10)-alkyloxy, if at least one of the remaining substituents R(1), R(2) or R(3) is a sufficiently lipophilic alkyl radical having 3 to 12 carbon atoms;
or one of the substituents R(1), R(2) or R(3) is R(4)~CnH2n~0m-;
m is zero or 1;
n is zero, 1, 2 or3;
R(4) is CpF2p+1;
p is1,2Or3,ifniszeroor1;
or R(4) is (C3-C12)-cycloalkyl, phenyl, pyridyl, quinolyl or isoquinolyl, where the aromatic and heteroaromatic ring systems are unsubstituted or substituted by a substituent selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(5)R(6);
R(5) and R(6) are hydrogen or (C1-C4)-alkyl;
or one of the substituents R(1), R(2) or R(3) is -C-CR(5) or-C[R(6)] = CR(5);
R(5) is phenyl, which is unsubstituted or substituted by 1 - 3 CA 02241~31 1998-06-2~

substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy, hydroxyl, amino, methylamino and dimethylamino, (C1 -Cg)-heteroaryl, which is unsubstituted or substituted as phenyl, or R(5) is (C1-C6)-alkyl, which is unsubstituted or substituted by 1 - 3 OH;
or R(5) is (C3-C8)-cycioalkyl, R(6) is hydrogen or methyl;
and their pharmacologically acceptable salts;
(93/F 153 - EP- Offenlegungsschrift 627 413, NZ 260 660) o) benzoylguanidines of the formula I
R(l ) R(2) )~JyNq/NH2 ( I ) R ( 3 ) R ( 4 ) ~ NH2 in which:
R(1) is hydrogen, F, Cl, Br, I, -NO2, -C-N, Xo-(CH2)p-(CF2)q-CF3, R(5)-SOm, R(6)-CO- or R(6)R(7)N-SO2-, where X is oxygen, S or NR(14);
m is zero, 1 or 2;
o iszeroor1;
p is zero, 1 or 2;
q is zero, 1, 2, 3, 4, 5 or6;
R(5) and R(6) are (C1-C8)-alkyl, (C3-C6)-alkenyl, -CnH2n-R(8) or CF3;
n is zero, 1, 2, 3 or 4;
R(8) is (C3-C7)-cycloalkyl or phenyl, CA 02241~31 1998-06-2~

which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H or C1-C4-alkyl;
or R(6) is H;
R(7) is H or (C1-C4)-alkyl;
or R(6) and R(7) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;

1 5R(2) is - y~3 ( C ) h - ( C H O H ) ~ - ( C H 2 ) i ~ ( C H O H ) ~ - R ( 1 1 ) or ~ ( C ) h - ( C H O H ) ~ - ( C H 2 ) I - ( C H O H ) k - R ( l l ) o or ~( C )h-( CHOH ) ~-( CH2) ~-( CHOH )k-R ( l l ) Y is oxygen, -S- or-NR(12)-;
R(11 ) and R(12) are hydrogen or (C1-C3)-alkyl;
h is zero or 1;
i, j and k independently are zero, 1, 2, 3 or 4;
but where h, i and k are not simultaneously zero, R(3) is defined as R(1), or is (C1-C6)-alkyl or -X-R(13);
X is oxygen, S or NR(14);
R(14) is H or (C1-C3)-alkyl;

CA 02241~31 1998-06-2~

R(13) is H~ (C1-C6)-alkyl, (C3-C8)-cycloalkyl or-CbH2b-R(15);
b iszero,1,2,3Or4;
or R(13) and R(14) together are 4 or 5 methylene groups, where one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(15) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H or (C1-C4)-alkyl;
R(4) is hydrogen, -OR(16) or -NR(16)R(17);
R(16) and R(17) independently are hydrogen or (C1-C3)-alkyl;
and their pharmaceutically tolerable salts;
(HOE 93/F 154 - EP- Offenlegungsschrift 628 543, NZ 260 681) p) benzoylguanidines of the formula I
R(l ) R ( 2 )~J~,R ( S ) R ( 3 )J~/ =NH2 R ( 4 ) O
in which:
R(1) is R(6)-CO or R(7)R(8)N-CO;
R(6) is (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CnH2n-R(9);
n is zero,1, 2, 3 or 4;
R(9) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, CA 02241~31 1998-06-2~

methoxy and NR(10)R(11);
R(10)and R(11) are H, (C1-C4)-alkyl or (C1-C4)-perfuoro-alkyl;
R(7) is H, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CnH2n-R(12);
n is zero,1, 2, 3 or 4;
R(12) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(13)R(14);
R(13) and R(14) are H, (C1-C4)-alkyl or (C1-C4)-perfuoro-alkyl;
R(8) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(7) and R(8) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(2) is defined [lacuna] R(1), or is H, F, Cl, Br, l, CN, NO2, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or-CnH2nR(15);
n iszero 1, 2, 3, 4;
R(15) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(16)R(17);
R(16) and R(17) are H, (C1-C4)-alkyl or (C1-C4)-perfuoro-alkyl;
or R(2) is (C1-Cg)-heteroaryl, which is linked via C or N and which is unsubstituted or CA 02241~31 1998-06-2~

substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(2) is SR(18), -OR(18), -NR(18)R(19), -CR(18)R(19)R(20);
R(18) is-CaH2a-(C1-Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
a is zero,1 or 2;
R(19) and R(20) independently of one another are defined as R(18) or are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
15 or R(2) is R(21)-SOm or R(22)R(23)N-SO2-;
m is 1 or 2;
R(21) is (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl, --CnH2n-R(24), n is zero,1, 2, 3 or 4;
R(24) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(27)R(28);
R(27) and R(28) are H, (C1-C4)-alkyl or (C1-C4)-perfuoro-alkyl;
R(22) is H, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl, -CnH2n-R(29);
n iszero,1,2,30r4;
R(29) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from CA 02241~31 1998-06-2~

the group consisting of F, Cl, CF3, methyl, methoxy and NR(30)R(31);
R(30) and R(31) are H, (C1-C4)-alkyl or (C1-C4)-perfuoro-alkyl;
R(23) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(22) and R(23) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
or R(2) is R(33)X-;
X is oxygen, S, NR(34), (D=O)A-, NR(34)C=MN(*)R(35)-;
M is oxygen or S;
A is oxygen or NR(34);
D isCorSO;
R(33) is (C1-C8)-alkyl, (C3-C8)-alkenyl, (CH2)bCdF2d+1~ ~CnH2n~
R(36), b is zero or 1;
d is 1, 2, 3, 4, 5, 6 or 7;
n is zero, 1, 2, 3 or 4;
R(36) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(37)R(38);
R(37) and R(38) are H, (C1-C4)-alkyl or (C~-C4)-perfuoro-alkyl;
R(34) is H, (C1-C4)-alkyl or(C1-C4)-perfuoroalkyl;
R(35) is defined as R(33);
or R(33) and R(34) together are 4 or 5 methylene groups, of which one CA 02241~31 1998-06-2~

CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
where A and N(~) are bonded to the phenyl nucleus of the benzoylguanidine parent structure;
5 or R(2) is -SR(40), -OR(40), -NHR(40), -NR(40)R(41), -CHR(40)R(42), -C[R(42)R(43)0H], -C-CR(45), -CR(46)=CHR(45), -[CR(47)R(48)]U-(CO)-[CR49)R(50)]V-R(44);
R(40), R(41) identically or differently are ~(CH2)p~(CHOH)q~(CH2)r~
(CHOH)t-R(51) or -(CH2)p-O-(CH2-CH2O)q-R(51);
R(51) is hydrogen or methyl;
u is1,2,3Or4;
v iszero,1,2,3Or4;
p,q,r identically or differently are zero,1, 2, 3 or 4;
t is1,2,3Or4;
R(42) and R(43) identically or differently are hydrogen or (C1-C6)-alkyl;
or R(42) and R(43) together with the carbon atom carrying them form a (C3-C8)-cycloalkyl;
R(44) is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or-CeH2e-R(45);
e iszero,1, 2, 3Or4;
R(45) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(52)R(53) where R(52) and R(53) are H or (C1-C4)-alkyl, or R(45) is (C1-Cg)-heteroaryl, which is unsubstituted or substituted as phenyl;
or R(45) is (C1 -C6)-alkyl, CA 02241~31 1998-06-2~

which is unsubstituted or substituted by 1 - 3 OH;
R(46), R(47), R(48), R(49) and R(50) are hydrogen or methyl;
or R(2) is R(55)-NH-SO2-;
R(55) is R(56)R(57)N-(C=Y)-;
Y is oxygen, S or N-R(58);
R(56) and R(57) identically or differently are H, (C1-C8)-alkyl, (C3-C6)-alkenyl or-CfH2fR(59);
f is zero,1, 2, 3 or 4;
R(59) is (C5-C7)-cycloalkyl or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methoxy and (C1-C4)-alkyl;
or R(56) and R(57) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(58) is defined as R(56) or is amidine;
R(3), R(4) and R(5) independently of one another are defined as R(1) or R(2);
25 and their pharmaceutically tolerable salts;
(HOE 93/F 220 - EP- Offenlegungsschrift 640 593, NZ 264 117) CA 02241~31 1998-06-2~

q) benzoylguanidines of the formula I

R(l ) R(2) ~

R ( 3 ) ~ N-, in which:
R(1) is hydrogen, F, Cl, Br, I, -N02, -C-N, -Xo-(CH2)p-(CF2)q-CF3, R(5)-SOm-, R(6)-C0-, R(6)R(7)N-C0- or R(6)R(7)N-S02-;
X is oxygen, -S- or NR(14);
m iszero,10r2;
o is zero or 1;
p is zero, 1 or 2;
q is zero, 1, 2, 3, 4, 5 or 6;
R(5) and R(6) are (C1-C8)-alkyl, (C3-C6)-alkenyl, -CnH2n-R(8) or CF3;
n iszero, 1, 2, 30r4;
R(8) is (C3-C7)-cycloalkyl, phenyl, which is not substituted or is substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(1 0);
R(9) and R(10) are H or (C1-C4)-alkyl;
or R(6) is hydrogen;
R(7) is hydrogen or (C1-C4)-alkyl;
or R(6) and R(7) together are 4 or 5 methylene groups, of which one CH2 CA 02241~31 1998-06-2~

group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(2) is - r ~ R( 1 1 ) , ~ R( 1 1 ) or ~ R( 1 1 ) R(11) is (C1-Cg)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino, dimethylamino and benzyl;
Y is oxygen, -S- or NR(12);
R(12) is H or (C1-C4)-alkyl;
R(3) is defined as R(1);
or R(3) is (C1-C6)-alkyl or-X-R(13);
X is oxygen, -S- or NR(14);
R(14) is H or (C1 -C3)-alkyl;
R(13) is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or-CbH2b-R(15);
b is zero,1, 2, 3 or 4;
or R(13) and R(14) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(15) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H or (C1-C4)-alkyl;
R(4) is hydrogen, -OR(16), -NR(16)R(17) or CrF2r+1;
R(16) and R(17) independently are hydrogen or (C1-C3)-alkyl;

CA 02241~31 1998-06-2~

r is 1, 2, 3 or 4;
and their pharmaceutically tolerable salts;, (HOE 93/F 223 K - EP 639 573, NZ 264 130) r) benzo-fused 5-membered ring heterocycles of the formula I
R(2) R ( 3 ) ~
4~3X
7~'r' \ ( I ) .

in which:
X is N or CRt6);
Y is oxygen, S or NR(7);
15 A, B together are a bond or A, B are both hydrogen, if X is simultaneously CR(6) and Y is NR(7);
one of the substituents R(1) to R(6) is a -CO-N=C(NH2)2 group;
the other substituents R(1) to R(6) in each case are hydrogen, F, Cl, Br, l or (C1-C6)-alkyl;
up to two of the other substituents R(1) to R(6) are CN, NO2, N3, (C1-C4)-alkyloxy or CF3;
up to one of the other substituents is R(8)-cnH2n-z-;
n is zero to 10;
where the alkylene chain -CnH2n- is straight-chain or branched and where one carbon atom can be replaced by an oxygen or sulfur atom or by a nitrogen atom;
R(8) is hydrogen, (C2-C6)-alkenyl or (C3-C10)-cycloalkyl, which is unsubstituted or substituted by 1 to 4 methyl groups or an OH group, or can contain an ethylene group -CH=CH-, and in which one methylene group can be replaced by an oxygen or sulfur atom or by a nitrogen atom;

CA 02241~31 1998-06-2~

or R(8) is phenyl, which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, Br, l, CF3, CH3-S(O)s- or R(9)-Wy~;
s is zero,1 or 2;
R(9) is H, methyl, ethyl, W is oxygen or NR(10);
R(10) is H or methyl;
y is zero or 1;
or R(8) is CmF2m+1;
m is1to3;
or R(8) is 1- or 2-naphthyl, pyridyl, quinolyl or isoquinolyl;
Z is -CO-, -CH2- or -[CR(11)(OH)]q-;
q is1,2Or3;
R(11) is H or methyl;
or Z is oxygen or-NR(12)-;
R(12) is H or methyl;
or Z is-S(O)s-;
s is zero,1 or 2;
or Z is -SO2-NR(13)-;
R(13) is H or (C1-C4)-alkyl;
R(7) is hydrogen~ (C1-C10)-alkyl, (C2-C10)-alkenyl or R(8)-CnH2n;
and their pharmaceutically tolerable salts;
(HOE 93/F 236 - EP- Offenlegungsschrift 638 548, NZ 264 216) CA 0224l~3l l998-06-2~

s) benzoylguanidines of the formula I
R(2) R ( ~ N H 2 R(S) 0 in which:
R(1), R(3) or R(4) is -NR(6) C=X NR(7)R(8);
X is oxygen or S;
R(6) is hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-Cg)-alkenyl 0r~CnH2n~R(9);
n is zero, 1, 2, 3 or 4;
R(9) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(1 O)R(1 1 );
R(10) and R(1 1 ) are H, (C1-C4)-alkyl or (C~-C4)-perfluoroalkyl;
R(7) is hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenYI or-COH2o~R(12);
o iszero, 1, 2, 30r4;
R(12) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by l - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and CA 02241~31 1998-06-2~

NR(13)R(14);
R(13) and R(14) are H, (C1-C4)-alkyl or (C1-C4)-pernuoroalkyl;
R(8) is defined as R(7);
or R(7) and R(8) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
the remaining substituents R(2), R(3), R(4), R(5) or R(1), R(2), R(4), R(5) or R(1), R(2), R(3), R(5) in each case independently of one another are hydrogen, F, Cl, Br, l, -Ota(C1-C8)-alkyl, -Otb(C3-C8)-alkenyl, -~tc(CH2)bCdF2d+1 ~ -OtdCpH2pR(18), or up to 2 groups CN, NO2, NR(16)R(17), b is zero or 1;
d is1,2,3,4,5,6Or7;
ta is zero or 1;
tb iszero or 1;
tc is zero or 1;
td iszeroor1;
p is zero,1, 2, 3 or 4;
R(18) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(19)R(20);
R(19) and R(20) are hydrogen or (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(16) is hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl, ~CqH2q~R(21)~
q is zero,1, 2, 3 or 4;

CA 02241~31 1998-06-2~

R(21) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents from the group F, Cl, CF3, methyl, methoxy or NR(22)R(23), R(22) and R(23) are hydrogen, (C1-C4)-alkyl or (C1 -C4)-perfluoroalkyl;
R(17) is hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl, -CrH2r-R(24);
r iszero,1, 2, 3Or4;
R(24) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(25)R(26);
R(25) and R(26) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(16) and R(17) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
and their pharmaceutically tolerable salts;
(HOE 93/F 249 - EP- Offenlegungsschrift 640 587, NZ 264 282) t) diacyl-substituted guanidines of the formula I

X ( 1 ) ~NH~NH~X ( 2 ) ~ NH ~
in which:
X(1) and X(2) are CA 02241~31 1998-06-2~

R( l 0l ) R ( 1 0 2 )~ C C I R ( A ) R ( 0 ) I ~ --R( l 03~ R( 1 05) R ( l 0~ ) T1 is zero, 1, 2, 3 or 4;
R(A) and R(B) independently of one another are hydrogen, F, Cl, Br, I, CN, OR(106), (C1-C8)-alkyl, (C3-C8)-cycloalkyl, Ozk(CH2)zlCzmF2zm+
NR(107)R(108), phenyl or benzyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(109)R(1 10);
R(109) and R(1 10) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
zl is zero, 1, 2, 3 or 4;
zk is zero or 1;
zm is 1, 2, 3, 4, 5, 6, 7 or 8;
R(1 06) is hydrogen, (C1-C8)-alkyl, (C1-C8~perfluoroalkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(111 )R(11 2);
R(1 1 1 ) and R(112) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(107) and R(108) independently of one another are defined as R(106), or R(107) and R(108) together are 4 or 5 methylene groups, of which one CH2 CA 02241~31 1998-06-2~

group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
or X(1 ) and X(2) are R( 101 ) R(~) R ( 1 0 2 ) ~ C C I R ( A ) R ( ~ T 2 Q
~ ~ {C I R ( ~ ) R ( ~ T2 b R ( 1 0 3 ) ~r R ( 1 0 5 ) R ( ~ ) R ( 1 0 ~, ) T2a and T2b independently of one another are zero, 1 or 2;
where the double bond can have the (E)- or (Z)-configuration;
or X(1 ) and X(2) are R(Yl) R(Y2) R(10~ R(Z1) R(103) ~ 'Z- R(Z2) R(102) ~ ~ ~ CCIR(A)R(~ T3 R(101 / R(U2) R(D) R(Ul) T3 is zero, 1 or 2;
U, W and Z
independently of one another are C or N, where U, W, Z can carry the following number of substituents:
U, W or Z Bonded in the ring to Number of permitted a double bond substituents C yes C no 2 N yes 0 N no CA 02241~31 1998-06-2~

R(D) is hydrogen, (C1-C8)-alkyl or (C1-C8)-perfluoroalkyl, R(U1), R(U2), R(Y1), R(Y2), R(Z1), R(Z2) independently of one another are hydrogen, F, Cl, Br, l, CN, OR(114), (C1-C8)-alkyl, (C3-C8)-cycloalkyl, ~zka(CH2)zlaCzmaF2zma+1, NR(115)R(116), phenyl or benzyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy, NR(117)R(118), R(117) and R(118) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl, zka is zero or 1;
zla is zero, 1, 2, 3 or 4;
zma is1,2,3,4,5,6,7Or8;
R(114) is hydrogen, (C1-C8)-alkyl, (C1-C8)-pernuoroalkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(119)R(120);
R(119) and R(120) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(115) and R(116) independently of one another are defined as R(114);
or R(115) and R(116) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
but where the constitution of U is nitrogen (N), W is nitrogen (N) and Z is carbon (C) is excluded, R(101), R(102), R(103), R(104) and R(105) independently of one another are hydrogen, F, Cl, Br, l, -C-N, Xzoa~(C H2)Zpa~(CzqaF2zqa+1)~ R(11 Oa )-SOzbm, R(11 Ob)R(110c)N-CO, CA 02241~31 1998-06-2~

R(111 a)-CO- or R(112a)R(113a)N-SO2-, where the perfluoroalkyl group is straight-chain or branched, X is oxygen, S or NR(114a);
R(114a) is H or (C1-C3)-alkyl;
zoa is zero or 1;
zbm is zero,1 or 2;
zpa is zero, 1, 2, 3 or 4;
zqa is 1, 2, 3, 4, 5, 6, 7 or 8;
R(110a), R(110b), R(111a) and R(112a) independently of one another are (C1-C8)-alkyl, (C3-C8)-alkenyl, -CznH2zn-R(115a) or (C1-C8)-perfluoroalkyl;
zn iszero,1, 2, 30r4;
R(115a) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(116a)R(117a);
R(116a) and R(117a) are hydrogen, (C1-C4)-perfluoroalkyl or (C1-C4)-alkyl;
or R(11 Ob), R(111 a) and R(112a) are hydrogen;
R(110c) and R(113a) independently are hydrogen, (C1-C4)-perfluoroalkyl or (C1 -C4)-alkyl;
or R(110b) and R(110c) and R(112a) and R(113a) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
or R(101), R(102), R(103), R(104), R(105) independently of one another are (C1-C8)-alkyl, -CzalH2zalR(118a) or (c3-c8)-alkenyl, zal is zero, 1, 2, 3 or 4;
R(118a) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy or NR(119a)R(119b);
R(119a) and R(119b) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(101), R(102), R(103), R(104), R(105) independently of one another are (C1-Cg)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(101), R(102), R(103), R(104), R(105) independently of one another are -C-C-R(193);
R(193) is phenyl which is not substituted or is substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy or NR(194)R(195);
R(194) and R(195) are hydrogen or CH3;
or R(101), R(102), R(103), R(104), R(105) independently of one another are -Y-para-C6H4-(CO)zh-(CHOH)zj-(CH2)zj-(CHOH)zk-R(123), -y-meta-c6H4-(co)zad-(cHoH)zae-(cH2)zaf(cHoH)za9-R(124) CA 02241~31 1998-06-2~

or ortho C6H4-(co)zah-(cHoH)zao-(cH2)zap-(cHoH)zak-R(125);
Y is oxygen, -S- or-NR(122d)-;
zh, zad, zah independently are zero or 1;
zi, zj, zk, zae, zaf, zag, zao, zap and zak independently are zero,1, 2, 3 or 4;
but where in each case zh, zi and zk are not simultaneously zero, zad, zae and zag are not simultaneously zero, and zah, zao and zak are not simultaneously zero, R(123), R(124) R(125) and R(122d) independently are hydrogen or (C1-C3)-alkyl;
or R(101), R(102), R(103), R(104) and R(105) independently of one another are SR(129), -OR(130), -NR(131)R(132) or -CR(133)R(134)R(135);
R(129), R(130), R(131) and R(133) independently are -CzabH2zab-(c1-cg)-heteroaryl~
which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
zab is zero,1 or 2;
R(132), R(134) and R(135) independently are defined as R(129) or are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(101), R(102), R(103), R(104) and R(105) independently of one another are -W-para-(C6H4)-R(196), -W-meta-(C6H4)-R(197) or -W-ortho-(C6H4)-R(198);
R(196), R(197) and R(198) independently of one another are (C1-Cg)-heteroaryl, which is linked via C or N and which is unsubstituted or CA 02241~31 1998-06-2~

substituted by 1 to 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino, dimethylamino and benzyl;
W is oxygen, S or NR(136)-;
R(136) is hydrogen or (C1-C4)-alkyl;
or R(101), R(102), R(103), R(104) and R(105) independently of one another are R(146)X(1a)-;
X(1a) is oxygen, S, NR(147), (D=O)A-, NR(148)C=MN(~)R(149)-;
M is oxygen or sulfur;
A is oxygen or NR(150);
D is C or SO;
R(146) is (C1-C8)-alkyl, (C3-C8)-alkenyl, (CH2)zbzCzdzF2zdz+1 or ~CzxaH2zxa~R(151);
zbz is zero or 1;
zdz is1,2,3,4,5,6Or7;
zxa iszero,1, 2, 3 or4;
R(151) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(152)R(153);
R(152) and R(153) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(147), R(148) and R(150) independently are hydrogen, (C1-C4)-alkyl, (C1-C4)-perfluoroalkyl;
R(149) is defined as R(146), or CA 02241~31 1998-06-2~

R(146) and R(147), or R(146) and R(148) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
where A and N(~) are bonded to the phenyl nucleus of the alkanoyl parent structure;
or R(101), R(102), R(103), R(104) and R(105) independently of one another are -SR(164), -OR(165), -NHR(166), -NR(167)R(168), -CHR(169)R(170), -CR(154)R(155)0H, -C--CR(156), -CR(158)=CR(157) or -[CR(159)R(160)]zu-(C=O)-[CR(161)R(162)]zv-R(163);
R(164), R(165), R(166), R(167), R(169) identically or differently are -(CH2)zy~(CHOH)zz~(CH2)zaa~
(CHOH)Zt-R(171) or -(CH2)zab-O~(cH2-cH2o)zac-R(172);
R(171) and R(172) are hydrogen or methyl;
zu is1,2,30r4;
zv is zero,1, 2, 3 or 4;
zy,z,zaa,zab,zac identically or differently are zero,1, 2, 3 or 4;
zt is 1, 2, 3 or 4;
R(168), R(170), R(154), R(155) identically or differently are hydrogen or (C1-C6)-aikyl, or R(169) and R(170), or R(154) and R(155) together with the carbon atom carrying them are a (C3-C8)-cycloalkyl;
R(163) is hydrogen, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or ~CzebH2zeb~R(173);
zeb is zero,1, 2, 3 or 4;
R(156), R(157) and R(173) independently are phenyl which is unsubstituted or is CA 02241~31 1998-06-2~

substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(174)R(175);
R(174) and R(175) are hydrogen or (C1-C4)-alkyl;
or R(156), R(157) and R(173) independently are (C1-Cg)-heteroaryl, which is unsubstituted or substituted as phenyl;
R(158), R(159), R(160), R(161) and R(162) are hydrogen or methyl, or R(101), R(102), R(103), R(104), R(105) independently of one another are R(176)-NH-SO2-;
R(176) is R(177)R(178)N-(C=Y')-;
Y' is oxygen, S or N-R(179);
R(177) and R(178) identically or differently are hydrogen, (C1-C8)-alkyl, (c3-c6)-alkenyl or-czfaH2zfa-R(18o);
zfa is zero,1, 2, 3 or 4;
R(180) is (C5-C7)-cycloalkyl or phenyl, which [lacuna] unsubstituted [lacuna] by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methoxy or (C1-C4)-alkyl;
or R(177) and R(178) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;

R(179) CA 02241~31 1998-06-2~

is defined as R(177) or is amidine, or R(101), R(102), R(103), R(104), R(105) independently of one another are NR(184a)R(185), OR(184b), SR(184c) or ~CznxH2znx~R(184d);
znx is zero, 1, 2, 3 or 4;
R(184d) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(116k)R(117k);
R(116k) and R(117k) are hydrogen or C1-C4-alkyl;
R(184a), R(184b), R(184c), R(185) independently of one another are hydrogen, (C1-C8)-alkyl, (C1-c8)-perfluoroalkyl or (CH2)zaO-R(184g);
zao is zero, 1, 2, 3 or 4;

is (C3-C7)-cycloalkyl or phenyl, which is not substituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(184u)R(184v);
R(184u) and R(184v) are hydrogen or C1-C4-alkyl;
or R(184a) and R(185) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
and their pharmaceutically tolerable salts;

CA 02241~31 1998-06-2~

(HOE 93/F 254 - EP-Offenlegungsschrift 640 588, NZ 264 307) u) benzoylguanidines of the formula I
R(l ) 2 ( 2 )~ R 2 R(4) ~
in which:
R(1) is H, F, Cl, Br, l, CN, NO2, (C1-C8)-alkyl, (C3-C8)-cycloalkyl or Xa-(cH2)b-(cF2)c-cF3;
X is oxygen, S or NR(5);
a is zero or 1;
b iszero, 1 or2;
c is zero,1, 2 or 3;
R(5) is H, (C1-C4)-alkYI ~r-CdH2dR(6);
d is zero, 1, 2, 3 or 4;
R(6) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(7)R(8);
R(7) and R(8) independently are H or (C1-C4)-alkyl;
or R(1) is -SR(10), -OR(10) or -CR(10)R(11)R(12);
R(10) is -CfH2f(C3-C8)-cycloalkyl, -(C1-Cg)-heteroaryl or phenyl, where the aromatic systems are unsubstituted or substituted by one to 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

CA 02241~31 1998-06-2~

f is zero,1 or 2;
R(11) and R(12) independently of one another are defined as R(10) or are hydrogen or (C1-C4)-alkyl;
or R(1) is phenyl, naphthyl, biphenylyl or (C1-Cg)-heteroaryl, the latter linked via C or N, and which are unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(1) is -SR(13), -OR(13), -N HR(13), -NR(13)R(14), -CH R(13)R(15), -C[R(15)R(16)]0H, -C-CR(18), -C[R(19)]=CR(18), -[CR(20)R(21 )]k-(CO)-[CR(22)R(23)R(24)]
R(13) and R(14) identically or differently are -(CH2)9-(CHOH)h-(CH2)j-(CHOH)j-R(17), R(17) is hydrogen or methyl;
-(CH2)9-O-(CH2-CH20)h-R(24), 9, h, i identically or differently are zero,1, 2, 3 or 4;
is 1, 2, 3 0r 4;
R(15) and R(16) identically or differently are hydrogen, (C1-C6)-alkyl or together with the carbon atom carrying them are a (C3-C8)-cycloalkyl;
R(18) is phenyl, which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(25)R(26);
R(25) and R(26) are H or (C1-C4)-alkyl;
or CA 02241~31 1998-06-2~

R(18) is (C1 -Cg)-heteroaryl, which is unsubstituted or substituted as phenyl;
or R(18) is(C1-C6~alkyl, which is unsubstituted or substituted by 1 to 3 OH;
or R(18) is(C3-C8)-cycloalkyl;
R(19), R(20), R(21), R(22) and R(23) are hydrogen or methyl;
k iszero,1,2,30r4;
iszero,1,2,30r4;
R(24) is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or-CmH2m-R(18);
m is 1, 2, 3 or 4;
15 R(2) and R(3) independently of one another are defined as R(1);
R(4) is (C1-C3)-alkyl, F, Cl, Br, l, CN or-(CH2)n-(CF2)0-CF3;
n iszeroor1;
o iszero,10r2;
20 and their pharmaceutically tolerable salts;
(HOE 93/F 436 - EP-Offenlegungsschrift 659 748), NZ 270 264) v) acylguanidines of the formula I

I J 1- N~NH2 ( I ) 8 ~ NH2 in which:
X is carbonyl, sulfonyl, R(1) is H, (C1-Cg)-alkyl, unsubstituted or substituted by hydroxyl, (C3-C8)-cycloalkyl, phenyl, which is unsubstituted or substituted by 1 - 3 substituents from the group F, Cl, CF3, CH3, methoxy, hydroxyl, amino, CA 02241~31 1998-06-2~

methylamino or dimethylamino, R(2) is H, (C1-C4)-alkyl, and their pharmaceutically tolerable salts;
(HOE 94/F 014 K - EP-Offenlegungsschrift 666 252, NZ 270 370) 5 w) phenyl-substituted alkycarboxylic acid guanidides, carrying perfluoroalkyl groups, of the formula I
R(~) R(~) R(l) \
R ( 2 )~ ( C ) ~Nq~NH2 ( I ) R (3 ) R ( 5) ~ NH2 R ( ~ ) in which:
R(A) is hydrogen, F, Cl, Br, l, CN, OR(6), (C1-C8)-alkyl, (C3-C8)-cycloalkyl, Or(CH2)aCbF2b+1 or NR(7)R(8);
ris zero or 1;
a iszero,1,2,3Or4;
b is1,2,3,4,5,6,7Or8;
R(6) is hydrogen, (C1-C8)-alkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;

R(7) and R(8) independently of one another are defined as R(6);
R(B) independently is defined as R(A);
X is 1, 2 or3;
R(1) is hydrogen, (C1-C8)-alkyl, (C3-C8)-cycloalkyl, -Ot(CH2)dCeF2e+1, F, Cl, Br, l or CN;
t is zero or 1;

CA 02241~31 1998-06-2S

d iszero,1,2,30r4;
e is 1, 2, 3, 4, 5, 6, 7 or 8;
R(2), R(3), R(4) and R(5) independently of one another are defined as R(1);
5 but with the condition that at least one of the substituents R(1), R(2), R(3), R(4), R(5), R(A) and R(B) is an -Ot(CH2)dCeF2e+1 or an Or(CH2)aCbF2b+1 group~
and their pharmaceutically tolerable salts;
(HOE 94/F 094 - EP-Offenlegungsschrift 676 395, NZ 270 894) 10 x) heteroaroylguanidines of the formua I

R(3) R(2) ~ I
R(4) HA R( l ) in which:
HA is SOm, O or NR(5);
m is zero,1 or 2;
R(5) is hydrogen, (C1-Cg)-alkyl or ~CamH2amR(81);
am iszero,1 or2;
R(81) is (C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(82)R(83);
R(82) and R(83) Is H or CH3;
or R(81) is(C1-Cg)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

CA 02241~31 1998-06-2~

one of the two substituents R(1) and R(2) is -CO-N=C(NH2)2;
and the other in each case is hydrogen, F, Cl, Br, l, (C1-C3)-alkyl, -OR(6), CrF2r+1~ -CO-N=C(NH2)2 or NR(6)R(7);
R(6) and R(7) independently are hydrogen or (C1-C3)-alkyl;
r is 1, 2, 3 or 4;
R(3) and R(4) independently of one another are hydrogen, F, Cl, Br, l, -C-N, X-(CH2)p-(Cq-F2q+1), R(8)-SObm, R(9)R(10)N-CO, R(11)-CO-or R(12)R(13)N-s02-~
where the perfluoroalkyl group is straight-chain or branched, X is oxygen, S or NR(14);
R(14) is H or (C1-C3)-alkyl;
bm is zero,1 or 2;
p is zero,1 or 2;
q iszero, 1,2,3,4,50r6;
R(8), R(9), R(11)and R(12) independently are (C1-C8)-alkyl, (C3-C6)-alkenyl, H2n-R(15)~ CF3;
n iszero,1,2,30r4;
R(15) is (C3-C7)-cycloalkyl or phenyl;
which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy or NR(16)R(17);
R(16) and R(17) are H or C1-C4-alkyl;
or R(9), R(11) and R(12) are H;
R(10) and R(13) independently are H or (C1-C4)-alkyl;
or CA 02241~31 1998-06-2~

R(9) and R(10), and R(12) and R(13) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl, or 5 R(3) and R(4) independently of one another are (C1-C8)-alkyl or -CalH2alR(18);
al is zero, 1 or 2;
R(18) is (C3-C8)-cycloalkyl or phenyl;
which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(19)R(20);
R(19) and R(20) are H or CH3;
or R(3) and R(4) independently of one another are (C1-Cg)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(3) and R(4) independently of one another are o Y~ ( C ) h ~ ( C H 0 H ) I - ( C H 2 ) i ~ ( C H 0 H ) k ~ R ( 2 3 ) o r ~3 ( C ) a d ~ ( C H O H ) a ~ ~ ( C H 2 ) a f ~ ( C H O H ) O 9 - R ( 2 4 ) y o o r ~ ( C ) a h ~ ( C H O H ) a O ~ ( C H 2 ) a p - ( C H O H ) a ~ ~ R ( 2 5 ) CA 02241~31 1998-06-2~

Y is oxygen, -S- or -NR(22)-;
h, ad, ah independently are zero or 1;
i, j, k, ae, af, ag, ao, ap and ak independently are zero,1, 2, 3, 4, but where in each case h, i and k are not simultaneously zero, ad, ae and ag are not simultaneously zero, ah, ao and ak are not simultaneously zero, R(23), R(24) R(25) and R(22) independently are hydrogen or (C1-C3)-alkyl;
10 or R(3) and R(4) independently are hydrogen, F, Cl, Br, l, CN, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or-CgH29R(26);
g is zero,1, 2, 3 or 4;
R(26) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(27)R(28);
R(27) and R(28) are H, (C1-C4)-alkyl or (C1-C4)-pefluoroalkyl;
or R(3) and R(4) independently of one another are SR(29), -OR(30), -NR(31)R(32) or -CR(33)R(34)R(35);
R(29), R(30), R(31) and R(33) independently of one another are -CaH2a-(C1-Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
a is zero,1 or 2;
R(32), R(34) and R(35) independently of one another are defined as R(29) or are CA 02241~31 1998-06-2~

hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(3) and R(4) independently of one another are -- W~R(96) ~ ~R(97) or ~R(98) --W W--R(96), R(97) and R(98) independently are (C1-Cg)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino, dimethylamino or benzyl;
W is oxygen, S or N R(36)-;
R(36) is H or (C1-C4)-alkyl;
or R(3) and R(4) independently of one another are R(37)-SOCm or R(38)R(39)N-SO2-;
cm is 1 or 2;
R(37) is(C1-C8)-alkyl,(C1-C8)-perfluoroalkyl,(C3-C8)-alkenyl or -CsH2sR(4o);
s is zero, 1, 2, 3 or 4;
R(40) is(C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and N R(41)R(42);
R(41) and R(42) are H, (C1-C4)-alkyl or (C,-C4)-perfluoroalkyl;
R(38) is H, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CwH2w-R(43);
w is zero, 1, 2,3 or 4;

CA 0224l~3l l998-06-2~

R(43) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(44)R(45);
R(44) and R(45) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(39) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(38) and R(39) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
or R(3) and R(4) independently of one another are R(46)X(1 ~;
X(1) is oxygen, S, NR(47), (D=O)A-, NR(48)C=MN(~)R(49)-, M is oxygen or S;
A is oxygen or NR(50);
D is CorSO;
R(46) is (C1-C8)-alkyl, (C3-C8)-alkenyl, (CH2)bCdF2d+1 ~r-CxH2x R(51);
b is zero or 1;
d is 1, 2, 3, 4, 5, 6 or 7;
x iszero,1, 2, 3Or4;
R(51) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(52)R(53);
R(52) and R(53) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(47), R(48) and R(50) CA 0224l~3l l998-06-2~

independently are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(49) is defined as R(46);
or R(46) and R(47), or R(46) and R(48) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl, where A and N(*) are bonded to the phenyl nucleus of the benzoylguanidine parent structure;
or R(3) and R(4) independently of one another are -SR(64), -OR(65), -NHR(66), -NR(67)R(68), -CHR(69)R(70), -C(OH)R(54)R(55), -C-CR(56), -CR(58)=CHR(57), -[CR(59)R(60)]U-(CO)-[CR(61)R(62)]v-R(63);
R(64), R(65), R(66), R(67) and R(69) identically or differently are -(CH2)y~(CHOH)z~(CH2)aa~
(CH20H)t-R(71) or ~(CH2)ab-O-(CH2-CH2O)aC-R(72)~
R(71) and R(72) are hydrogen or methyl;
u is1,2,3Or4;
v iszero,1,2,3Or4;
y, z, aa identically or differently are zero,1, 2, 3 or 4;
t is 1, 2, 3 or4;
R(68), R(70), R(54) and R(55) identically or differently are hydrogen, (C1-C6)-alkyl;
or R(69) and R(70), or R(54) and R(55) together with the carbon atom carrying them are a (C3-C8)-cycloalkyl;
R(63) is H, (C1-C6)-alkyl, (c3-c8)-cycloalkyl or-ceH2e-R(73);
e iszero,1,2,3Or4;

CA 02241~31 1998-06-2~

R(56), R(57) and R(73) independently are phenyl, which are unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(74)R(75);
R(74) and R(75) are H or (C1-C4)-alkyl;
or R(56), R(57) and R(73) independently are (C1-Cg)-heteroaryl, which is unsubstituted or substitued as phenyl;
R(58), R(59), R(60), R(61) and R(62) are hydrogen or methyl, or R(3) and R(4) independently of one another are R(76)-NH-SO2-;
R(76) is R(77)R(78)N-(C=Y')-;
Y' is oxygen, S or N-R(79);
R(77) and R(78) identically or differently are H, (C1-C8)-alkyl, (C3-C6)-alkenyl, -CfH2f R(80);
f is zero,1, 2, 3 or 4;
R(80) is (C5-C7)-cycloalkyl or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methoxy and (C1-C4)-alkyl;
or R(77) and R(78) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl, R(79) is defined as R(77) or is amidine;
or R(3) and R(4) CA 02241~31 1998-06-2~

independently of one another are NR(84)R(85);
R(84) and R(85) independently of one another are H, (C1-C4)-alkyl, or together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl; or of which one or two CH2 groups can be replaced by CH-CdmH2dm+1, and their pharmaceutically tolerable salts;
(HOE 94/F 123 - EP-Offenlegungsschrift 682 017, NZ 272 058) 10 y) bicyclic heteroaroylguanidines of the formula I

R ( ~, ) R ( 3 ) R ( S ) ~v~wy,x~y~R ( 2 ) ~U~l~z~Nq~ N H 2 R ( 7 ) R ( l ) ~ NH2 in which:~0 T, U,V,W,X,YandZ
independently of one another are nitrogen or carbon;
but with the restriction that X and Z are not simultaneously nitrogen, and that T, U, V, W, X, Y and Z carry no substituents if they are nitrogen, and that no more than four of them are simultaneously nitrogen, R(1) and R(2) independently of one another are hydrogen, F, Cl, Br, l, (C1-C3)-alkyl, (C1-C3)-perfluoroalkyl, OR(8), NR(8)R(9) or C(=O)N=C(NH2)2;
R(8) and R(9) independently of one another are hydrogen or (C1-C3)-alkyl, or R(8) and R(9) together are 4 or 5 methylene groups, of which one CH2 CA 02241~31 1998-06-2~

group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(3), R(4), R(5), R(6) and R(7~
independently of one another are hydrogen, F, Cl, Br, l, -C-N, Xk-(CH2)p~(CqF2q+1)~ R(10a)-SObm, R(1 Ob)R(10c)N-CO, R(11)-CO- or R(12)R(13)N-s02-~
where the perfluoroalkyl group is straight-chain or branched;
X is oxygen, S or NR(14);
R(14) is H or C1-C3)-alkyl;
bm is zero,1 or 2;
p iszero,1 or2;
k is zero or 1;
q 1,2,3,4,50r6;
R(10a), R(10b), R(11)and R(12) independently of one another are (C1-C8)-alkyl, (C3-C6)-alkenyl, -CnH2n-R(15) or (C1-C8)-perfluoroalkyl;
n is zero,1, 2, 3 or 4;
R(15) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(16)R(17);
R(16) and R(17) are H or C1-C4-alkyl;
or R(10b), R(11)and R(12) are hydrogen;
R(10c) and R(13) independently are hydrogen or (C1-C4)-alkyl;
or R(1 Ob) and R(10c) and R(12) and R(13) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are (C1-C8)-alkyl, -CalH2alR(18) or (C3-C8)-alkenyl;
al is zero, 1 or 2;
R(18) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(1 9a)R(1 9b);
R(1 9a) and R(1 9b) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
10 or R(3), R(4), R(5), R(6) and R(7) independently of one another are (C1-Cg)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino or dimethylamino;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are o r ~ b- ( ~CHOH:) ~o~~ -H~OH ) ,~ - R~ ~ 2 Y is oxygen, -S-or-NR(22)-;
h, ad, ah independently of one another are zero or 1;
i,j,k,ae,af,ag,ao,apandak independently of one another are zero, 1, 2, 3 or 4;

but where in each case h, i and k are not simultaneously zero, ad, ae and ag are not simultaneously zero, and ah, ao and ak are not simultaneously zero, R(23), R(24) R(25) and R(22) independently of one another are hydrogen or (C1-C3)-alkyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are SR(29), -OR(30), -NR(31)R(32) or -CR(33)R(34)R(35);
R(29), R(30), R(31) and R(33) independently of one another are -CaH2a-(C1-Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
a is zero,1 or 2;
R(32), R(34) and R(35) independently of one another are defined as R(29) or are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are R(96), R(97) and R(98) independently of one another are (C1-Cg)-heteroaryl, which is linked via C or N and which is unsubstitued or substituted by 1 to 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino, dimethylamino or benzyl;
W is oxygen, S or NR(36)-;
R(36) is H or (C1-C4)-alkyl;

CA 02241~31 1998-06-2~

or R(3), R(4), R(5), R(6) and R(7) independently of one another are R(46)X(1)-;
X(1) is oxygen, S, NR(47), (D=O)A- or NR(48)C=MN(*)R(49)-;
M is oxygen or sulfur;
A is oxygen or NR(50);
D is C or SO;
R(46) is (C1-C8)-alkyl, (C3-C8)-alkenyl, (CH2)bCdF2d+1 or-CxH2x R(51);
b iszeroor1;
d is1,2,3,4,5,6Or7;
x is zero,1, 2, 3 or 4;
R(51) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(52)R(53);
R(52) and R(53) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(47), R(48) and R(50) independently are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(49) is defined as R(46);
or R(46) and R(47), or R(46) and R(48) together are 4 or 5 methylene groups, of which one CH2 groups can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
where A and N(*) are bonded to the phenyl nucleus of the heteroaroylguanidine parent structure;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are -SR(64), -OR(65), -NHR(66), -NR(67)R(68), -CHR(69)R(70) or-CR(54)R(55)0H, -C-CR(56), -CA 02241~31 1998-06-2~

CR(58)=CR(57) or -[CR(59)R(60)]U-CO-[CR(61)R(62)]v-R(63);
R(64), R(65), R(66), R(67) and R(69) identically or differently are -(cH2)y-(cHoH)z-(cH2)aa-(cHoH)t-R(71) or -(cH2)ab-o-(cH2-cH2o)ac-R(72);
R(71), and R(72) independently of one another are hydrogen or methyl;
u is1,2,3Or4;
v iszero,1, 2, 3Or4;
y, z, aa identically or differently are zero,1, 2, 3 or 4;
t is1,2,3Or4;
R(68), R(70), R(54) and R(55) identically or differently are hydrogen or (C1-C6)-alkyl;
or R(69) and R(70), or R(54) and R(55) together with the carbon atom carrying them are (C3-C8)-cycloalkyl;
R(63) is hydrogen, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or -CeH2e-R(73);
e is zero,1, 2, 3 or 4;
R(56), R(57) and R(73) independently are phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(74)R(75);
R(74) and R(75) are hydrogen or (C1-C4)-alkyl;
or R(56), R(57) and R(73) independently are (C1-Cg)-heteroaryl, which is unsubstituted or substituted as phenyl;
R(58), R(59), R(60), R(61) and R(62) are hydrogen or methyl;

CA 02241~31 1998-06-2~

or R(3), R(4), R(5), R(6) and R(7) independently of one another are R(76)-NH-SO2-;
R(76) is R(77)R(78)N-(C=Y')-;
Y' isoxygen, S orN-R(79);
R(77) and R(78) identically or differently are hydrogen, (C1-C8)-alkyl, (C3-C6)-alkenyl or-CfH2fR(80);
f is zero, 1, 2, 3 or 4;
R(80) is (C5-C7)-cycloalkyl or phenyl, which [lacuna]
unsubstituted [lacuna] by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methoxy and (C1-C4)-alkyl;
or R(77) and R(78) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
R(79) is defined as R(77) or is amidine;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are NR(84a)R(85), OR(84b), SR(84c) or -CnH2n-R(84d);
n iszero,1,2,3Or4;
R(84d) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(16)R(17);
R(16) and R(17) are hydrogen, or C1-C4-alkyl;
R(84a), R(84b), R(84c) and R(85) independently of one another are hydrogen, (C1-C8)-alkyl, (C~-Cg)-perfluoroalkyl or (CH2)aX-R(84g);
ax is zero, 1, 2, 3 or 4;

R(84g) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(84u)R(84v);
R(84u) and R(84v) are hydrogen or C1-C4-alkyl;
or R(84a) and R(85) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl, and their pharmaceutically tolerable salts;
(HOE 94/F 134 - EP-Offenlegungsschrift 686 627, NZ 272 103) z) benzoylguanidines of the formula I

in which:
R(1) is R(6)-SOm;
m is zero,1 or 2;
R(6) is perfluoroalkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, which is straight-chain or branched;
R(2) and R(3) independently of one another are hydrogen, F, Cl, Br, l, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms or phenoxy, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, methyl and methoxy;
or R(2) and R(3) independently of one another are pyrrol-1-yl, pyrrol-2-yl- or pyrrol-3-yl, which is not substituted or is substituted by 1 to 4 substituents selected from the group consisting of F, Cl, Br, I, CN, alkanoyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxycarbonyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, formyl, carboxyl, CF3, methyl and methoxy;
R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2 or 3 carbon atoms, F, Cl, Br, I, CN, OR(7), NR(8)R(9) or-(CH2)n-(CF2)O-CF3;
R(7), R(8) and R(9) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
n is zero or 1;
o is zero, 1 or 2;
and their pharmacologically acceptable salts;
(HOE 94/F 168 - EP-Offenlegungsschrift 690 048, NZ 272 373) ab) phenyl-substituted alkenylcarboxylic acid guanidides, carrying perfluoroalkyl groups, of the formula I

~t~:'l' ~

~ ~ ' R(S) /~ R(C3~ 0 i N~ H2 '~ R(A)R(B) - ~

in which:
R(A) is hydrogen, F, Cl, Br, I, CN, OH, OR(6), (C1-C8)-alkyl, Or(CH2)aCbF2b+1, (C3-C8)-cycloalkyl or NR(7)R(8);

CA 02241~31 1998-06-2~

r is zero or 1;
a iszero, 1, 2, 30r4;
b is1,2,3,4,5,6,70r8;
R(6) is (C1-C8)-alkyl, (C1-C4)-perfluoroalkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl;
where the aromatics are not substituted or are substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(1 0);
R(9) and R(10) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(7) and R(8) independently of one another are defined as R(6);
or R(7) and R(8) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
R(B) independently is defined as R(A);
20 X iszero, 1 or2;
Y is zero, 1 or 2;
R(C) is hydrogen, F, Cl, Br, I, CN, OR(12), (C1-C8)-alkyl, Op(CH2)fCgF29+
or (C3-C8)-cycloalkyl;
p iszeroor1;
f iszero, 1, 2, 30r4;
g is1,2,3,4,5,6,70r8;
R(1 2) is (C1-C8)-alkyl, (C1-C4)-perfluoroalkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl;
where the aromatics phenyl or benzyl are not substituted or are substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxyand NR(13)R(14);
R(13) and R(14) CA 0224l~3l l998-06-2~

independently of one another are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(D) independently is defined as R(C), R(1) is hydrogen, (C1-C8)-alkyl~ -Ot(CH2)dCeF2e+1~ (C3-Cg)-cycloalkyl~ F~
Cl, Br, l or CN;
t is zero or 1;
d is zero,1, 2, 3 or 4;
e is1,2,3,4,5,6,7Or8;
R(2), R(3), R(4) and R(5) independently of one another are defined as R(1);
but with the condition that at least one of the substituents R(A), R(B), R(C), R(D), R(1), R(2), R(4) or R(5) is a Or(CH2)aCbF2b+1~ Op(CH2)fCgF29~1 or Ot(CH2)dCeF2e+1 group and R(3) is not a Ot(CH2)dCeF2e+1 group;
and their pharmaceutically tolerable salts;
(HOE 94/F 182 - EP-Offenlegungsschrift 690 048, NZ 272 449) ac) ortho-amino-substituted benzoylguanidines of the formula I

R(2) R(3)~R(l) R(~,) ~N~NH2 R(S) O NH2 in which:
R(1) is NR(50)R(6), R(50) and R(6) independently of one another are hydrogen, (C1-C8)-alkyl or (C1-C8)-perfluoroalkyl;
R(2), R(3), R(4) and R(5) independently of one another are R(1 O)-SOa-, R(11)R(12)N-CO-, R(13)-CO- or R(14)R(15)N-SO2-;
a is zero,1 or 2, R(10), R(11), R(12), R(13), R(14) and R(15) independently of one another are (C1-C8)-alkyl, (C1-C8)-CA 02241~31 1998-06-2~

perfluoroalkyl, (C3-C6)-alkenYI ~r~CabH2ab~R(16);
ab is zero,1, 2, 3 or 4;
R(16) is (C3-C7)-cycloalkyl, phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy or NR(17)R(18);
R(17) and R(18) independently of one another are H, CF3 or (C1-C4)-alkyl;
or R(11), R(12), and also R(14)and R(15) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
or R(11), R(12), R(14)and R(15) independently of one another are hydrogen;
or R(2), R(3), R(4) and R(5) independently of one another are SR(21), -OR(22), -NR(23)R(24) or -CR(25)R(26)R(27);
R(21), R(22), R(23) and R(25) independently of one another are -CbH2b-(C1-Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
b is zero,1 or 2;
R(24), R(26) and R(27) independently of one another are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(2), R(3), R(4) and R(5) independently of one another are hydrogen, F, Cl, Br, l, CN, -(xa)dg-cdaH2da+1~ -(Xb)dh-(CH2)db-CdeF2de+1, (C3-C8)-alkenyl or CA 02241~31 1998-06-2~

-CdfH2dfR(30);
(Xa) is O, S or NR(33);
R(33) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
dg iszeroor 1;
(Xb) is O, S or NR(34);
R(34) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
dh is zero or 1;
da iszero,1,2,3,4,5,6,7,8;
db is zero, 1, 2, 3, 4;
de iszero, 1,2,3,4,5,6,7;
df iszero,1,2,3,4;
R(30) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics phenyl, biphenylyl or naphthyl are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(31 )R(32);
R(31 ) and R(32) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(2), R(3), R(4) and R(5) independently of one another are NR(40)R(41 ) or -(Xe)-(CH2)ebR(45);
R(40) and R(41 ) independently of one another are hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl or (CH2)e-R(42);
e is zero, 1, 2, 3 or 4;
R(42) is (C3-C7)-cycloalkyl, phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(43)R(44);

CA 02241~31 1998-06-2~

R(43) and R(44) independently of one another are H, CF3 or (C1 -C4)-alkyl;
or R(40) and R(41) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
(Xe) is O, S or NR(47);
R(47) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
eb iszero,1, 2, 3Or4;
R(45) is (C3-C7)-cycloalkyl, phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy, NR(50)R(51) and -(xfa)-(cH2)ed-(xfb)R(46);
Xfa is CH2, O, S or NR(48);
Xfb is O, S or NR(49);
ed is1,2,3Or4;
R(46) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(48), R(49), R(50) and R(51) independently of one another are H or (C1-C4)-alkyl or (C1 -C4)-perfluoroalkyl;
where R(3) and R(4), however, cannot be hydrogen, and their pharmaceutically tolerable salts;

HOE 94/F 265 - NZ 272 946, EP-Offenlegungsschrift 700 904) ad) benzoylguanidines of the formula I
, . , . ,, ~, . , .. ,, ~, ~, . . . . .

10 in which:
one of the three substituents R(1), R(2) and R(3) is (C1-Cg)-heteroaryl-N-oxide, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or one of the three substituents R(1), R(2) and R(3) is -SR(10), -OR(10), -NR(10)R(11) or -CR(10)R(11)R(12);
R(10) is -CaH2a-(C1-Cg)-heteroaryl-N-oxide, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting [lacuna] F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
a is zero,1 or 2;
R(11) and R(12) independently of one another are defined as R(10), are hydrogen or (C1-C4)-alkyl;~0 and the other substituents R(1), R(2) and R(3) in each case independently of one another are (C1-C8)-alkyl, (C2-C8)-alkenyl or -CmH2mR(14);
m is zero,1 or 2;
R(14) is (C3-C8)-cycloalkyl or phenyl, CA 02241~31 1998-06-2~

which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(15)R(16), R(15) and R(16) are hydrogen or CH3;
or the other substituents R(1), R(2) and R(3) in each case independently of one another are hydrogen, F, Cl, Br, l, -C-N, X-(CH2)p-(CqF2q+1), R(22)-SOU, R(23)R(24)N-CO, R(25)-CO- or R(26)R(27)N-s02-~
where the perfluoroalkyl group is straight-chain or branched;
X is a bond, oxygen, S or NR(28);
u is zero,1 or 2;
p iszero,1 or2;
q iszero,1,2,3,4,5Or6;
R(22), R(23), R(25) and R(26) independently are (C1-C8)-alkyl, (C2-C6)-alkenyl, -cnH2n-R(29) or CF3;
n iszero,1,2,3Or4;
R(28) is hydrogen or (C1-C3)-alkyl;
R(29) is (C3-C7)-cycloalkyl or phenyl;
which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(30)R(31);
R(30) and R(31) are hydrogen or C1-C4-alkyl, or R(23), R(25) and R(26) are also hydrogen;
R(24) and R(27) independently of one another are hydrogen or (C1-C4)-alkyl;
or CA 02241~31 1998-06-2~

R(23) and R(24), and also R(26) and R(27) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
or the other substituents R(1), R(2) and R(3) in each case independently of one another are OR(35) or NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or (C1-C6)-alkyl;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl, R(4) and R(5) independently of one another are hydrogen, (C1-C4)-alkyl, F, Cl, -OR(32), -NR(33)R(34) or CrF2r+1;
R(32), R(33) and R(34) independently of one another are hydrogen or (C1-C3)-alkyl;
r is 1, 2,3 or 4;
and their pharmaceutically tolerable salts;
(HOE 94/F 266 - EP-Offenlegungsschrift 702001, NZ 272948) ad) benzoylguanidines of the formula I
R(l ) 2s ~ ( 2 )~, N=~ H 2 R(4) ~
30 in which:
R(1) is hydrogen, F, Cl, Br, I, CN, NO2, OH, (C1-C8)-alkyl, (C3-C8)-cycloalkyl~ Oa-(cH2)b-(cF2)c-cF3;
a is zero or 1;
b is zero, 1 or 2;

CA 02241~31 1998-06-2~

c iszero,1,20r3;
or R(1 ) is R(5)-SOm or R(6)R(7)N-SO2-;
m is zero, 1 or 2;
R(5) and R(6) independently of one another are (C1-C8)-alkyl, (C3-C6)-alkenyl, CF3 or-CnH2n-R(8);
n iszero, 1, 2, 30r4;
R(7) is hydrogen or (C1-C4)-alkyl;
R(8) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) independently of one another are hydrogen or (C1-C4)-alkyl;
or R(6) is H;
or R(6) and R(7) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl, 20 or R(1 ) is -SR(11), -OR(11 ) or -CR(11 )R(1 2)R(13);
R(11) is-cpH2p-(c3-c8)-cycloalkyl~-(C1-Cg)-heteroarylorphenyl, where the aromatic systems are unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(12), R(13) independently of one another are defined as R(11 ) or are hydrogen or (C1-C4)-alkyl;
p is zero, 1 or 2;
or R(1) is phenyl, naphthyl, biphenylyl or (C1-Cg)-heteroaryl, the latter linked via C or N, CA 02241~31 1998-06-2S

which are unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(2) is-CF2R(14),-CF[R(15)][R(16)],-CF[(CF2)q-CF3)][R(15)], -C[(CF2)r-CF3]=CR(15)R(16);
R(14) is (C1-C4)-alkyl or (C3-C6)-cycloalkyl;
R(15) and R(16) independently of one another are hydrogen or (C1-C4)-alkyl;

q is zero,1 or2;
r is zero,1 or 2;
R(3) is defined as R(1);
R(4) is hydrogen, (C1-C3)-alkyl, F, Cl, Br, l, CN, -(CH2)s-(CF2)t-CF3;
s is zero or 1;
t iszero,1 or2;
and their pharmaceutically tolerable salts;
(HOE 94/F 267 - EP-Offenlegungsschrift 700 899, NZ 272 947) af) benzoylguanidines of the formula I

~;~

in which: -one of the three substituents R(1), R(2) and R(3) is -Y4-[(CH2)k-CHR(7)-(C=O)R(8)]-phenyl, -Y-3-(CH2)k-CHR(7)-(C=O)R(8)]-phenyl or -Y-2-[(CH2)k-CHR(7)-(C=O)R(8)]-pheny~, where the phenyl in each case is unsubstituted or substituted by 1 - 2 substituents from the group F, Cl, -CF3, methyl, hydroxyl, methoxy, or-NR(37)R(38);
R(37) and R(38) CA 02241~31 1998-06-2~

independently of one another are hydrogen or -CH3;
Y is a bond, oxygen, -S- or-NR(9);
R(9) is hydrogen or-(C1-C4)-alkyl;
R(7) is -OR(10) or -NR(10)R(11);
R(10) and R(11) independently of one another are hydrogen, -(C1-C8)-alkyl, -(C1 -C8)-alkanoyl, -(C1 -C8)-alkoxycarbonyl, benzyl, benzyloxycarbonyl;
or R(10) is trityl;
R(8) is -OR(12) or -NR(12)R(13);
R(12) and R(13) independently of one another are hydrogen, -(C1-C8)-alkyl or benzyl;
k is zero,1, 2, 3 or4;
and the other radicals R(1), R(2) and R(3) in each case independently of one another are -(C1-C8)-alkyl, -(C2-C8)-alkenyl or -(CH2)mR(14);
m is zero,1 or 2;
R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) are hydrogen or-CH3;
or the other radicals R(1), R(2) and R(3) in each case independently of one another are R(18)R(19)N-(C=Y')-NH-SO2-;
Y' is oxygen, -S- or-N-R(20);
R(18) and R(19) independently of one another are hydrogen, -(C1-C8)-alkyl, -(C3-C6)-alkenyl or-(CH2)t-R(21);
t is zero,1, 2, 3 or 4;
R(21) is -(C5-C7)-cycloalkyl or phenyl, CA 02241~31 1998-06-2~

which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methoxy and -(C1-C4)-alkyl;
or R(18) and R(19) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -N-CH3 or -N-benzyl;
R(20) is defined as R(18) or is amidine;
or the other radicals R(1), R(2) and R(3) in each case independently of one another are hydrogen, F, Cl, Br, l, -C- N, X-(CH2)p-(CqF2q+1), R(22)-SOU-, R(23)R(24)N-CO-, R(25)-CO- or R(26)R(27)N-SO2-, where the perfluoroalkyl group is straight-chain or branched;
X is a bond, oxygen, -S- or-NR(28);
u is zero,1 or 2;
p is zero, 1 or 2;
q is 1, 2, 3, 4, 5 or 6;
R(22), R(23), R(25) and R(26) independently of one another are -(C1-C8)-alkyl, ~ -(C3-c6)-alkenYl~ -(CH2)n-R(29) or -CF3;
n iszero,1,2,3Or4;
R(28) is hydrogen or-(C1-C3)-alkyl;
R(29) is -(C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl, methoxy and -NR(30)R(31);
R(30) and R(31) are hydrogen or-(C1-C4)-alkyl;
or R(23), R(25) and R(26) are hydrogen;

CA 02241~31 1998-06-2~

R(24) and R(27) independently of one another are hydrogen or -(C1-C4)-alkyl;
or R(23) and R(24), and also R(26) and R(27) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, - N-CH3 or -N-benzyl;
or the other radicals R(1), R(2) and R(3) in each case independently of one another are -OR(35) or -NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or -(C1-C6)-alkyl;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -N-CH3 or -N-benzyl;
R(4) and R(5) independently of one another are hydrogen, -(C1-C4)-alkyl, F, Cl, -OR(32), -NR(33)R(34) ~r~CrF2r+1;
R(32), R(33) and R(34) independently of one another are hydrogen or -(C1-C3)-alkyl;
r is 1, 2, 3 or 4;
and their pharmaceutically tolerable salts;
(HOE 94/F 352 - EP-Offenlegungsschrift 713 684, NZ 280 517) ag) benzoylguanidines of the formula I
R(l ) R ( 3 ~ N H 2 R ( 4 ) O
in which:
R(1) is R(6)-CO or R(7)R(8)N-CO;
R(6) is (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl CA 0224l~3l l998-06-2~

or -CnH2n-R(9), n iszero,1, 2, 30r4;
R(9) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(10)R(11), R(10) and R(11) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(7) is H, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or-CnH2n-R(12);
n is zero,1, 2, 3 or 4;
R(12) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(13)R(14);
R(13) and R(14) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(8) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(7) and R(8) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(2) is defined as R(1), or is H, OH, F, Cl, Br, l, CN, NO2, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or-CnH2nR(15);
n iszero, 1, 2, 30r4;
R(15) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, CA 02241~31 1998-06-2~

where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(16)R(17);
R(16) and R(17) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(2) is (C1-Cg)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(2) is SR(18), -OR(18), -NR(18)R(19) or-CR(18)R(19)R(20);
R(18) -is CaH2a-(C1-Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino, dimethylamino;
a is zero, 1 or 2;
R(19) and R(20) independently of one another are defined as R(18) or are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(2) is R(21 )-S~m or R(22)R(23)N-SO2-;
m is1Or2;
R(21 ) is (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CnH2n-R(24);
n iszero,1,2,3Or4;

R(24) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(27)R(28);

CA 02241~31 1998-06-2~

R(27) and R(28) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(22) is H, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CnH2n-R(29);
n is zero, 1, 2, 3 or 4;
R(29) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(30)R(31);
R(30) and R(31) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(23) is hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(22) and R(23) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
or R(2) is R(33)X-;
X is oxygen, S, NR(34), (D=O)A- or NR(34)C=MN(~)R(35)-;
M is oxygen or S;
A is oxygen or NR(34);
D is C or SO;
R(33) is (c1-c8)-alkyl~ (c3-c8)-alkenyl~ (CH2)bCdF2d+1 or -CnH2n-R(36);
b iszeroor1;
d is 1, 2, 3, 4, 5, 6 or 7;
n iszero,1,2,3,or4;
R(36) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are CA 02241~31 1998-06-2~

substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(37)R(38);
R(37) and R(38) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(34) is hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(35) is defined as R(33);
or R(33) and R(34) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
where A and N(*) are bonded to the phenyl nucleus of the benzoylguanidine parent structure;
or R(2) is -SR(40), -OR(40), -NHR(40), -NR(40)R(41), -CHR(40)R(42), -CR(42)R(43)0H, -C-CR(45), -CR(46)=CR(45) or -[CR(47)R(48)]U-CO-[C(R49)R(50)~V-R(44);
R(40) and R(41) independently of one another are ~(CH2)p~(CHOH)q~(CH2)r~
(CHOH)t-R(51) or ~(CH2)p~O~(CH2~CH2O)q~R(51);
R(51) is hydrogen or methyl;
u is 1, 2, 3 or 4;
v iszero,1,2,3Or4;
p, q and r independently of one another are zero,1, 2, 3 or 4;
t is 1, 2, 3 or 4;
R(42) and R(43) independently of one another are hydrogen or (C1-C6)-alkyl;
or R(42) and R(43) together with the carbon atom carrying them are a (C3-C8)-cycloalkyl;

CA 02241~31 1998-06-2~

R(44) is hydrogen, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, -CeH2e-R(45);
e is zero, 1, 2, 3 or 4;
R(45) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(52)R(53);
R(52) and R(53) are H or (C1-C4)-alkyl;
or R(45) is(C1-Cg)-heteroaryl, which is unsubstituted or substituted as phenyl;
or R(45) is (C1-C6)-alkyl, which is unsubstituted or substituted by 1 - 3 OH;
R(46), R(47), R(48), R(49) and R(50) independently of one another are hydrogen or methyl;
or R(2) is R(55)-NH-SO2-;
R(55) is R(56)R(57)N-(C=Y)-;
Y is oxygen, S orN-R(58);
R(56) and R(57) independentiy of one another are hydrogen, (C1-C8)-alkyl, (C3-C6)-alkenyl or-CfH2fR(59);
f iszero,1,2,3Or4;
R(59) is (C5-C7)-cycloalkyl, phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methoxy and (C1-C4)-alkyl;
or R(56) and R(57) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(58) CA 02241~31 1998-06-2~

is defined as R(56) or is amidine;
R(3), R(4) and R(5) are independently of one another defined as R(1) or R(2), but where at least one of the substituents R(2), R(3), R(4) and R(5) must be OH;
5 and their pharmaceutically tolerable salts;
(HOE 95/F 007 K - EP-Offenlegungsschrift 723 956, NZ 280 887) ah) benzoylguanidines of the formula I

R(l ) R ( 2 ) ~ R ( S ) R ( 3 ) J~N~ NH2 R ( ~ ) ~ NH2 15 in which:
one of the three substituents R(1), R(2) and R(3) is R(6)-A-B-D-;
R(6) is a basic protonatable radical, i.e. an amino group -NR(7)R(8), an amidino group R(7)R(8)N-C[=N-R(9)]- or a guanidino group R(7) R( l 0) R ( 8 ) --N~N' R ( 9 ) R(7), R(8), R(9) and R(10) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(7) and R(8) together are CaH2a;
a is 4, 5, 6 or 7;
where if a = 5, 6 or 7 a methylene group of the group CA 02241~31 1998-06-2~

CaH2a can be replaced by a heteroatom group O, S~m or NR(11), or R(8) and R(9) or R(9) and R(10) or R(7) and R(10) are a group CaH2a;
a is2,3,4Or5;
where if a = 3, 4 or 5 a methylene group of the group CaH2a can be replaced by a heteroatom group O, S~m or NR(11);
m iszero,1 or2;
R(11) is hydrogen or methyl;
or R(6) is a basic heteroaromatic ring system having 1 - 9 carbon atoms;
A is CbH2b;
b is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
where in the group CbH2b one or two methylene groups can be replaced by one of the groupings selected from the group consisting of -O-, -CO-, -CH[OR(20)]-, ~SOm~~ -NR(20)-, -NR(20)-CO-, -NR(20)-CO-NH-, -NR(20)-CO-NH-SO2-( ~ ) a a - R ( 2 0 ) N -S -I NR( 1 9 ) I bb and -SOaa[NR(1 9)]bb-;
and where in the group CbH2b a methylene group can be replaced by -CH-R(99), where R(99) together with R(7) forms a pyrrolidine or piperidine ring;
aa is 1 or2;
bb is 0 or 1;
aa + bb = 2;
R(19) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;

CA 02241~31 1998-06-2~

R(20) is hydrogen or methyl;
B is a phenylene or naphthylene radical R( l 2) R( l 2) 5 ~$

R( 1 3) ~p R ( 1 3 ) R(12) and R(13) independently of one another are hydrogen, methyl, F, Cl, Br, I, CF3 or-SOw-R(14);
R(14) is methyl or NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
w is zero, 1 or 2;
D iS-cdH2d-xf;
d is zero, 1, 2, 3 or 4;
X is -O-, -CO-, -CH[OR(21)]-, ~SOm~ or -NR(21)-;
f is zero or 1;
R(21 ) is hydrogen or methyl;
m is zero, 1 or 2;
and the other substituents R(1 ) and R(2) and R(3) in each case independently of one another are hydrogen, F, Cl, Br, I, -CN, -(C1-C8)-alkyl, -(C2-C8)-alkenyl, -NR(35)R(36) or R(17)-CgH29~Zh~;
g is zero, 1, 2, 3 or 4;
h is zero or 1;
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or CA 02241~31 1998-06-2~

R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
Z is -O-, -CO-, -SOv- ,-NR(18)-, -NR(18)-CO-, -NR(18)-CO-NH-or -NR(18)-SO2-;
R(18) is hydrogen or methyl;
v is zero, 1 or 2;
R(17) is hydrogen, cycloalkyl having 3, 5 or 6 carbon atoms or CkF2k+1 -;
k is1,2Or3, or R(17) is pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, l,-CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl and methoxy;
or R(17) -is (C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, hydroxyl, methoxy, -NR(37)R(38), CH3SO2- and H2NO2S-;
R(37) and R(38) are hydrogen or-CH3;
R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(32), -NR(33)R(34) or-CrF2r+1;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2 or 3 carbon atoms;
r is 1, 2, 3 or 4;
and their pharmacologically tolerable salts;
(HOE 95/F 072 - EP-Offenlegungsschrift 738 712, NZ 286 380 CA 02241~31 1998-06-2~

ai) indenoylguanidines of the formula I

R(3)R(2) ~-R(8) ~ 1 / R(9) x A

R(6)R(l) R(7) R(10) in which:
R(1 ) and R(2) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms. O-Alkyl having 1, 2, 3 or 4 carbon atoms, O-C(=O)-alkyl having 1, 2, 3 or 4 carbon atoms or CmH2m-NR(1 2)R(13);
R(12) and R(13) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
m is zero, [lacuna] 2, 3 or 4;
NH-C(=O)-NH2, C(=O)-O-alkyl having 1, 2, 3 or 4 carbon atoms, C(=O)-NH2, C(=O)-NH-alkyl having 1, 2, 3 or 4 carbon atoms, C(=O)-N(alkyl)2 having 1, 2, 3 or 4 carbon atoms in each alkyl group, alkenyl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, alkynyl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, alkylaryl having 1, 2, 3 or 4 carbon atoms in the alkyl group, alkenylaryl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms in the alkenyl group, alkynylaryl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms in the alkynyl group, C1-C4-alkyl-substituted aryl, C1-C4-alkylheteroaryl, C1-C4-alkenylheteroaryl, aminoalkylaryl having 1, 2, 3 or 4 carbon atoms in the alkyl group, substituted aryl, heteroaryl and substituted heteroaryl;
R(3), R(4), R(5) and R(6) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, O-alkyl having 1, 2, 3, 4, 5, 6, 7, 8, CA 0224l~3l l998-06-2~

9 or 10 carbon atoms, halogen, (such as F, Cl, Br, I), OH, aryl, substituted aryl, heteroaryl, substituted heteroaryl, O-lower alkyl, O-aryl, O-lower alkylaryl, O-substituted aryl, O-lower alkyl-substituted aryl, O-C(=O)-C1-C4-alkylaryl, O-C(=O)-NH-C~-C4-alkyl, O-C(=O)-N(C1-C4-alkyl)2, N02, CN, CF3, NH2, NH-C(=O)-C1-C4-alkyl, NH-C(=O)-NH2, COOH, C(=O)-O-C~-C4-alkyl, C(=O)-NH2, C(=O)-NH-C1-C4-alkyl, C(=O)-N(C1-C4-alkyl)2, C1-C4-COOH, C1-C4-alkyl-C(=O)-O-C1-C4-alkyl, SO3H, S02-alkyl, SO2-alkylaryl, SO2-N-(alkyl)2, S02-N(alkyl)(alkylaryl), C(=O)-R(11), C1-C10-alkyl-C(=O)-R(11), C2-C10-alkenyl-C(=O)-R(11), C2-C10-alkynyl-C(=O)-R(11), NH-C(=O)-C1-C10-alkyl-C(=O)-R(11), 0-C,-C, 1-alkyl-C(=O)-R(1 1 );
R(11 ) is C1-C4-alkyl, C1-C4-alkynyl, aryl, substituted aryl, NH2, NH-C1-C4-alkyl, N-(C1-C4-alkyl)2, S03H, SO2-alkyl, SO2-alkylaryl, S02-N-(alkyl)2, SO2-N(alkyl)(alkylaryl);
X isO,SorNH;
R(7), R(8), R(9) and R(10) independently of one another are hydrogen, alkyl, cycloalkyl, aryl, alkylaryl;
or R(8) and R(9) together are part of a 5, 6 or 7-membered heterocyclic ring;
A is absent or is a nontoxic organic or inorganic acid.
(HOE 95/F 109 - EP 748 795, NZ 286 583) ak) benzyloxycarbonylguanidines of the formula I

R ( l ) R ( 2 ) ~ R ( S ) R ( 3 ) J~X~N~ N H 2 R ( 4 ) R ( 6 ) \ ~ N H 2 R ( 7 ) in which:
R(1), R(2) and R(3) independently of one another are -Y-[4-R(8)-phenyl], -Y-[3-R(8)-phenyl] or-Y-[2-R(8)-phenyl], CA 02241~31 1998-06-2~

where the phenyl is in each case unsubstituted or substituted by 1 - 2 substituents from the group consisting of F, Cl, -CF3, methyl, hydroxyl, methoxy and -NR(96)R(97);
R(96) and R(97) independently of one another are hydrogen or -CH3;
Y is a bond, CH2, oxygen, -S- or-NR(9);
R(9) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(8) is SOa[NR(98)]bNR(99)R(10);
a is 1 or 2;
b isOor1;
a + b = 2;
R(98), R(99) and R(10) independently of one another are hydrogen, -(C1-C8)-alkyl, benzyl, -(C2-C8)-alkylene-NR(11)R(12), (C2-C8)-alkylene-NR(13)-(C2-C8)-alkylene-NR(37)R(38) or (CO-C8)-alkylene-CR(39)R(40)CR(41 )R(42)(Co-C8)-alkylene-NR(43)R(44);
R(11), R(12), R(13), R(37), R(38), R(43) and R(44) independently of one another are hydrogen, -(C1-C8)-alkyl or benzyl:
R(39), R(40), R(41) and R(42) independently of one another are hydrogen, -(C1-C8)-alkyl or-(CO-C3)-alkylenephenyl, where the phenyl is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl,-CF3, methyl and methoxy;
or R(99) and R(10) together are 4 - 6 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -N-CH3 or -N-benzyl;
or R(8) is SOa[NR(98)]bNR(95)-C[=N-R(94)]-NR(93)R(92);

CA 02241~31 1998-06-2~

R(92), R(93), R(94) and R(95) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(1), R(2) and R(3) independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, I, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl, methoxy;
or R(1), R(2) and R(3) independently of one another are hydrogen, -(C1-C8)-alkyl, -(C2-C8)-alkenyl or-(CH2)mR(14);
m is zero, 1 or 2;
R(14) is-(C3-C8)-cycloalkylorphenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and -Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) are hydrogen or-CH3;
or R(1), R(2) and R(3) independently of one another are -Q4-[(CH2)k-CHR(17)-(C=O)R(20)]-phenyl, -Q-3-(CH2)k-CHR(17)-(C=O)R(20)]-phenyl or -Q-2-~(CH2)k-CHR(1 7)-(C=O)R(20)]-phenyl, where the phenyl in each case is unsubstituted or substituted by 1 - 2 substituents from the group F, Cl, -CF3, methyl, hydroxyl, methoxy and -NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or -CH3;
Q is a bond, oxygen, -S- or-NR(18);
R(18) is hydrogen or-(C1-C4)-alkyl;

CA 02241~31 1998-06-2~

R(17) is -OR(21) or -NR(21)R(22);
R(21) and R(22) independently of one another are hydrogen, -(C1-C8)-alkyl, -(C1 -C8)-alkanoyl, -(C1 -C8)-alkoxycarbonyl, benzyl, benzyloxycarbonyl;
or R(21) istrityl;
R(20) is -OR(23) or -NR(23)R(24);
R(23), R(24) independently of one another are hydrogen, -(C1-C8)-alkyl or benzyl;
k iszero,1,2,3cr4;
or R(1), R(2) and R(3) independently of one another are (C1-Cg)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents from the group F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(1), R(2) and R(3) are -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is-CfH2f(C1-Cg)-heteroaryl~
which is unsubstituted or substituted by 1 - 3 substituents from the group F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
f is zero, 1 or 2;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or (C1-C4)-alkyl, or R(1), R(2) and R(3) independently of one another are (C1-Cg)-heteroaryl-N-oxide, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group CA 02241~31 1998-06-2~

consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(1), R(2) and R(3) independently of one another are -SR(28), -OR(28), -NR(28)R(29) or -CR(28)R(29)R(30);
R(28) is-CgH29-(C1-Cg)-heteroaryl-N-oxide, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
g is zero,1 or 2;
R(29), R(30) independently of one another are defined as R(28), hydrogen or (C1-C4)-alkyl;
or R(1), R(2) and R(3) independently of one another are hydrogen, F, Cl, Br, l, -C-N, T-(CH2)h-(CjF2j+1), R(31)SOI-, R(32)R(33)N-CO-, R(34)-CO-or R(45)R(46)N-SO2, where the perfluoroalkyl group is straight-chain or branched;
T is a bond, oxygen, -S- or -NR(47);
is zero,1 or 2;
h is zero,1 or 2;
is 1, 2, 3, 4, 5 0r 6;
R(31), R(32), R(34) and R(45) independently of one another are -(C1-C8)-alkyl, -(C3-C6)-alkenyl, (CH2)nR(48) or-CF3;
n iszero,1,2,30r4;
R(47) is hydrogen or alkyl with 1, 2 or 3 carbon atoms;
R(48) is -(C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl, methoxy and CA 02241~31 1998-06-2~

-NR(49)R(50);
R(49) and R(50) are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(32), R(34) and R(45) are hydrogen;
R(33) and R(46) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(32) and R(33), and R(45) and R(46) together are 5 or 6 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
or R(1), R(2) and R(3) independently of one another are R(51)-A-G-D-;
R(51) is a basic protonatable radical, i.e. an amino group -NR(52)R(53), an amidino group R(52)R(53)N-C[=N-R(54)]-or a guanidino group R(52)R(53)N-C[=N-R(54)]-NR(55)-;
R(52), R(53), R(54) and R(55) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(52) and R(53) are a group C~H2~;
a is4,5,60r7;
where if a = 5, 6 or 7 a carbon atom of the group C~H2~ can be replaced by a heteroatom group 0, S~d or NR(56), or R(53) and R(54) or R(54) and R(55) or R(52) and R(55) are a group CyH2y;
y is2,3,40r5;

CA 02241~31 1998-06-2~

whereify=3,40r5acarbonatomofthegroup CyH2y can be replaced by a heteroatom group 0, S~d or NR(56);
d is zero,1 or 2;
R(56) is hydrogen or methyl;
or R(51) is a basic heteroaromatic ring system having 1 - 9 carbon atoms;
A is a group CeH2e;
e is zero,1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
where in the group CeH2e a carbon atom can be replaced by one of the groupings -O-, -CO-, -CH[OR(57)]-, -SOr-, -NR(57)-, -NR(57)-CO-, -NR(57)-CO-NH-, -NR(57)-CO-NH-S02- or -NR(57)-SO2-;
r is zero,1 or 2;
G is a phenylene radical R(58) R ( S 9 ) R(58) and R(59) independently of one another are hydrogen, methyl, methoxy, F, Cl, Br, l, CF3 or-SOs-R(60);
R(60) is methyl or NR(61)R(62);
R(61) and R(62) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
D is-cvH2v-Ew-;
v is zero,1, 2, 3 or 4;
E is -O-, -CO-, -CH[OR(63)]-, -SOaa- or -N R(63)-;
w is zero or 1;
aa is zero,1 or 2 R(63) is hydrogen or methyl, CA 02241~31 1998-06-2~

or R(1), R(2) and R(3) independently of one another are -CF2R(64), -CF[R(65)][R(66)], ~CF[(CF2)q~CF3)][R(65)] ~ -C[(CF2)p-CF3]=CR(65)R(66);
R(64) is alkyl having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms;
R(65) and R(66) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
q is zero,1 or 2;
p is zero,1 or 2;
or R(1), R(2) and R(3) independently of one another are -OR(67) or -NR(67)R(68);
R(67) and R(68) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(67) and R(68) together are 4, 5, 6 or 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, SO2, -NH-, -NCH3 or -N-benzyl;
R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(69), -NR(70)R(71) or-CzF2z+1;
R(69), R(70) and R(71) independently of one another are hydrogen or alkyl having 1, 2 or 3 carbon atoms;
z is1,2,30r4;
R(6) and R(7) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
X is oxygen or NR(72);
R(72) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;

CA 02241~31 1998-06-2~

(HOE 95/F 115 - EP 744 397, NZ 286 622) al) alkenylcarboxylic acid guanidides, carrying fluorophenyl groups, of the formula I
R(2) R(1 ) R ( 3 ) ~/ R ( 6 ) H
R ( ~ ) ~ N~yN~

R ( S ) H H

in which:
R(6) is hydrogen, (C1-C8)-alkyl, (C3-C8)-cycloalkyl or phenyl, where the phenyl group is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(7) independently is defined as R(6);
R(1), R(2), R(3), R(4) and R(5) independently of one another are hydrogen or F;
where, however, at least one of the radicals R(1), R(2), R(3), R(4) and R(5) must be fluorine;
and their pharmaceutically tolerable salts;
(HOE 95/F 167 - NZ 299 015) am) benzoylguanidines of the formula I
R(l ) R(2) ~
R ( 3 ) J~N~ NH2 ~ NH2 in which:
R(1) is R(4)~S0m or R(5)R(6)N-SO2-;

CA 02241~31 1998-06-2~

m is 1 or 2;
R(4) and R(5) independently of one another are alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 3, 4, 5 or 6 carbon atoms, CF3 or-CnH2n-R(7);
n iszero,1,2,30r4;
R(6) is H or alkyl having 1, 2, 3 or 4 carbon atoms;
R(7) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(8)R(9);
R(8) and R(9) are H or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(5) is also hydrogen;
or R(5) and R(6) together are 4 or 5 methylene groups, of which a CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
or R(1 ) is -Op~(CH2)q-(CF2)r-CF3;
p iszeroor1;
q is zero, 1 or 2;
r is zero, 1, 2 or 3;
or R(1 ) is -SR(10), -OR(10) or -CR(1 O)R(11 )R(12);
R(10), R(11)and R(12) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, -CsH2s-(C3-C8)-cycloalkyl or an aromatic system selected from the group consisting of pyridyl, pyrrolyl, quinolyl, isoquinolyl, imidazolyl or phenyl;

CA 02241~31 1998-06-2~

s is zero, 1 or 2;
where the aromatic systems pyridyl, pyrrolyl, quinolyl, isoquinolyl, imidazolyl and phenyl are unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(2) is-(cH2)u-(cF2)t-cF3;
t iszero,1,20r3;
u is zero or 1;
R(3) is hydrogen or independently is defined as R(1 );
and their pharmaceutically tolerable salts;
(HOE 95/F 173 - NZ 299 052) an) substituted cinnamic acid guanidides of the formula I
R ( 2 ) R ( 3 ) ~R (Rl()6 ) R ( ~ ) J~N~ N H 2 R ( 5 )R ( 7 )~ NH2 in which:
at least one of the substituents R(1), R(2), R(3), R(4) and R(5) is -Xa-Yb-Ln-U;
X is CR(16)R(17), O, S or NR(18);
R(16), R(17) and R(18) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
a iszeroor1;
Y is alkylene having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkylene-T having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group, T, T-alkylene having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group;
T is NR(20), O, S or phenylene, where the phenylene is not substituted or is CA 02241S31 1998-06-2~

substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(21)R(22);
R(20), R(21) and R(22) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
b is zero or 1;
L is O, S, NR(23) or CkH2k;
k is 1, 2, 3, 4, 5, 6, 7, 8;
n iszeroor1;
U is NR(24)R(25) or an N-containing heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms;
R(24) and R(25) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
or R(24) and R(25) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
where the N-containing heterocycles are N- or C-bridged and are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(27)R(28);
R(23), R(27) and R(28) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
and the other substituents R(1), R(2), R(3), R(4) and R(5) in each case independently of one another are H, F, Cl, Br, l, CN, -On-CmH2m+1, CA 02241~31 1998-06-2~

-Op-(CH2)s-CqF2q+1 or-CrH2rR(10);
n iszeroor1;
m is zero 1, 2, 3, 4, 5, 6, 7 or 8;
p iszeroor1;
q is1,2,3,4,5,6,70r8;
s is zero, 1, 2, 3 or 4;
r is zero, 1, 2, 3 or 4;
R(1 0) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, where the phenyl is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxyand NR(11)R(12);
R(11)and R(12) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
R(6) and R(7) independently of one another are hydrogen, F, Cl, Br, I, CN, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(14)R(15);
R(14) and R(15) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;~nd their pharmaceutically tolerable salts;

CA 02241~31 1998-06-2~

(HOE 95/F 220 - NZ 299 052) ao) benzoylguanidines of the formula I

R(l ) R(2) ~J~R(5) R ( 3 ) J~N~N H 2 R ( ~ ) 0 NH2 in which:
at least one of the substituents R(1), R(2) and R(3) is R(6)-C(OH)2-;
R(6) is perfluoroalkyl having 1, 2 or 3 carbon atoms, which is straight-chain or branched;
and the other substituents R(1), R(2) and R(3) independently of one another are hydrogen, OH, F, Cl, Br, l, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl with 3, 4, 5 or 6 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms or phenoxy, which is unsubstituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, methyl and methoxy;
or the other substituents R(1), R(2) and R(3) independently of one another are alkyl-SOx, -CR(7)=CR(8)R(9) or -C -- CR(9);
x is zero,1 or 2;
R(7) is hydrogen or methyl;
R(8) and R(9) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl and methoxy;

CA 02241S31 1998-06-2~

or the other substituents R(1), R(2) and R(3) independently of one another are phenyl, C6H5-(C1-C4)-alkyl, naphthyl, biphenylyl, quinolinyl, isoquinolinyl or imidazolyl, where quinolinyl, isoquinolinyl or imidazolyl are bonded via C
or N and where phenyl, C6H5-(C1-C4)-alkyl, naphthyl, biphenylyl, quinolinyl, isoquinolinyl and imidazolyl are unsubstituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or the other substituents R(1), R(2) and R(3) independently of one another are SR(10), -OR(10), -CR(10)R(11)R(12);
R(10) is-CfH2f(C3-C8)-cycloalkyl, quinolinyl, isoquinolinyl, pyridinyl, imidazolyl or phenyl, where the aromatic systems quinolinyl, isoquinolinyl, pyridinyl, imidazolyl and phenyl are unsubstituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
f is zero,1 or 2;
R(11) and R(12) independently of one another are defined as R(10), hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2 or 3 carbon atoms, F, Cl, Br, l, CN, OR(13), NR(14)R(15), -(CH2)n-(cF2)o-cF3;
R(13), R(14) and R(15) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
n iszeroor1;

CA 02241~31 1998-06-2~

o is zero, 1 or 2;
and their pharmacologically acceptable salts;
(HOE 95/F 253 - NZ 299 682) ap) sulfonimidamides of the formula I
, R 1 O= --R2 .N~

in which:
at least one of the three substituents R(1), R(2) and R(3) is a benzoylguanidine, N~,~NH2 which is unsubstituted or substituted in the phenyl moiety by 1 - 4 radicals selected from the group consisting of alkyl having 1, 2, 3,4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3,4, 5, 6, 7 or 8 carbon atoms, -(CH2)m-R(14), F, Cl, Br, l, -C-N, CF3, R(22)SO2-, R(23)R(24)N-CO-, R(25)-CO-, R(26)R(27)N-S02, -OR(35), -SR(35) or-NR(35)R(36);
m iszero,10r2;
R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or-CH3;
R(22), R(23), R(25) and R(26) independently of one another are alkyl having 1, 2, 3, CA 02241~31 1998-06-2~

4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3,4, 5, 6, 7 or 8 carbon atoms, (CH2)nR(29) or-CF3;
n iszero,1,2,3Or4;
R(29) is -(C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl, methoxy and -NR(30)R(31);
R(30) and R(31) are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(23), R(25) and R(26) are hydrogen;
R(24) and R(27) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(23) and R(24), and also R(26) and R(27) together are 5 or 6 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or-N-benzyl;
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
or R(35) is phenyl, which is not substituted or is substituted by 1 - 3 CA 02241~31 1998-06-2~

substituents selected from the group consisting of F, Cl, -CF3, methyl, methoxy, SO2R(5), SO2NR(6)R(7) and -NR(32)R(33);
R(5) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms R(6) and R(7) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(32) and R(33) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(35) is C1-Cg-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
and the other substituents R(1), R(2) and R(3) in each case independently of one another are alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, (CH2)pR(10) p is zero, 1, 2, 3 or 4;
R(10) is phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl, methoxy, -SO2NR(1 7)R(8) and -SO2R(9);
R(17) and R(8) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(9) is alkyl having 1, 2, 3 or 4 carbon atoms;
or the other radical R(1 ) and R(3) in each case CA 02241~31 1998-06-2~

are hydrogen, R(4) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;
(HOE 95/F 265 - NZ 299 739) aq) benzoylguanidines of the formula I
o O=S--R1 R3~, R6 ~5 0 NH2 in which:
R(1) is alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or NR(7)R(8);
R(7) and R(8) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms R(2) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or -SO2R(9);
R(9) independently is defined as R(1);
R(3) is hydrogen, -SR(25), -OR(25), -NR(25)R(26) or -CR(25)R(26)R(27);
R(25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(25) is -(C1-Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

CA 02241~31 1998-06-2~

R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
R(4) is hydrogen, F, Cl, Br, l, OH, -C-N, CF3, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or-(CH2)mR(14);
m is zero,1 or 2;
R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or -CH3;
R(5) and R(6) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(32), -NR(33)R(34) or CF3;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;
(HOE 95/F 269 K) ar) benzenedicarboxylic acid diguanidides of the formula I

R3~ R 1 R4~ N~ NH2 in which:
one of the radicals R(1), R(2), R(3) and R(4) is -CO-N=C(NH2)2;
and the other radicals R(1), R(2), R(3) and R(4) in each case are:
R(1) is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, l, CA 02241~31 1998-06-2~

-OR(32), -NR(33)R(34) or CF3;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(2) and R(4) independently of one another are hydrogen, F, Cl, Br, l, OH, -CN, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3,4, 5, 6, 7 or 8 carbon atoms or -(CH2)mR(14);
m is zero,1 or 2;
R(14) is-(C3-C8)-cycloalkylorphenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) are hydrogen or-CH3;
or R(2) and R(4) independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, not which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, l, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl,-CF3, methyl, methoxy;
or R(2) and R(4) independently of one another are R(22)-SO2-, R(23)R(24)N-CO-, R(28)-CO- or R(29)R(30)N-SO2;
R(22) and R(28) independently of one another are methyl or -CF3;
R(23), R(24), R(29) and R(30) independently of one another are hydrogen or methyl;
or R(2) and R(4) CA 02241~31 1998-06-2 independently of one another are -OR(35) or -NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or-N-benzyl;
R(3) is hydrogen, -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is hydrogen, alkyl having 1, 2, 3,4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(25) is-(C1-Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
R(5) is alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, l, X-(CH2)y~CF3 or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F and Cl, -CF3, methyl, methoxy and -NR(6)R(7);
R(6) and R(7) independently of one another are hydrogen or -CH3;
X is a bond or oxygen;
y is zero,1 or 2;
and their pharmaceutically tolerable salts;

CA 02241~31 1998-06-2~

(HOE 95/F 269 BK) as) benzenedicarboxylic acid diguanidides of the formula I

R3~R1 R4~ N~ NH2 in which:
one of the radicals R(1), R(2), R(3) and R(5) is -CO-N=C(NH2)2;
and the other radicals R(1), R(2), R(3) and R(5) in each case are:
R(1) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(32), -NR(33)R(34) or CF3;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(2) is hydrogen, F, Cl, Br, l, OH, -C~N, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or-(CH2)mR(14);
m is zero,1 or 2;
R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or -CH3;
or R(2) is R(22)-SO2-, R(23)R(24)N-CO-, R(28)-CO- or R(29)R(30)N-SO2;
R(22) and R(28) independently of one another are methyl or -CF3;
R(23), R(24), R(29) and R(30) independently of one another are hydrogen or methyl;

CA 02241~31 1998-06-2~

or R(2) is -OR(35) or-NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or-N-benzyl;
R(3) is hydrogen, -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(25) is-(C1-Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
R(4) is CF3, alkyl having 1, 2, 3,4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, -(C3-C8)-cycloalkyl or -(CH2)mR(14);
m is1 or2;
R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) CA 02241~31 1998-06-2~

independently of one another are hydrogen or -CH3;
or R(4) is phenyl, which is substituted by 2, 3, 4 or five substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and -NR(1 5)R(1 6);
R(15) and R(16) independently of one another are hydrogen or CH3;
and their pharmaceutically tolerable salts;
(HOE 96/F 013) at) diaryldicarboxylic acid diguanidides of the formula I

R4~R~ $ RR8 in which:
one of the radicals R(1), R(2), R(3), R(4) and R(5) is -CO-N=C(NH2)2;
the other radicals R(1 ) and R(5) in each case independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(32), -NR(33)R(34) or CF3;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
the other radicals R(2) and R(4) in each case independently of one another are hydrogen, F, Cl, Br, I, OH, -CN, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or -(CH2)mR( 1 4);
m is zero, 1 or 2;

CA 02241~731 1998-06-2~7 R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) are hydrogen or-CH3;
or the other radicals R(2) and R(4) in each case independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, l, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl, methoxy;
or the other radicals R(2) and R(4) in each case are R(22)-SO2-, R(23)R(24)N-CO-, R(28)-CO- or R(29)R(30)N-SO2;
R(22) and R(28) independently of one another are methyl or -CF3;
R(23), R(24), R(29) and R(30) independently of one another are hydrogen or methyl;
or the other radicals R(2) and R(4) in each case independently of one another are -OR(35) or -NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3,4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
the other radical R(3) in each case is hydrogen, -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms CA 02241~31 1998-06-2~

or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(25) is-(C1-Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
one of the radicals R(6), R(7), R(8), R(9) and R(10) is -CO-N=C(NH2)2;
the other radicals R(6) and R(10) in each case independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(132), -NR(133)R(134) or CF3;
R(132), R(133) and R(134) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
the other radicals R(7) and R(9) in each case independently of one another are hydrogen, F, Cl, Br, l, OH, -CN, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3,4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or -(CH2)mmR(114);
mm is zero,1 or 2;
R(114) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxyand -NR(115)R(116);
R(115) and R(116) CA 02241~31 1998-06-2~

are hydrogen or-CH3;
or the other radicals R(7) and R(9) in each case independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, l, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl and methoxy;
or the other radicals R(7) and R(9) in each case are R(122)-SO2-, R(123)R(124)N-CO-, R(128)-CO- or R(129)R(130)N-so2;
R(122) and R(128) independently of one another are methyl or-CF3;
R(123), R(124), R(129) and R(130) independently of one another are hydrogen or methyl;
or the other radicals R(7) and R(9) in each case independently of one another are -OR(135) or -NR(135)R(136);
R(135) and R(136) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(135) and R(136) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
the other radical R(8) in each case is hydrogen, -SR(125), -OR(125), -NR(125)R(126) or -CR(125)R(126)R(127);
R(125) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or substituted by 1 - 3 CA 02241~31 1998-06-2~

substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(125) is -(C1 -Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(126) and R(127) independently of one another are defined as R(125) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
A is absent or is -NR(11)-CO-, -NR(12)-CO-NR(13)-, -NR(17)-CO-NR(18)-SO2-, -NR(19)-SO2-, -SO2-NR(19)-SO2-, -SO2-NR(19)-CO-, -O-CO-NR(19)-SO2- or -CR(20)=CR(21)-;
R(11), R(12), R(13), R(17), R(18), R(19), R(20) and R(21) independently of one another are hydrogen or alkyl having 1, 2, 3,4, 5, 6, 7 or 8 carbon atoms and their pharmaceutically tolerable salts;
(HOE 96/F 026) au) substituted thiophenylalkenylcarboxylic acid guanidides of the formula I

R(11 S ~ N~NHz R(4) ~ NH2 in which:
at least one of the substituents R(1), R(2) and R(3) is -Op-(CH2)s-CqF2q+1, R(40)CO or R(31)SOk;
p is zero or 1;
s iszero,1,2,3Or4;
q is 1, 2, 3, 4, 5, 6, 7 or 8;

CA 02241~31 1998-06-2~

k is zero, 1 or 2;
R(40) is alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl and methoxy;
R(31 ) is alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl or methoxy;
or R(31 ) is NR(41 )R(42);
R(41 ) and R(42) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, perfluoroalkyl having 1, 2, 3 or 4 carbon atoms, or R(41 ) and R(42) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
and the other substituents R(1), R(2) and R(3) in each case independently of one another are H, F, Cl, Br, I, CN, -Ona-CmaH2ma+1 ~r~~gaCraH2raR(1~);
na is zero or 1;
ma is zero, 1, 2, 3, 4, 5, 6, 7 or 8;
ga is zero or 1;
ra is zero, 1, 2, 3 or 4;
R(10) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, Where the phenyl is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of CA 02241~31 1998-06-2~

F, Cl, CF3, methyl and methoxy;
R(4) and R(5) independently of one another are hydrogen, F, Cl, Br, I, CN, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(14)R(15);
R(14) and R(15) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;
(HOE 96/F 032) av) ortho-substituted benzoylguanidines of the formula I
F~F

R(2) ~,~

R(3) /~ N~ NH2 Cl O NH2 in which:
R(2) and R(3) independently of one another are hydrogen, Cl, Br, I, (C1-Cg)-alkyl, (C3-Cg)-cycloalkyl or-OR(5);
R(5) is (C1-Cg)-alkyl or-CdH2d-(C3-C8)-CYcl~alkYl;
d is zero, 1 or 2;
where one of the two substituents R(2) and R(3) is always hydrogen but both substituents R(2) and R(3) are not simultaneously hydrogen, and their pharmaceutically tolerable salts;
(HOE 96/F 042) CA 02241~31 1998-06-2~

ax) benzoylguanidines of the formula I
R(1 ) R(2~

R(3)~N~NH2 R(4) ~ NH2 in which:
R(1 ) is H, F, Cl, Br, I, CN, N02, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxy having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkoxy having 3, 4, 5, 6, 7 or 8 carbon atoms or Xa~(CH2)b~(CF2)c~CF3;
X is oxygen, S, NR(5), a is zero or 1;
b is zero, 1 or 2;
c is zero, 1, 2 or 3;
R(5) is H, alkyl having 1, 2, 3 or 4 carbon atoms or -CdH2dR(6);
d iszero,1,2,30r4;
R(6) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, phenyl, biphenylyl or naphthyl, where the aromatics phenyl, biphenylyl or naphthyl are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(7)R(8);
R(7) and R(8) independently are H or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(1 ) is -SR(10), -OR(10) or -CR(1 O)R(11 )R(12);
R(10) is ~CfH2fcycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms in the cycloalkyl ring, or phenyl, where phenyl is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, CA 02241~31 1998-06-2~

Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
f is zero, 1 or 2;
R(11 ) and R(12) independently of one another are defined as R(10) or are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(1 ) is phenyl, naphthyl, biphenylyl or heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, with the latter being linked via a carbon atom or a nitrogen atom of the ring, which are in each case unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino, or R(1 ) is -SR(13), -OR(13), -NHR(13), -NR(1 3)R(14), -CHR(1 3)R(15), -C[R(1 5)R(1 6)0H], -C -CR(18), -C[R(1 9)]=CHR(18), -C[R(20)R(21 )]k-(CO)-[CR(22)R(23)]l-R(24), k is zero, 1, 2, 3 or 4;
is zero, 1, 2, 3 or 4;
R(13) and R(14) identically or differently are -(CH2)9-(CHOH)h-(CH2)j-(CHOH)j-R(17) or -(CH2)g-0-(CH2-CH20)h-R(24);
R(17) is hydrogen or methyl, 9, h and i identically or differently are zero, 1, 2, 3 or 4;
is 1, 2, 3 or 4;

CA 02241~31 1998-06-2~

R(15) and R(16) identically or differently are hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or, together with the carbon atom carrying them, are cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms;
R(18) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(25)R(26);
R(25) and R(26) are H or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(18) is heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, which is unsubstituted or substituted as phenyl;
or R(18) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, which is unsubstituted or substituted by 1 - 3 OH;
or R(18) is cycloalkyl having 3,4, 5, 6, 7 or 8 carbon atoms;
R(19), R(20), R(21), R(22) and R(23) identically or differently are hydrogen or methyl;
R(24) is H, alkyl having 1, 2, 3,4, 5 or 6 carbon atoms, cycloalkyl having 3,4, 5, 6, 7 or 8 carbon atoms or -CmH2m-R(18); ??
very wide with all R(18) m is 1, 2, 3 or 4;
R(2) and R(3) are defined as R(1);
R(4) is alkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;
(HOE 96/F 043) CA 02241~31 1998-06-2~

ay) ortho-substituted benzoylguanidines of the formula I
R(1) R(2~

R(3) ~ N~ NH2 R(4) ~ NH2 in which:
R(1 ) is H, F, Cl, Br, I, CN, NO2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxy having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkoxy having 3, 4, 5, 6, 7 or 8 carbon atoms or Xa~(CH2)b~(CF2)c~CF3;
X is oxygen, S, NR(5), a iszeroor1;
b is zero, 1 or 2;
c is zero, 1, 2 or 3;
R (5) is H, alkyl having 1, 2, 3 or 4 carbon atoms or -CdH2dR(6);
d is zero, 1, 2, 3 or 4;
R(6) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, phenyl, biphenylyl or naphthyl, where the aromatics phenyl, biphenylyl or naphthyl are unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(7)R(8);
R(7) and R(8) independently are H or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(1 ) is -SR(10), -OR(10) or -CR(1 0)R( 1 1 )R(12);
R(10) is -C~H2fcycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms in the cycloalkyl ring, or phenyl, where phenyl is unsubstituted or substituted by 1 - 3 CA 02241~31 1998-06-2~

substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
f is zero, 1 or 2;
R(1 1 ) and R(12) independently of one another are defined as R(10), or hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(1 ) is phenyl, naphthyl, biphenylyl or heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, with the latter being linked via a carbon atom or a nitrogen atom of the ring, which are in each case unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino, or R(1 ) is -SR(13), -OR(13), -NHR(13), -NR(1 3)R(14), -CHR(1 3)R(15), -C[R(1 5)R(1 6)0H], -C--CR(18), -C[R(1 9)]=CHR(18), -C[R(20)R(21 )]k-(CO)-[CR(22)R(23)]l-R(24), k is zero, 1, 2, 3 or 4;
is zero, 1, 2, 3 0r 4;
R(13) and R(14) identically or differently are -(CH2)9-(CHOH)h-(CH2)j-(CHOH)j-R(17) or -(CH2)9-0-(CH2-CH20)h-R(24);
R(17) is hydrogen or methyl, 9, h and i identically or differently are zero, 1, 2, 3 or 4;
is 1 , 2, 3 0r 4;
R(15) and R(16) identically or differently are hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or, together with the carbon atom carrying them, are cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms;
R( 1 8) CA 02241~31 1998-06-2~

is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(25)R(26);
R(25) and R(26) are H or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(18) is heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, which is unsubstituted or substituted as phenyl;
or R(18) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, which is unsubstituted or substituted by 1 - 3 OH;
or R (18) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms;
R(19), R(20), R(21), R(22) and R(23) identically or differently are hydrogen or methyl;
R(24) is H, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or -CmH2m-R(18);
m is 1, 2, 3 or 4;
one of the two substituents R(2) and R(3) is hydroxyl;
and the other of the substituents R(2) and R(3) in each case is defined as R(1);
R(4) is alkyl having 1, 2, 3 or 4 carbon atoms; alkoxy having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, l or-(CH2)n-(CF2)O-CF3;
n iszeroor1;
o is zero or 1;
and their pharmaceutically tolerable salts.

(DE 195 02 895, DE 44 30 212, EP 667 341, DE 44 04 183, EP 708 088, EP 723 963, EP 0 694 537, DE 44 21 495, EP 699 660, EP 699 663, EP 699 666, DE 43 37 611, EP 0719 766, WO 94/26709, WO 96 04 241, CA 02241~31 1998-06-2~

EP 726 254, US 4 251 545, DE 35 02 629, WO 84100875, Kumamoto et al., Pharm. Bull. [1966], 7 - 13; US 3 780 027, JP 8225513) Il. Also suitable are compounds of the formula R(3) R(2) ~",~( 1 ) R(4) ~ NH2 in which:
W, Y and Z
are a nitrogen atom or a carbon atom substituted by R(2) or R(3) or R(4);
R(1) is hydrogen, A, Hal, -CF3, -CH2F, -CHF2, -CH2CF3, -C2Fs, -CN, -NO2, -ethynyl, or an X-R';
A is alkyl having 1 to 6 carbon atoms;
Hal is F, Cl, Br or l;
X is oxygen, S or NR";
R" is hydrogen, A or a cyclic methylene chain having 3 to 7 carbon atoms;
R' is H, A, HO-A-, HOOC-A-, (C3-C7)-cycloalkyl, (C6-C8)-cycloalkylalkyl, CF3, CH2F, CHF2, CH2-CF3, Ph, -CH2-Ph or Het;
Ph is phenyl, naphthyl or biphenylyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, NR'R", Hal, CF3;
Het is a mono- or binuclear saturated, unsaturated or aromatic heterocycle having 1 to 4 nitrogen, oxygen and/or sulfur atoms, which is unsubstituted or mono-, di- or trisubstituted by Hal, CF3, A, OH, OA, -X-R', -CN, -NO2, and/or carbonyl oxygen, where Het is bonded via N or an alkylene chain CmH2m where m = zero to 6;
or CA 02241~31 1998-06-2~

R'and R"
together are alkylene having 4 - 5 carbon atoms, in which one CH2 group can also be replaced by oxygen, S, NH, N-A, N-Ph and N-CH2-Ph;
R(2) and R(3) independently of one another are hydrogen, Hal, A, HO-A-, X-R', -C(=N-OH)-A, A-O-CO-(C1-C4)-alkyl-, CN, NO2, COOH, halogen-substituted A, in particular CF3, CH2F, CHF2, C2Fs, CH2CF3, or S(O)nR"';
R"' is A, Ph or -Het;
n is zero, 1 or 2;
or R(2) and R(3) independently of one another are SO2NR'R", Ph or -O-Ph, -O-CH2-Ph, -CO-A, -CHO, -COOA, -CSNR'Rn, CONR'R", -CH=CH-COOH, -CH=CH-COOA, indenyl, indanyl, decahydronaphthyl, cyclopentenyl, dihydrothienyl, dihydrofuryl, heterobicyclyl, alkylthienyl, halothienyl, haloalkylthienyl, acylthienyl, halofuryl, haloalkylfuryl or pyrrolyl;
or R(2) and R(3) independently of one another are R(5)-0-;
R(5) is hydrogen, A, (C1-C6)-alkenyl or (C3-C7)-cycloalkyl;
R(4) is Ph, Het, -O-Het; CF3, S(O)nR"', -SO2NR'R", alk;

R..'N~
N~
or two of the substituents R(1 ) to R(4) together are a group -O-CR(6)R(7)-CO-NR(8)-, R(Y\~R(9) ~R(2)1 0 to 4 where R(2) has the meaning indicated;

R(6), R(7), R(8) and R(9) independently of one another are H or A;
or R(8) is (C5-C7,)-cycloalkyl;
or R(9) is cyano;
alk is straight-chain or branched (C1-C8)-alkyl or ~C3-C8)-cycloalkyl, which is unsubstituted or mono-, di- or trisubstituted by A;
or alk is an ethenyl or ethynyl radical which is substituted by H, A, Ph or Het:
tDE 41 27 026, ~:)E 4337609, JP 07025768, Edward J. Cragoe, Jr., DIURETICS lChemistry, Pharmacology and Medicine), J. Wiley & Sons (1983), 303-341];
Ill. Compounds of the formula Z~N ~ y Xl~N~ N~ NH2 in which:
X is H, Hal, (Hal)3C-, (C1-C6)~alkyl, (C,3-C6)-cycloalkyl, substituted phenyl, (C1-C~)-alkyl-S- or (C1-C5)-alkyl-SO2-;
Y is NH2 or substituted amino;
or X and Z
to~ether are a -~CH2)4- or a 1,3-butadienylene chain;
or Z is H, Hal, OH, HS, (C1-C5)-alkyl, (C3-C6)-cycloalkyl, substituted phenyl;
or Z is an amino group -NR(1)R(2);
R(1) is H, straight- and branched-chain, optionally substituted (C1-C8)-alkyl, which can be interrupted by oxygen;

CA 02241~31 1998-06-2~

or R(1 ) is (C3-C8)-alkenyl, (C3-C8)-alkynyl, (C3-C7)-cycloalkyl or OH-substituted phenyl or OH-substituted phenyl-(C1-C4)-alkyl or OH-substituted (C3-C7)-cycloalkyl;
R(2) is 1-morpholino, hydrogen or a straight or branched (C1-C8)-alkyl chain, which can be interrupted by oxygen or an amino group, which straight or branched (C1-C8)-alkyl chain is unsubstituted or substituted by a substituted or unsubstituted mono- or polynuclear heterocycle which contains nitrogen, oxygen or sulfur atoms;
or which alkyl chain is substituted by phenyl, optionally mono- or polysubstituted by (C1-C4) alkoxy, optionally substituted by OH, alkylamino, alkyl or phenyl;
or by an aminocarbonyl group or by hydroxyl or (C1-C4)-alkoxy groups, or~(2) is phenyl, unsubstituted or substituted by alkyl, alkoxy, an amino group, which as substituents carries:
H, a mono- or polynuclear heterocycle which contains nitrogen, oxygen or sulfur atoms, which is unsubstituted or substituted by H, Hal or (C1-C4)-alkyl;
a phenyl radical, unsubstituted or substituted by a substituent selected from the group consisting of (C1-C4)-alkyl, (C1-C4)-CA 02241~31 1998-06-2~

alkoxy, Hal and OH;
or R(2) is 1-piperidino, unsubstituted or substituted in the 4-position by an acyl radical of an aliphatic, alicyclic, aromatic or heteroaromatic carboxylic acid, (C1-C8) alkyl, which for its part can be substituted by OH or (C1-C4)-alkoxy or a (C1-C4)-alkoxy-substituted phenyl radical;
or R(2) is amidino, which is unsubstituted or substituted by phenyl, which is unsubstituted or substituted by Hal or alkyl;
or R(2) is an acyl radical of an aliphatic, alicyclic, aromatic or heteroaromatic carboxylic acid, or R(2) is a (C1-C8) alkyl chain, which can be substituted by a phenyl radical carrying OH, alkoxy or alkyl radicals.
or R(1 ) and R(2) together with the nitrogen atom to which they are bonded, are a piperazine ring, which is unsubstituted or via a (C1-C6)-methylene chain carries a mono- or polynuclear heterocycle, which contains nitrogen, oxygen or sulfurs (DE 41 27 026 and DE 43 37 609).
Hal is F, Cl, Br or l;

CA 02241~31 1998-06-2~

( EP 708 091, EP 622 356, JP 5-125085) IV. Likewise suitable are indoloylguanidine derivatives of the formula ~N~ Nq~ NH2 R(2) ~ NH2 in which R(2) is hydrogen, unsubstituted or substituted (C1-C8)-alkyl, (C3-C7)-cycloalkyl, OH, (C1-C6)-alkyl-O-, an aromatic radical or a group -CH2-R(20);
R(20) is (C2-C6)-alkenYI or (C2-C6)-alkYnYI;
R(1) is 1 to 5 identical or different substituents, which are:
hydrogen, unsubstituted or substituted (C1-C8)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl. (C3-C7)-cycloalkyl, halogen,-NO2 (C2-C8)-alkanoyl, arylalkanoyl having up to 10 carbon atoms, aroyl having up to 11 carbon atoms, -COOH, (C2-C6)-alkoxycarbonyl, an aromatic group or one of the following mentioned groups: -OR(3), -NR(6)R(7) or -S(O)nR(40);
R(3) is hydrogen, (C1-C8)-alkyl, substituted (C1-C8)-alkyl, (C3-C7)-cycloalkyl, an aromatic radical or a group -CH2-R(30) R(30) is alkenyl or alkynyl;
R(6) and R(7) independently of one another are hydrogen, unsubstituted or substituted (C1-C8)-alkyl, (C3-C7)-cycloalkyl, (C2-C8)-alkanoyl, an arylalkanoyl group having up to 10 carbon atoms, an aroyl group having up to 11 carbon atoms, an aromatic group or -CH2-R(60);
R(60) is (c2-c6)-alkenyl or (C2-C6)-alkYnYI;
or R(6) and R(7) together with the nitrogen atom are a 5 - 7-membered cyclic amine, which can additionally contain further heteroatoms in the ring;
n is zero,1 or 2;

R(40) is unsubstituted or substituted (C1-C8)-alkyl, or an aromatic group, or a group A ~ R.

A is oxygen, ~S(O)n~ or -N(R50)-;
R(50) is hydrogen or (C1-C8)-alkyl;
R' is hydrogen, unsubstituted or substituted (C1-C8)-alkyl, in which the ring represents a sa~urated 3 - 8 membered heterocycle having a nitrogen atom, said substituted alkyl carries one or more groups selected from the group consisting of halogen, -OH, (C1-C6)-alkoxy, -CN, -COOH, (C2-C6)-alkoxycarbonyl, (C2-C8)-alkanoyl, arylalkanoyl having up to 10 carbon atoms, aroyl having up to 11 carbon atoms, an aromatic group, -CONR(4)(R5), R(4) and R~5) identically or differently are hydrogen or (C1-C8)-alkyl;
or R(4) and R(5) are connected to one another and together form a 5 -7-membered cyclic amine which can additionally contain further heteroatoms in the ring, or said substituted alkyl carries a group A ~-R"

in which:
E is a nitrogen atom or a CH group;
R" is hydrogen, (C1-C8)-alkyl which is unsubstituted or substituted by OH or substituted (C~-C8)-alkyl, (C1-C61-alkoxy, -CN, -COOH, (C2-C6)-alkoxycarbonyl, (C2-C8)-alkanoyl, aralkanoyl having up to 10 carbon atoms, aroyl having up to 11 carbon atoms, an aromatic group, -NR(6)R(7), -CONR(4)R(5);
R(4) and R(5) independently of one another are hydrogen or (C1-C8)-alkyl;
where the cyclic system of the formula A ~3 CA 02241~31 1998-06-2~

is a 3 - 8 membered saturated aliphatic or heterocyclic ring system having a nitrogen atom, and where the aromatic groups mentioned are an aryl radical having up to 10 carbon atoms, a 5- or 6-membered heteroaryl radical having 1 - 4 nitrogen atoms, a 5- or 6-membered heteroaryl group containing 1 or 2 nitrogen atoms and a heteroatom which is oxygen or sulfur, or furyl, and where the aryl radicals mentioned can be unsubstituted or substituted by unsubstituted (C1-C8)-alkyl or substituted (C1-C8)-alkyl, halogen, -NO2, (C2-C6)-alkoxycarbonyl, COOH, -OR(3), NR(6)R(7), -CONR(4)R(5), -SO2NR(6)R(7) or S(O)nR(40), where R(1 ) and the guanidinocarbonyl radical can be in any desired position of the 5- or 6-membered ring of the indole system, and the appropriate pharmaceutically tolerable salts.

(WO 95 04052) V. Additionally suitable are heterocyclic guanidine derivatives of the formula Rj1) N ~I~ N

in which:
X is -O-, -S-, -NH-, -N[(C1-C4)-alkyl]- or-N(phenyl)-;
R(1), R(2) and R(3) are hydrogen, halogen, (C1-C4)-alkyl, (C1-C4)-alkyl-O-, phenyl, benzyl;
or two of the substituents R(1), R(2) and R(3) together with one side of the benzo system are a 4 - 6-membered carbocyclic ring;
R(4) and R(5) independently of one another are hydrogen, (C1-C12)-alkyl, CA 02241C731 1998-06-2C, benzhydryl, aralkyl, which is unsubstituted or substituted by one or more substituents from the groups halogen, (C1-C4)-alkyl, (C1-C4)-alkyl-O- or-CF3. ~(CH2)m~CH2~
m iszeroto3;
T is -CO-O-T(1 );
T(1 ) is hydrogen or (C1 -C4)-alkyl;
Cy is a benzo-fused unsaturated or dihydro-5-membered ring heterocycle ~, R(6) a pyrazole or imidazole ring of the formula ~N or ~ N ( ) R(7) R(~) R(6) R(7) R(ll) a naphthyl radical or a dihydro- or tetrahydronaphthyl radical $~o R(6) a 2-, 3- or 4-pyridyl radical R(8)--j'~~
~ ~ R(6) R(7) Z is N- or CH;
a thienyl radical ~6) ~ R(7) R(6) is hydrogen, halogen, hydroxyl, (C1-C10)-alkyl, (C1-C10)-alkyl-O-, phenoxy, (C1-C10)-alkyloxymethyloxy- or-(O)nS-R(9);
R(9) is (C1-C10)-alkyl, thienyl, pyridyl-, thiazolyl, thiadiazolyl, imidazolyl, pyrazolyl or phenyl, each of which is unsubstituted or mono- or disubstituted by halogen, (C1-C4)-alkyl or (C1 -C4)-alkyl-O-;
R(7) and R(8) is hydrogen, halogen, hydroxyl, (C1-C10)-alkyl, CA 0224l~3l l998-06-2~

(C1-C10)-alkyl-O-, phenyl, phenoxy or (C1 -C1 0)-alkoxymethyloxy;
or Cy is phenyl, which is unsubstituted or mono- or disubstituted by halogen, (C1-C4)-alkyl or (C1-C4)-alkyl-O-;
or Cy is-Gr-Am;
Gr is -R(13)-R(12)-(CH2)q-C[W][W(1)]-(CH2)q-; R(13)R(14)- or -R(1 5)-;
R(12) is a single bond, -~-, -(~)nS-, -CO- or-CONH-;
R(13) is a single bond, phenyl, thienyl, pyridyl, thiazolyl, thiadiazolyl, imidazolyl or pyrazolyl;
R(14) is a single bond [lacuna] SO2-;
R(15) is (C2-C~0)-alkenyl- or (C2-C10)-alkynyl;
W and W(1 ) independently of one another are hydrogen, (C1-C4)-alkyl;
or W and W(1 ) cyclically connected to one another are a (C3-C8)-hydrocarbon ring;
q and q' are zero to 9;
Am is -NR(1 0)R(1 1 );
R(10) is hydrogen, (C1-C4)-alkyl or benzyl, R(1 1 ) is (C1-C4)-alkyl, phenyl or benzyl;
or R(10) and R(11 ) together are a (C3-C10)-alkylene group, which is unsubstituted or substituted by -COOH, (C1-C5)-alkoxycarbonyl, (C2-C4)-hydroxyl-alkylene or benzyl;
or CA 02241~31 1998-06-2~

Am is pyrrolyl, pyridyl, pyrazolyl, morpholinyl, dihydropyridyl, tetrahydropyridyl, quinuclidinyl, imidazolyl, 3-azabicyclo[3.2. 1 ]octyl, which is unsubstituted or substituted by (C1-C4)-alkyl, or Am is azabicyclo[3.2.2]nonyl;
or Am is a piperazine group of the formula ~N-R(' ~NJ
R(16) is hydrogen, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, phenyl, tolyl, methoxyphenyl, halophenyl, diphenylmethylene, benzyl or pyridyl;
or Am is an azido group -(O)t-(CH2)q-C[W][W(1 )]-(CH2)q'-N3;
t is zero or 1;
where W and W(1 ) have the previously indicated meaning;
and the optical enantiomers and the pharmacologically tolerable salts.

Preferably, NHE exchange inhibitors of subt,vpe 3 are used:
(HOE 93/F 223 K - EP 639 573, NZ 264 130) r) benzo-fused 5-membered ring heterocycles, of the formula I
R(2) R ( 3 )~3 X
R( ~ Y \R( 1 ) ( I ) .

R ( 5 ) in which:
X is N or CR(6);
Y is oxygen, S or NR(7);
A, B together are a bond or A, B are both hydrogen, if X is CR(6) and Y is simultaneously NR(7);

CA 02241~31 1998-06-2~

one of the substituents R(1 ) to R(6) is a -CO-N=C(NH2)2 group;
the other substituents R(1 ) to R(6) in each case are hydrogen, F, Cl, Br, I or (C1-C6)-alkyl;
up to two of the other substituents R(1 ) to R(6) are CN, NO2, N3, (C1-C4)-alkyloxy or CF3;
up to one of the other substituents is R(8)-cnH2n-z-;
n is zero to 10;
where the alkylene chain -CnH2n- is straight-chain or branched and where a carbon atom can be replaced by an oxygen or sulfur atom or by a nitrogen atom;
R(8) is hydrogen, (C2-C6)-alkenyl or (C3-C10)-cycloalkyl, which is unsubstituted or substituted by 1 to 4 methyl groups or an OH group, or can contain an ethylene group -CH=CH-, and wherein a methylene group can be replaced by an oxygen or sulfur atom or by a nitrogen atom;
or R(8) is phenyl, which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, CF3, CH3-S(O)s- or R(9)-Wy~;
s is zero, 1 or 2;
R(9) is H, methyl, ethyl, W is oxygen or NR(10);
R(10) is H or methyl;
y is zero or 1;
or R(8) is CmF2m+1;
m is1to3;
or R(8) is 1- or 2-naphthyl, pyridyl, quinolyl or isoquinolyl;
Z is -CO-, -CH2- or -[CR(11 )(OH)]q-;
q is 1, 2 or 3;

CA 02241~31 1998-06-2~

R(11) is H or methyl;
or Z is oxygen or-NR(12)-;
R(12) isHormethyl;
or Z is-S(O)s-;
s is zero, 1 or 2;
or Z is -SO2-NR(13)-;
R(13) is H or (C1-C4)-alkyl;
( ) is hydrogen~ (C1-C10)-alkyl~ (c2-c1o)-alkenyl orR(3)~CnH2n;
and their pharmaceutically tolerable salts;

(HOE 93/F 436 - EP-Offenlegungsschrift 659 748), NZ 270 264) v) acylguanidines of the formula I

N~N H 2 ( I ) in which:
X is carbonyl, sulfonyl, R(1) is H, (C1-C8)-alkyl, unsubstituted or substituted by hydroxyl, (C3-C8)-cycloalkyl, phenyl, which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino or dimethylamino, R(2) is H, (C1-C4)-alkyl, and their pharmaceutically tolerable salts;
(HOE 94/F 014 K - EP-Offenlegungsschrift 666 252, NZ 270 370) w) phenyl-substituted alkylcarboxylic acid guanidides, carrying perfluoroalkyl groups, of the formula I

CA 02241~31 1998-06-2 R(~) R(~) R(l) \
R ( 2 )~ ( C ) ~Nq~/N H 2 ( I ) R ( 3 ) R ( 5 ) ~ NH2 R ( ~ ) in which:
R(A) is hydrogen, F, Cl, Br, I, CN, OR(6), (C1-C8)-alkyl, (C3-C8)-cycloalkyl, Or(CH2)aCbF2b+, or NR(7)R(8);
r is zero or 1;
a is zero, 1, 2, 3 or 4;
b is 1 , 2, 3, 4, 5, 6, 7 or 8;
R(6) is hydrogen, (C1-C8)-alkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(1 0);
R(9) and R(10) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(7) and R(8) independently of one another are defined as R(6);
R(B) independently is defined as R(A);
X is 1, 2 or 3;
R(1) is hydrogen, (C~-C8)-alkyl, (C3-Cg)-cycloalkyl, ~~t(CH2)dCeF2e+1~ F~
Cl, Br, I or CN;
t is zero or 1;
d is zero, 1, 2, 3 or 4;
e is 1, 2, 3, 4, 5, 6, 7 or 8;
R(2), R(3), R(4) and R(5) independently of one another are defined as R(1 );
but with the condition that at least one of the substituents R(1), R(2), R(3), R(4), R(5), R(A) and R(B) is an -Ot(CH2)dCeF2e+~ or an ~r(CH2)aCbF2b+1 group~

CA 02241~31 1998-06-2~

and their pharmaceutically tolerable salts;

(HOE 94/F 123 - EP-Offenlegungsschrift 682 017, NZ 272 058) y) bicyclic heteroaroylguanidines of the formula I
R(~) R(3) R ( S ) ~v~wy~x~y~R ( 2 ) ,U~T~ Nq~ N H 2 R(7) R( l ) ~ NH2 in which:
T, U, V, W, X, Y and Z
independently of one another are nitrogen or carbon;
but with the restriction that X and Z are not simultaneously nitrogen, and that T, U, V, W, X, Y and Z carry no substituents when they are nitrogen, and that no more than four of them are simultaneously nitrogen, R(1) and R(2) independently of one another are hydrogen, F, Cl, Br, l, (C1-C3)-alkyl, (C1-C3)-perfluoroalkyl, OR(8), NR(8)R(9) or C(=O)N=C(NH2)2;
R(8) and R(9) independently of one another are hydrogen or (C1-C3)-alkyl, or R(8) and R(9) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(3), R(4), R(5), R(6) and R(7) independently of one another are hydrogen, F, Cl, Br, l, -C-N, Xk-(CH2)p-(CqF2q+1), R(10a)-SObm, R(10b)R(10c)N-CO, R(11)-CO-or R(12)R(13)N-s02-where the perfluoroalkyl group is straight-chain or branched;
X is oxygen, S or NR(14);
R(14) is H or C1-C3)-alkyl;

CA 02241~31 1998-06-2~

bm is zero,1 or 2;
p is zero,1 or 2;
k is zero or 1;
q is1,2,3,4,5Or6;
R(10a), R(10b), R(11)and R(12) independently of one another are (C1-C8)-alkyl, (c3-c6)-alkenyl~ -CnH2n-R(15) or (C1-C8)-PerflU~r~alkYl;
n is zero, 1, 2, 3 or 4;
R(15) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(16)R(17);
R(16) and R(17) are H or C1-C4-alkyl;
or R(10b), R(11) and R(12) are hydrogen;
R(10c) and R(13) independently are hydrogen or (C1-C4)-alkyl;
or R(10b) and R(10c) and also R(12) and R(13) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
25 or R(3), R(4), R(5), R(6) and R(7) independently of one another are (C1-C8)-alkyl, -CalH2alR(18) or (C3-C8)-alkenyl;
al is zero,1 or 2;
R(18) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatic are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(19a)R(19b);
R(19a) and R(19b) CA 02241~31 1998-06-2~

are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are (C1-Cg)-heteroaryl which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino or dimethylamino;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are O -. ! ' ~' - Y~3 ( C ) h ~ ( C H 0 H ) i ~ ( C H 2 ) I - ( C H 0 H ) k - R ( 2 3 ) ~.

~ l l i~ ~
l _ . . ._ l _ l I~ _ _~1 11 ~ 1~1 ~ 1 ~ .

'~;~1 Y is oxygen, -S- or-NR(22)-;
h, ad, ah independently of one another are zero or 1;
i,j,k,ae,af,ag,ao,apandak independently of one another are zero, 1, 2, 3 or 4;
but where in each case h, i and k are not simultaneously zero, ad, ae and ag are not simultaneously zero, and ah, ao and ak are not simultaneously zero, R(23), R(24) R(25) and R(22) CA 02241~31 1998-06-2~

independently of one another are hydrogen or (C1-C3)-alkyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are SR(29), -OR(30), -NR(31)R(32) or -CR(33)R(34)R(35);
R(29), R(30), R(31) and R(33) independently of one another are -CaH2a-(C1-Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
a is zero,1 or 2;
R(32), R(34) and R(35) independently of one another are defined as R(29) or hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
15 or R(3), R(4), R(5), R(6) and R(7) independently of one another are -- W ~R(96) ~ ~R(97) or ~R(98) R(96), R(97) and R(98) independently of one another are (C1-Cg)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 to 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino, dimethylamino or benzyl;
W is oxygen, S or NR(36)-;
R(36) is H or (C1-C4)-alkyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are R(46)X(1)-;
X(1) is oxygen, S, NR(47), (D=O)A- or NR(48)C=MN(~)R(49)-;
M is oxygen or sulfur;

CA 02241~31 1998-06-2~

A is oxygen or NR(50);
D is C or SO;
R(46) is (C~-C8)-alkyl, (c3-c8)-alkenyl~ (CH2)bCdF2d+1 or -CXH2X-R(51 );
~ b iszero or 1;
d is 1, 2, 3, 4, 5, 6 or 7;
x iszero,1,2,3Or4;
R(51) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatic are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(52)R(53);
R(52) and R(53) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(47), R(48) and R(50) independently are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(49) is defined as R(46);
or R(46) and R(47), or R(46) and R(48) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
where A and N(*) are bonded to the phenyl nucleus of the heteroaroylguanidine parent structure;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are -SR(64), -OR(65), -NHR(66), -NR(67)R(68), -CHR(69)R(70) or-CR(54)R(55)0H, -C-CR(56), -CR(58)=CR(57) or -[CR(59)R(60)]U-CO-[CR(61)R(62)]v-R(63);
R(64), R(65), R(66), R(67) and R(69) identically or differently are -(cH2)y-(cHoH)z-(cH2)aa-(cHoH)t-R(71) or -(cH2)ab-o-(cH2-cH2o)ac-R(72);

CA 02241~31 1998-06-2~

R(71), and R(72) independently of one another are hydrogen or methyl;
u is1,2,3Or4;
v is zero, 1, 2, 3 or 4;
y, z, aa iden~cally or differently are zero, 1, 2, 3 or 4;
t is 1, 2, 3 or4;
R(68), R(70), R(54) and R(55) identically or differently are hydrogen or (C1-C6)-alkyl;
or R(69) and R(70), or R(54) and R(55) together with the carbon atom carrying them, are a (C3-C8)-cycloalkyl;
R(63) is hydrogen, (C1-C6)-alkyl, (C3-C8~cycloalkyl or -CeH2e-R(73);
e is zero, 1, 2, 3 or 4;
R(56), R(57) and R(73) independently are phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(74)R(75);
R(74) and R(75) are hydrogen or (C1-C4)-alkyl;
or R(56), R(57) and R(73) independently are (C1-Cg)-heteroaryl, which is unsubstituted or substituted as phenyl;
R(58), R(59), R(60), R(61) and R(62) are hydrogen or methyl;
30 or R(3), R(4), R(5), R(6) and R(7) independently of one another are R(76)-NH-SO2-;
R(76) is R(77)R(78)N-(C=Y')-;
Y' is oxygen, S or N-R(79);

CA 02241~31 1998-06-2~

R(77) and R(78) identically or differently are hydrogen, (C1-C8)-alkyl, (C3-C6)-alkenyl or-CfH2fR(80);
f is zero, 1, 2, 3 or 4;
R(80) is (C5-C7)-cycloalkyl or phenyl, which [lacuna]
unsubstituted [lacuna] by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methoxy and (C1-C4)-alkyl;
or R(77) and R(78) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
R(79) is defined as R(77) or is amidine;
15 or R(3), R(4), R(5), R(6) and R(7) independently of one another are NR(84a)R(85), OR(84b), SR(84c) or -CnH2n-R(84d);
n is zero,1, 2, 3 or 4;
R(84d) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(16)R(17);
R(16) and R(17) are hydrogen, or C1-C4-alkyl;
R(84a), R(84b), R(84c) and R(85) independently of one another are hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl or (CH2)aX-R(84g);
ax is zero, 1, 2, 3 or 4;
R(849) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(84u)R(84v);

R(84u) and R(84v) are hydrogen or C1-C4-alkyl;
or R(84a) and R(85) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl, and their pharmaceutically tolerable salts;
(HOE 94/F 168 - EP-Offenlegungsschrift 690 048, NZ 272 373) ab) phenyl-substituted alkenylcarboxylic acid guanidides, carrying perfluoroalkyl groups, of the formula I

in which:
R(A) is hydrogen, F, Cl, Br, l, CN, OH, OR(6), (C1-C8)-alkyl, Or(CH2)aCbF2b+1, (C3-Cg)-cycloalkyl or NR(7)R(8);
r is zero or 1;
a iszero,1,2,3Or4;
b is 1, 2, 3, 4, 5, 6, 7 or 8;
R(6) is (C1-C8)-alkyl, (C1-C4)-perfluoroalkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl;
where the aromatic are not substituted or are substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) CA 02241~31 1998-06-2~

are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(7) and R(8) independently of one another are defined as R(6);
or R(7) and R(8) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
R(B) independently is defined as R(A);
10 X iszero, 1 or2;
Y is zero, 1 or 2;
R(C) is hydrogen, F, Cl, Br, I, CN, OR(12), (C1-C8)-alkyl, Op(CH2)fCgF29+
or (C3-C8)-cycloalkyl;
p is zero or 1;
f iszero,1,2,30r4;
g is1,2,3,4,5,6,70r8;
R(12) is (C1-C8)-alkyl, (C1-C4)-perfluoroalkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl;
where the aromatics phenyl or benzyl are not substituted or are substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(1 3)R(14);
R(13) and R(14) independently of one another are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(D) independently is defined as R(C), R(1 ) is hydrogen, (C1-C8)-alkyl, -~t(CH2)dCeF2e+1 (C3-C8)-cycloalkyl, F~
Cl, Br, I or CN;
t is zero or 1;
d iszero, 1, 2, 30r4;
e is 1, 2, 3, 4, 5, 6, 7 or 8;
R(2), R(3), R(4) and R(5) independently of one another are defined as R(1 );

CA 02241~31 1998-06-2~

but with the condition that at least one of the substituents R(A), R(B), R(C), R(D), R(1), R(2), R(4) or R(5) is a Or(CH2)aCbF2b+1~ Op(CH2)fCgF29+1 or Ot(CH2)dCeF2e+1 group and R(3) is not a Ot(CH2)dCeF2e+1 group;
and their pharmaceutically tolerable salts;
(HOE 95/F 007 K - EP-Offenlegungsschrift 723 956, NZ 280 887) ah) benzoylguanidines of the formula I
R ( l ) R ( 2 ) ~ R ( S ) R(3)J~N~NH2 R ( ~ ) ~ NH2 in which:
one of the three substituents R(1), R(2) and R(3) is R(6)-A-B-D-;
R(6) is a basic protonatable radical, i.e. an amino group -NR(7)R(8), an amidino group R(7)R(8)N-C[=N-R(9)]- or a guanidino group R ( 7 ) R ( l 0 ) ~N N~
R ( 8 ) ~f R ( 9 )~

R(7), R(8), R(9) and R(10) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(7) and R(8) together are CaH2a;
a is4, 5, 6Or7;
where if a = 5, 6 or 7 a methylene group of the group CaH2a can be replaced by a heteroatom group O, S~m or NR(11), or CA 02241~31 1998-06-2~

R(8) and R(9) or R(9) and R(10) or R(7) and R(10) are a group CaH2a;
a is2,3,4Or5;
where if a = 3, 4 or 5 a methylene group of the group CaH2a can be replaced by a heteroatom group O, S~m or NR(11);
m is zero, 1 or 2;
R(11) is hydrogen or methyl;
or R(6) is a basic heteroaromatic ring system having 1 - 9 carbon atoms;
A is CbH2b;
b is 1, 2, 3,4, 5, 6, 7, 8, 9 or 10;
where in the group CbH2b one or two methylene groups can be replaced by one of the groupings selected from the group consisting of -O-, -CO-, -CH[OR(20)]-, ~SOm~~ -NR(20)-, -NR(20)-CO-, -NR(20)-CO-NH-, -NR(20)-CO-NH-SO2-llo)oo - R ( 2 0 ) N -S -I N R ( 1 9 ) I b b and -SOaa[NR(1 9)]bb-;
and where in the group CbH2b a methylene group can be replaced by -CH-R(99), where R(99) together with R(7) forms a pyrrolidine or piperidine ring;
aa is 1 or 2;
bb is 0 or 1;
aa + bb = 2;
R(19) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms, R(20) is hydrogen or methyl;

CA 02241~31 1998-06-2~

B is a phenylene or naphthylene radical, R(12) R(12) R( l 3) R( l 3) R(12) and R(13) independently of one another are hydrogen, methyl, F, Cl, Br, l, CF3 or -SOw-R(14);
R(14) is methyl or NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
w iszero,10r2;
D iS-CdH2d-Xf;
d iszero,1, 2, 30r4;
X is -O-, -CO-, -CH[OR(21)]-, -SOm- or -NR(21)-;
f is zero or 1;
R(21) is hydrogen or methyl;
m is zero,1 or 2;
and the other substituents R(1) and R(2) and R(3) in each case independently of one another are hydrogen, F, Cl, Br, l, -CN, -(C1 -C8)-alkyl, -(C2-C8)-alkenyl, -NR(35)R(36) or R(17)-CgH29-Zh-;
9 iszero,1,2,30r4;
h iszeroor1;
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
Z is -O-, -CO-, -SOv- ,-NR(18)-, -NR(18)-CO-, -NR(18)-CO-NH-CA 02241~31 1998-06-2~

or -NR(18)-SO2-;
R(18) is hydrogen or methyl;
v is zero,1 or 2;
R(17) is hydrogen, cycloalkyl having 3, 5 or 6 carbon atoms or CkF2k+1-;
k is1,20r3, or R(17) is pyrrol-1 -yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, l,-CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl and methoxy;
or R(17) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, hydroxyl, methoxy, -NR(37)R(38), CH3SO2- and H2NO2S-;
R(37) and R(38) are hydrogen or-CH3;
R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(32), -NR(33)R(34) or-CrF2r+1;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2 or 3 carbon atoms;
r is 1, 2, 3 or 4;

and their pharmacologically tolerable salts;

(HOE 95/F 072 - EP-Offenlegungsschrift 738 712, NZ 286 380 ai) indenoylguanidines of the formula I

CA 02241~31 1998-06-2~

R ( 3 )R ( 2 ) N-R ( 8 ) R ( ~ / R ( 9 ) " A

R(6)R( l ) R(7) R( l0) in which:
R(1 ) and R(2) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms. O-Alkyl having 1, 2, 3 or 4 carbon atoms, O-C(=O)-alkyl having 1, 2, 3 or 4 carbon atoms or CmH2m-NR(12)R(13);
R(12) and R(13) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
m is zero, [lacuna] 2, 3 or 4;
NH-C(=O)-NH2, C(=O)-O-alkyl having 1, 2, 3 or 4 carbon atoms, C(=O)-NH2, C(=O)-NH-alkyl having 1, 2, 3 or 4 carbon atoms, C(=O)-N(alkyl)2 having 1, 2, 3 or 4 carbon atoms in each alkyl group, alkenyl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, alkynyl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, alkylaryl having 1, 2, 3 or 4 carbon atoms in the alkyl group, alkenylaryl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms in the alkenyl group, alkynylaryl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms in the alkynyl group, C1-C4-alkyl-substituted aryl, C1-C4-alkylheteroaryl, C1-C4-alkenylheteroaryl, aminoalkylaryl having 1, 2, 3 or 4 carbon atoms in the alkyl group, substituted aryl, heteroaryl and substituted heteroaryl;
R(3), R(4), R(5) and R(6) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, O-alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, halogen, (such as F, Cl, Br, I), OH, aryl, substituted aryl, heteroaryl, substituted heteroaryl, O-lower-alkyl, O-aryl, O-lower-alkylaryl, O-substituted aryl, O-lower-alkyl-CA 02241~31 1998-06-2~

substituted aryl, O-C(=O)-C1-C4-alkylaryl, O-C(=O)-NH-C1-C4-alkyl, O-C(=O)-N(C1-C4-alkyl)2~ NO2, CN, CF3, NH2, NH-C( O)-C1-C4 alkyl, NH-C(=O)-NH2, COOH, C(=O)-O-C1-C4-alkyl, C(=O)-NH2, C(=O)-NH-C1-C4-alkyl, C(=O)-N(C1-C4-alkyl)2, C1-C4-COOH, C1-C4-alkyl-C(=O)-O-C1-C4-alkyl, SO3H, SO2-alkyl, SO2-alkylaryl, SO2-N-(alkyl)2, SO2-N(alkyl)(alkylaryl), C(=O)-R(11), C1-C10-alkyl-C(=O)-R(11), C2-C10-alkenyl-C(=O)-R(11), C2-C10-alkynyl-C(=O)-R(11), NH-C(=O)-C1 -C10-alkyl-C(=O)-R(11), O-C1 -C11 -alkyl-C(=O)-R(11);
R(11) is C1-C4-alkyl, C1-C4-alkynyl, aryl, substituted aryl, NH2, NH-C1-C4-alkyl, N-(C1-C4-alkyl)2, SO3H, SO2-alkyl, SO2-alkylaryl, SO2-N-(alkyl)2, S02-N(alkyl)(alkylaryl);
X isO,SorNH;
R(7), R(8), R(9) and R(10) independently of one another are hydrogen, alkyl, cycloalkyl, aryl, alkylaryl;
or R(8) and R(9) together are part of a 5, 6 or 7-membered heterocyclic ring;
A is absent or is a nontoxic organic or inorganic acid.
(HOE 95/F 109 - EP 748 795, NZ 286 583) ak) benzyloxycarbonylguanidines of the formula I
R(l ) R(2)~R(5) R ( 3 ) ~X~ NH2 R ( 4 ) R ( 6 )\ ~ N H 2 R(7) in which:
R(1), R(2) and R(3) independently of one another are -Y-[4-R(8)-phenyl], -Y-[3-R(8)-phenyl] or-Y-[2-R(8)-phenyl], where the phenyl in each case is unsubstituted or substituted by 1 - 2 substituents from the group consisting of F, Cl, -CF3, methyl, hydroxyl, methoxy and -NR(96)R(97);

CA 02241~31 1998-06-25 R(96) and R(97) independently of one another are hydrogen or-CH3;
Y is a bond, CH2, oxygen, -S- or-NR(9);
R(9) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(8) is SOa[NR(98)]bNR(99)R(10);
a is 1 or 2;
b isOor1;
a + b = 2;
R(98), R(99) and R(10) independently of one another are hydrogen, -(C1-C8)-alkyl, benzyl,-(C2-C8)-alkylene-NR(11)R(12), (C2-C8)-alkylene-NR(13)-(C2-C8)-alkylene-NR(37)R(38) or (CO-C8)-alkylene-CR(39)R(40)CR(41 )R(42)(Co-C8)-alkylene-NR(43)R(44);
R(11), R(12), R(13), R(37), R(38), R(43) and R(44) independently of one another are hydrogen, -(C1-C8)-alkyl or benzyl:
R(39), R(40), R(41) and R(42) independently of one another are hydrogen, -(C1-C8)-alkyl or-(CO-C3)-alkylenephenyl, where the phenyl is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl and methoxy;
or R(99) and R(10) together are 4 - 6 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -N-CH3 or -N-benzyl;
or R(8) is SOa[NR(98)]bNR(95)-C[=N-R(94)]-NR(93)R(92);
R(92), R(93), R(94) and R(95) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;

CA 02241~31 1998-06-2~

or R(1), R(2) and R(3) independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, l, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl, methoxy;
or R(1), R(2) and R(3) independently of one another are hydrogen, -(C1-C8)-alkyl, -(C2-C8)-alkenyl or-(CH2)mR(14);
m is zero,1 or 2;
R(14) is-(C3-C8)-cycloalkylorphenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) are hydrogen or-CH3;
or R(1), R(2) and R(3) independently of one another are -Q-4-[(CH2)k-CHR(17)-(C=O)R(20)]-phenyl, -Q-3-(CH2)k-CHR(17)-(C=O)R(20)]-phenyl or -0-2-[(CH2)k-CHR(17)-(c=O)R(20)]-phenyl~
where the phenyl in each case is unsubstituted or substituted by 1 - 2 substituents from the group consisting of F, Cl, -CF3, methyl, hydroxyl, methoxy and -NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or -CH3;
Q is a bond, oxygen, -S- or-NR(18);
R(18) is hydrogen or-(C1-C4)-alkyl;
R(17) is -OR(21) or -NR(21)R(22);

CA 02241~31 1998-06-2~

R(21) and R(22) independently of one another are hydrogen, -(C1-C8)-alkyl, -(C1 -C8)-alkanoyl, -(C1 -C8)-alkoxycarbonyl, benzyl, benzyloxycarbonyl;
or R(21) is trityl;
R(20) is -OR(23) or -NR(23)R(24);
R(23), R(24) independently of one another are hydrogen, -(C1-C8)-alkyl or benzyl;
k is zero,1, 2, 3 or 4;
or R(1), R(2) and R(3) independently of one another are (C1-Cg)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(1), R(2) and R(3) are-SR(25),-OR(25),-NR(25)R(26),-CR(25)R(26)R(27);
R(25) is-CfH2f(C1-Cg)-heteroaryl~
which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
f is zero,1 or 2;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or (C1-C4)-alkyl, 30 or R(1), R(2) and R(3) independently of one another are (C1-Cg)-heteroaryl-N-oxide, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group CA 02241~31 1998-06-2~

consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(1), R(2) and R(3) independently of one another are -SR(28), -OR(28), -NR(28)R(29) or -CR(28)R(29)R(30);
R(28) is-CgH29-(C1-Cg)-heteroaryl-N-oxide, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
g is zero,1 or 2;
R(29), R(30) independently of one another are defined as R(28), or are hydrogen or (C1-C4)-alkyl;
or R(1), R(2) and R(3) independently of one another are hydrogen, F, Cl, Br, l, -C-N, T-(CH2)h-(CjF2j+1), R(31)SOI-, R(32)R(33)N-CO-, R(34)-CO-or R(45)R(46)N-SO2, where the perfluoroalkyl group is straight-chain or branched;
T is a bond, oxygen, -S- or-NR(47);
is zero,1 or 2;
h is zero, 1 or 2;
i is1,2,3,4,5Or6;
R(31), R(32), R(34) and R(45) independently of one another are -(C1-C8)-alkyl, -(C3-C6)alkenyl, (CH2)nR(48) or -CF3;
n is zero,1, 2, 3 or 4;
R(47) is hydrogen or alkyl having 1, 2 or 3 carbon atoms;
R(48) is -(C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl, methoxy and CA 02241~31 1998-06-2~

-NR(49)R(50);
R(49) and R(50) are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(32), R(34) and R(45) are hydrogen;
R(33) and R(46) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(32) and R(33) and also R(45) and R(46) together are 5 or 6 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
15 or R(1), R(2)and R(3) independently of one another are R(51)-A-G-D-;
R(51) is a basic protonatable radical, i.e. an amino group -NR(52)R(53), an amidino group R(52)R(53)N-C[=N-R(54)]-or a guanidino group R(52)R(53)N-C[=N-R(54)]-NR(55)-;
R(52), R(53), R(54) and R(55) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(52) and R(53) are a group CaH2~;
a is4,5,6Or7;
where if a = 5, 6 or 7 a carbon atom of the group CaH2a can be replaced by a heteroatom group O, S~d or NR(56), or R(53) and R(54) or R(54) and R(55) or R(52) and R(55) are a group CyH2y;
y is2,3,4Or5;

CA 02241~31 1998-06-2~

where if y = 3, 4 or 5 a carbon atom of the group CyH2y can be replaced by a heteroatom group 0, S~d or NR(56);
d is zero,1 or 2;
R(56) is hydrogen or methyl;
or R(51) is a basic heteroaromatic ring system having 1 - 9 carbon atoms;
A is a group CeH2e;
e iszero,1,2,3,4,5,6,7,8,90r10;
where in the group CeH2e a carbon atom can be replaced by one of the groupings -O-, -CO-, -CH[OR(57)]-, -SOr-, -NR(57)-, -NR(57)-CO-, -NR(57)-CO-NH-, -NR(57)-CO-NH-SO2- or-NR(57)-SO2-;
r iszero,10r2;
G is a phenylene radical, ~R ( 58 ) ~' R ( 59 ) R(58) and R(59) independently of one another are hydrogen, methyl, methoxy, F, Cl, Br, l, CF3 or-SOs-R(60);
R(60) is methyl or NR(61)R(62);
R(61) and R(62) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
D is-cvH2v-Ew-;
v iszero,1, 2, 30r4;
E is -O-, -CO-, -CH[OR(63)]-, -SOaa- or -NR(63)-;
w is zero or 1;
aa is zero,1 or 2 CA 02241~31 1998-06-2~

R(63) is hydrogen or methyl, or R(1), R(2) and R(3) independently of one another are -CF2R(64), -CF[R(65)][R(66)], -CF[(CF2)q-CF3)][R(65)], -C[(CF2)p-CF3]=CR(65)R(66);
R(64) is alkyl having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms;
R(65) and R(66) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
q iszero,1Or2;
p is zero, 1 or 2;
or R(1), R(2) and R(3) independentiy of one another are -OR(67) or -NR(67)R(68);
R(67) and R(68) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(67) and R(68) together are 4, 5, 6 or 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, SO2, -NH-, -NCH3 or -N-benzyl;
R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(69), -NR(70)R(71) or-CzF2z+1;
R(69), R(70) and R(71 ) independently of one another are hydrogen or alkyl having 1, 2 or 3 carbon atoms;
z is 1, 2, 3 or 4;
R(6) and R(7) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
X is oxygen or NR(72);
R(72) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;

CA 02241~31 1998-06-2~

and their pharmaceutically tolerable salts;

(HOE 95/F 115 - EP 744 397, NZ 286 622) al) alkenylcarboxylic acid guanidides, carrying fluorophenyl groups, of the 5 formula I
( ) R(l) R(3) ~ R(6) H
R(4) ~ N~y N~

R(S) ~ H' R(7) in which:
R(6) is hydrogen, (C1-C8)-alkyl, (C3-C8)-cycloalkyl or phenyl, where the phenyl group is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(7) independently is defined as R(6);
R(1), R(2), R(3), R(4) and R(5) independently of one another are hydrogen or F;
where, however, at least one of the radicals R(1), R(2), R(3), R(4) and R(5) must be fluorine;
and their pharmaceutically tolerable salts;
(HOE 95/F 173 - NZ 299 052) an) substituted cinnamic acid guanidides of the formula I
R(2) R(3) ~ R(Rl()6~
R(~) ~ N ~ NH2 R(S)R(7)0 NH2 in which:

CA 02241~31 1998-06-2~

at least one of the substituents R(1), R(2), R(3), R(4) and R(5) is ~Xa~Yb~Ln~U;
X is CR(16)R(17), O, S or NR(18);
R(16), R(17) and R(18) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
a iszeroor1;
Y is alkylene having 1, 2, 3,4, 5, 6, 7 or 8 carbon atoms, alkylene-T having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group, T or T-alkylene having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group;
T is NR(20), O, S or phenylene, where the phenylene is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(21)R(22);
R(20), R(21) and R(22) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
b is zero or 1;
L is O, S, NR(23) or CkH2k;
k is 1, 2, 3, 4, 5, 6, 7, 8;
n is zero or 1;
U is NR(24)R(25) or an N-containing heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms;
R(24) and R(25) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
or CA 02241~31 1998-06-2~

R(24) and R(25) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
where the N-containing heterocycles are N- or C-bridged and are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(27)R(28);
R(23), R(27) and R(28) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
and the other substituents R(1), R(2), R(3), R(4) and R(5) in each case independently of one another are H, F, Cl, Br, l, CN, -0n CmH2m+1, -Op-(CH2)s-CqF2q+1 or -CrH2rR(10);
n is zero or 1;
m iszero1,2,3,4,5,6,70r8;
p is zero or 1;
q is1,2,3,4,5,6,70r8;
s is zero,1, 2, 3 or 4;
r is zero,1, 2, 3 or 4;
R(10) is cycloalkyl having 3,4, 5, 6, 7 or 8 carbon atoms, or phenyl, where the phenyl is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(11)R(12);
R(11) and R(12) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
R(6) and R(7) independently of one another are hydrogen, F, Cl, Br, l, CN, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 CA 02241~31 1998-06-2~

carbon atoms, or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(14)R(15);
R(14) and R(15) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;
(HOE 9S/F 269 K) ar) benzenedicarboxylic acid diguanidides of the formula I

R3~,~ R1 R4~ N ~ NH2 in which:
one of the radicals R(1), R(2), R(3) and R(4) is-CO-N=C(NH2)2;
and the other radicals R(1), R(2), R(3) and R(4) in each case are:
R(1) is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, l, -OR(32), -NR(33)R(34) or CF3;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(2) and R(4) independently of one another are hydrogen, F, Cl, Br, l, OH, -CN, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3,4, 5, 6, 7 or 8 carbon atoms or -(CH2)mR(14);
m is zero,1 or 2;
R(14) is-(C3-C8)-cycloalkylorphenyl, which is not substituted or is substituted by 1 - 3 CA 02241~31 1998-06-2~

substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) are hydrogen or-CH3;
or R(2) and R(4) independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, each of which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, l, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl, methoxy;
or R(2) and R(4) independently of one another are R(22)-SO2-, R(23)R(24)N-CO-, R(28)-CO- or R(29)R(30)N-SO2;
R(22) and R(28) independently of one another are methyl or -CF3;
R(23), R(24), R(29) and R(30) independently of one another are hydrogen or methyl;
or R(2) and R(4) independently of one another are -OR(35) or -NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3,4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
R(3) is hydrogen, -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or substituted by 1 - 3 CA 02241~31 1998-06-2~

substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(25) is-(C1-Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
R(5) is alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, X-(CH2)y~CF3 or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F and Cl, -CF3, methyl, methoxy and -NR(6)R(7);
R(6) and R(7) independently of one another are hydrogen or-CH3;
X is a bond or oxygen;
y is zero, 1 or 2;
and their pharmaceutically tolerable salts;
(HOE 95/F 269 BK) as) benzenedicarboxylic acid diguanidides of the formula I

R3 l R1 R4~f N~ NH2 30in which:
one of the radicals R(1), R(2), R(3) and R(5) is -CO-N=C(NH2)2;
and the other radicals R(1), R(2), R(3) and R(5) in each case are:

CA 02241~31 1998-06-2~

R(1) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(32), -NR(33)R(34) or CF3;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(2) is hydrogen, F, Cl, Br, l, OH, -C~N, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or -(CH2)mR(14);
m iszero,1Or2;
R(14) is-(C3-C8)-cycloalkylorphenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or -CH3;
or R(2) is R(22)-SO2-, R(23)R(24)N-CO-, R(28)-CO- or R(29)R(30)N-SO2;
R(22) and R(28) independently of one another are methyl or -CF3;
R(23), R(24), R(29) and R(30) independently of one another are hydrogen or methyl;
or R(2) is -OR(35) or -NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
R(3) is hydrogen, -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is hydrogen, alkyl having 1, 2, 3,4, 5, 6, 7 or 8 carbon atoms CA 02241~31 1998-06-2~

or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(25) is-(C1-Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
R(4) is CF3, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, -(C3-C8)-cycloalkyl or ~(CH2)mR(14);
m is 1 or 2;
R(14) is-(C3-C8)-cycloalkylorphenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or -CH3;
or R(4) is phenyl, which is substituted by 2, 3, 4 or five substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or CH3;
and their pharmaceutically tolerable salts;

CA 02241~31 1998-06-2~

(HOE 96/F 013) at) diaryldicarboxylic acid diguanidides of the formula I

R3 ~3~R~R8 in which:
one of the radicals R(1), R(2), R(3), R(4) and R(5) is-CO-N=C(NH2)2;
the other radicals R(1 ) and R(5) in each case independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(32), -NR(33)R(34) or CF3;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
the other radicals R(2) and R(4) in each case independently of one another are hydrogen, F, Cl, Br, I, OH, -CN, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or -(CH2)mR( 1 4);
m is zero, 1 or 2;
R(14) is-(C3-C8)-cycloalkylorphenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) are hydrogen or-CH3;
or the other radicals R(2) and R(4) in each case independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, I, -CN, CA 02241~31 1998-06-2~

(C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl, methoxy;
or the other radicals R(2) and R(4) in each case are R(22)-SO2-, R(23)R(24)N-CO-, R(28)-CO- or R(29)R(30)N-SO2;
R(22) and R(28) independently of one another are methyl or -CF3;
R(23), R(24), R(29) and R(30) independently of one another are hydrogen or methyl;
or the other radicals R(2) and R(4) in each case independently of one another are -OR(35) or-NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
the other radical R(3) in each case is hydrogen, -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(25) is-(C1-Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(26) and R(27) CA 02241~31 1998-06-2~

independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
one of the radicals R(6), R(7), R(8), R(9) and R(10) is -CO-N=C(NH2)2;
the other radicals R(6) and R(10) in each case independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(132), -NR(133)R(134) or CF3;
R(132), R(133) and R(134) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
the other radicals R(7) and R(9) in each case independently of one another are hydrogen, F, Cl, Br, l, OH, -CN, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3,4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3,4, 5, 6, 7 or 8 carbon atoms or -(CH2)mmR(114);
mm is zero,1 or 2;
R(114) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(115)R(116);
R(115) and R(116) are hydrogen or-CH3;
or 25 the other radicals R(7) and R(9) in each case independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, l, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl and methoxy;
or the other radicals R(7) and R(9) in each case are R(122)-SO2-, R(123)R(124)N-CO-, R(128)-CO- or CA 02241~31 1998-06-2~

R(129)R(130)N-SO2;
R(122) and R(128) independently of one another are methyl or -CF3;
R(123), R(124), R(129) and R(130) independently of one another are hydrogen or methyl;
or the other radicals R(7) and R(9) in each case independently of one another are -OR(135) or -NR(135)R(136);
R(135) and R(136) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(135) and R(136) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
the other radical R(8) in each case is hydrogen, -SR(125), -OR(125), -NR(125)R(126) or -CR(125)R(126)R(127);
R(125) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(125) is -(C1 -Cg)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(126) and R(127) independently of one another are defined as R(125) or are CA 02241~31 1998-06-2~

hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
A is absent or is -NR(11)-CO-, -NR(12)-CO-NR(13)-, -NR(1 7)-CO-NR(1 8)-SO2-, -NR(1 9)-SO2-, -SO2-NR(1 9)-SO2-, -SO2-NR(19)-CO-, -O-CO-NR(19)-SO2- or-CR(20)=CR(21)-;
R(11), R(12), R(13), R(17), R(18), R(19), R(20)and R(21) independently of one another are hydrogen or alkyl having 1, 2,3,4,5,6,7Or8carbonatoms and their pharmaceutically tolerable salts;
(HOE 96/F 026) 10 au) substituted thiophenylalkenylcarboxylic acid guanidides of the formula I

R(2~ R(3) ~ ~ R(5) R(1~ ~ N~"NH2 R(4) ~ NH2 in which:
at least one of the substituents R(1), R(2) and R(3) is -Op-(CH2)s-CqF2q+1, R(40)CO- or R(31 )SOk-;
p iszeroor1;
s iszero,1,2,3Or4;
q is1,2,3,4,5,6,7Or8;
k is zero, 1 or 2;
R(40) is alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl and methoxy;
R(31 ) is alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, which is not substituted or is substituted by 1 - 3 CA 02241~31 1998-06-2~

substituents selected from the group consisting of F, Cl, CF3, methyl or methoxy;
or R(31) is NR(41)R(42);
R(41) and R(42) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, perfluoroalkyl having 1, 2, 3 or 4 carbon atoms, or R(41) and R(42) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
and the other substituents R(1), R(2) and R(3) in each case independently of one another are H, F, Cl, Br, l, CN, -ona-CmaH2ma+1 ~r~~gaCraH2raR(1~);
na is zero or 1;
ma iszero,1,2,3,4,5,6,7Or8;
ga is zero or 1;
ra iszero,1, 2, 3Or4;
R(10) is cycloalkyl having 3,4, 5, 6, 7 or 8 carbon atoms or phenyl, where the phenyl is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl and methoxy;
R(4) and R(5) independently of one another are hydrogen, F, Cl, Br, l, CN, alkyl having 1, 2, 3,4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3,4, 5, 6, 7 or 8 carbon atoms or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(14)R(15);
R(14) and R(15) independently of one another are H, alkyl having 1, 2, CA 02241~31 1998-06-2~

3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;

5 For inhibitors of Na+/H+ exchange of this type, numerous medicinal uses have already been described, such as, for example, forms of illness which occur due to chronic or acute undersupply of blood to an organ (ischemia), in particular of the heart. They are therefore suitable, for example, for the treatment of ischemically induced arrhythmias, different forms of angina 10 pectoris, in heart transplants, in cardiac surgery and in angioplastic surgical interventions. Other indications described for NHE inhibitors are stroke and cerebral edema, shock and proliferation-related diseases, such as atherosclerosis, diabetic late damage, fibrotic disorders and organ hypertrophy.
It has now surprisingly been found that NHE inhibitors can stimulate the ,espi,~lion by means of an increase in the chemosensitivity of the respiratory chemoreceptors. These chemoreceptors are responsible to a considerable extent for the maintenance of an orderly respiratory activity.
20 They are activated by hypoxia, pH decrease and increase in CO2 (hyperkapnia) in the body and lead to an adjustment of the respiratory minute volume. During sleep, the respiration is particularly susceptible to interference and is dependent to a high extent on the activity of the chemoreceptors.
An improvement of the respiratory drive by stimulation of the chemoreceptors with substances which inhibit the sodium-proton exchange leads to an improvement of the respiration in the following clinical conditions and illnesses:
30 disordered central respiratory drive (e.g. central sleep apnea, sudden infant death, postoperative hypoxia), muscle-related respiratory disorders, respiratory disorders after long-term ventilation, respiratory disorders during adaptation in a high mountain area, obstructive and mixed forms of sleep apnea, acute and chronic lung diseases with hypoxia and CA 02241~31 1998-06-2~

hypercapnia.

The compounds mentioned are therefore advantageously used individually or alternatively in multiples for the production of a medicament for the 5 treatment of disordered respiratory drive; for the production of a medicament for the treatment of muscle-related respiratory disorders; for the production of a medicament for the treatment of respiratory disorders after long-term ventilation; for the production of a medicament for the treatment of respiratory disorders during adaptation in high mountain 10 areas; for the production of a medicament for the treatment of obstructive, central and mixed forms of sleep apnea; for the production of a medicament for the treatment of acute and chronic lung diseases with hypoxia and hypercapnia; particularly for the production of a medicament for the treatment of the illnesses mentioned in combinations with an 15 inhibitor of carboanhydratase, preferably with acetazolamide.

A combination of an NHE inhibitor with a carboanhydrase inhibitor (e.g.
acetazolamide), the latter producing a metabolic acidosis and thereby even increasing the respiratory activity, proves to be a favorable combination 20 with increased action and decreased use of active compound.

The administration of sodium-proton exchange inhibitors as novel pharmaceuticals for improvement of the respiration, respiratory stimulants, and also the combination of sodium-proton exchange inhibitors with 25 carboanhydrase inhibitors is claimed.

Claims (10)

Patent claims
1. The use of an Na+/H+ exchange inhibitor for the production of a medicament for the treatment of impaired respiratory drive.
2. The use I as claimed in claim 1, which comprises employing as Na+/H+
exchange inhibitor:
I. a) benzoylguanidines of the formula I

in which:
R(1) or R(2) is R(6)-S(O)n- or R(7)R(8)N-O2S-;
and the other substituent R(1) or R(2) in each case is H, F, Cl, Br, (C1-C4)-alkyl, (C1-C4)-alkoxy or phenoxy, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of fluorine, chorine, methyl and methoxy;
or the other substituent R(1) or R(2) in each case is R(6)-S(O)n or R(7)R(8)N-;
n is zero, 1 or 2;
R(6) is (C1-C6)-alkyl, (C5-C7)-cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy;
R(7) and R(8) identically or differently are H or (C1-C6)-alkyl;
or R(7) is phenyl-(CH2)m;
m is 1-4;
or R(7) is phenyl, which is unsubstituted or substituted by 1 - 2 substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy;
or R(7) and R(8) together are a straight-chain or branched (C4-C7)-chain, where the chain can additionally be interrupted by O, S or NR(9);
R(9) is H or methyl;
or R(7) and R(8) together with the nitrogen atom to which they are bonded, are a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system;
R(3), R(4) and R(5) independently of one another are H or (C1-C2)-alkyl, or R(3) and R(4) together are a (C2-C4)-alkylene chain;
or R(4) and R(5) together are a (C4-C7)-alkylene chain;
and their pharmaceutically tolerable salts;

b) benzoylguanidines of the formula I

in which:
R(1) is R(4)-SOm or R(5)R(6)N-SO2-;
m is zero, 1 or 2;

R(4) and R(5) are C1-C8-alkyl, C3-C6-alkenyl or-CnH2n-R(7);
n is zero, 1, 2, 3 or 4;
R(7) is C5-C7-cycloalkyl or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(8)R(9);
R(8) and R(9) are H or C1-C4-alkyl;
or R(5) is H;
R(6) is H or C1-C4-alkyl, or R(5) and R(6) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by an O, S, NH, N-CH3 or N-benzyl;
R(2) is hydrogen, F, Cl, Br, (C1-C4)-alkyl-, O-(CH2)mCpF2p+1 or-X-R(10);
m is zero or 1;
p is 1, 2 or 3;
X is O, S or NR(11);
R(10) is H, C1-C6-alkyl, C5-C7-cycloalkyl, cyclohexylmethyl, cyclopentylmethyl or-CnH2n-R(12);
n is zero, 1,2,3 or 4;
R(12) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy und NR(8)R(9);
R(8) and R(9) are H or C1-C4-alkyl;
R(11) is hydrogen or C1-C3-alkyl;
or R(10) and R(11) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by O, S, NH, N-CH3 or N-benzyl;
R(3) is defined as R(1), or is C1-C6-alkyl, nitro, cyano, trifluoromethyl, F, Cl, Br, I or-X-R(10);
X is O, S or NR(11);
R(10) is H, C1-C6-alkyl, C5-C7-cycloalkyl, cyclohexylmethyl, cyclopentylmethyl or-CnH2n-R(12);
n is zero to 4;
R(12) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy und NR(8)R(9);
R(8) and R(9) are H or C1-C4-alkyl;
R(11) is C1-C3-alkyl, or R(10) and R(11) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by O, S, NH, N-CH3 or N-benzyl;
and their pharmaceutically tolerable salts;

c) ortho-substituted benzoylguanidines of the formula I

in which:
R(1) is F, Cl, Br, I, C1-C6-alkyl or -X-R(6);
X is O, S, NR(7) or Y-ZO;
Y is O or NR(7);

Z is C or SO;
R(6) is H, C1-C6-alkyl, C5-C7-cycloalkyl, cyclohexylmethyl, cyclopentylmethyl, -(CH2)mCpF2p+1 or -CnH2n-R(8);
m is zero or 1;
p is 1 - 3;
n is zero to 4;
R(8) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of the groups F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H or C1-C4-alkyl;
R(7) is H or C1-C3-alkyl;
or R(6) and R(7) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by O, S, NH, N-CH3 or N-benzyl;
R(3) is H or -X-R(6);
X is O, S, NR(7) or Y-ZO;
R(7) is H or C1-C3-alkyl;
Y is O or NR(7);
where Y is bonded to the phenyl radical of the formula 1, Z is C or SO;
R(6) is H, C1-C6-alkyl, C5-C7-cycloalkyl, cyclohexylmethyl, cyclopentylmethyl, -(CH2)mCpF2p+1 or -CnH2n-R(8);
m is zero or 1;
p is 1 - 3;
n is zero to 4;
R(8) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);

R(9) and R(10) are H or C1-C4-alkyl;
or R(6) and R(7) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by O, S, NH, N-CH3 or N-benzyl;
R(2) and R(4) identically or differently are R(11)-SOq- or R(12)R(13)N-SO2-;
q is zero - 2;
R(11) is C1-C4-alkyl, which is unsubstituted or carries phenyl as a substituent, where phenyl is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H or C1-C4-alkyl;
R(12) and R(13) are defined as R(6) and R(7);
or one of the two radicals R(2) or R(4) is hydrogen or is defined as R(1);
R(5) is H, methyl, F, Cl or methoxy, and their pharmaceutically tolerable salts.

d) benzoylguanidines of the formula I

in which:
R(1) or R(2) is an amino group -NR(3)R(4);
R(3) and R(4) identically or differently are H, C1-C6-alkyl or C3-C7-cycloalkyl;
or R(3) is phenyl-(CH2)p-;
p is O, 1, 2, 3 or 4;
or R(3) is phenyl, where the phenyl in each case is unsubstituted or carries one to two substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy;
or R(3) and R(4) together can be a straight-chain or branched C4-C7-methylene chain, where one -CH2- member of the methylene chain can be replaced by oxygen, S or NR(5);
R(5) is H or lower alkyl;
the other substituent R(1) or R(2) in each case is H F, Cl, C1-C4-alkyl. C1-C4-alkoxy, CF3, CmF2m+1-CH2-, benzyl or phenoxy, where the respective phenyl radical is unsubstituted or carries one to two substituents selected from the group consisting of methyl, methoxy, fluorine and chlorine;
m is 1, 2 or 3;
and their pharmaceutically tolerable salts;

e) benzoylguanidines of the formula I

in which:
R(1) is R(4)-SOm or R(5)R(6)N-SO2-;
m is zero, 1 or 2;

R(4) and R(5) are C1-C8-alkyl, C3-C6-alkenyl or -CnH2n-R(7);
n is zero, 1, 2, 3 or 4;
R(7) is C5-C7-cycloalkyl or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(8)R(9);
R(8) and R(9) are H or C1-C4-alkyl;
or R(5) is H;
R(6) is H or C1-C4-alkyl;
or R(5) and R(6) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by an O, S, NH, N-CH3 or N-benzyl;
R(2) is hydrogen, straight-chain or branched (C5-C8)-alkyl, -CR(13)=CHR(12) or -C~CR(12);
R(12) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(14)R(15);
R(14) and R(15) are H or (C1-C4)-alkyl;
or R(12) is (C1-C9)-heteroaryl, which is unsubstituted or substituted as phenyl, or R(12) is (C1-C6)-alkyl, which is unsubstituted or substituted by 1 - 3 OH, or R(12) is (C3-C8)-cycloalkyl;
R(13) is hydrogen or methyl, or R(12) is (C3-C8)-cycloalkyl, (C3-C8)-cycloalkyl-(C1-C4)-alkyl, phenyl, C6H5-(C1-C4)-alkyl, naphthyl, biphenylyl, 1,1-diphenyl-(C1-C4)-alkyl, cyclopentadienyl, pyridyl, pyrrolyl, furanyl, thienyl, thiazolyl, oxazolyl, indenyl, quinolyl, indolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indazolyl, isoquinolyl, phthalazinyl, quinoxalinyl, quinazolinyl or cinnolinyl;
R(3) is defined as R(2);
and where the aromatic substituents R(2) and R(3) are unsubstituted or substituted by 1 - 3 substituents from the groups F, Cl, CF3, (C1-C4)-alkyl or -alkoxy, or NR(10)R(11) with R(10) and R(11) being H or (C1-C4)-alkyl;
and their pharmaceutically tolerable salts.

f) benzoylguanidines of the formula I

in which:
R(1) or R(2) is R(3)-S(O)n- or the other substituent R(1) or R(2) in each case is H, OH, F, Cl, Br, I, C1-C4-alkyl, C1-C4-alkoxy, benzyloxy or phenoxy, which is unsubstituted or carries one to three substituents selected from the group consisting of fluorine, chlorine, methyl, methoxy, hydroxyl or benzyloxy, R(3)-S(O)n, -NR4)R(5) or 3,4-dehydropiperidine R(3) is C1-C6-alkyl, c5-c7-cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl, which is unsubstituted or substituted by one to three substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy;
R(4) and R(5) identically or differently, are H or C1-C6-alkyl;
or R(4) is phenyl-(CH2)m-;
m is 1, 2,3 or 4;
or R(4) is phenyl, which is unsubstituted or carries one to two substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy;
or R(4) and R(5) together are a straight-chain or branched C4-C7-chain, where the chain can additionally be interrupted by O, S or N R(6), R(6) is H or methyl;
or R(4) and R(5) together with the nitrogen atom to which they are bonded, are a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system;
n is zero, 1 or 2;
and their pharmaceutically tolerable salts;

g) isoquinolines of the formula I

in which:
R(1) is hydrogen, alkyl, cycloalkyl, arylalkyl, alkenyl, substituted aminoalkyl or an aryl or heteroaryl ring;
where the rings are unsubstituted or substituted by 1 - 3 groups selected from the group consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl, trifluoromethyl, R(2) is hydrogen, halogen, alkyl or aryl;
which is unsubstituted or substituted by 1 - 3 groups selected from the group consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl, G is X(2), X(3) and X(4) independently of one another are hydrogen, halogen, nitro, amino, alkyl, sulfonamide, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, benzyloxy, hydroxyl;
X(1) is hydrogen, oxygen, sulfur or NR(7);
R(7) is hydrogen, alkyl, cycloalkyl, arylalkyl, alkenyl, substituted aminoalkyl or an aryl or a heteroaryl ring;
which rings are unsubstituted or substituted by 1 - 3 groups selected from the group consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl and trifluoromethyl;
in which substituents each alkyl chain or alkenyl chain can be interrupted by oxygen, sulfur or NR(8);
R(8) is hydrogen, alkyl, cycloalkyl, arylalkyl, alkenyl, substituted aminoalkyl or an aryl or heteroaryl ring, which rings are unsubstituted or substituted by 1 - 3 groups selected from the group consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl and trifluoromethyl;
and their pharmaceutically acceptable salts;

h) compounds of the formula I

in which:
R(1) is hydrogen, F, Cl, Br, I, -NO2, -C~N, -CF3, R(4)-SOm or R(5)R(6)N-SO2-;
m is zero, 1 or 2;
R(4) and R(5) are (C1-C8)-alkyl, (C3-C6)-alkenyl, -CnH2n-R(7) or CF3;
n is zero, 1, 2, 3 or 4;
R(7) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(8)R(9);
R(8) and R(9) are H or C1-C4-alkyl;
or R(5) is H;
R(6) is H or (C1-C4)-alkyl;
or R(5) and R(6) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(2) is -SR(10), -OR(10), -NHR(10), -NR(10)R(11), -CHR(10)R(12), -[CR(12)R(13)OR(13')], -{C-[CH2-OR(13')]R(12)(R(13)} or -[CR(18)R(17)]p-(CO)-[CR(19)R(20)]q-R(14);
R(10), R(11) identically or differently are -[CHR(16)]s-(CH2)p-(CHOH)q-(CH2)r-(CHOH)t-R(21) or -(CH2)p-O-(CH2-CH2O)q-R(21), R(21) is hydrogen, methyl, p, q, r identically or differently are zero, 1, 2, 3 or 4;
s is zero or 1;
t is 1, 2, 3 or 4;
R(12) and R(13) identically or differently are hydrogen, (C1-C6)-alkyl or, together with the carbon atom carrying them, are a (C3-C8)-cycloalkyl, R(13') is hydrogen or (C1-C4)-alkyl;
R(14) is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or-CaH2a-R(15);
a is zero, 1, 2, 3 or 4;
R(15) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(8)R(9);
R(8) and R(9) are H or (C1-C4)-alkyl;
or R(15) is (C1-C9)-heteroaryl, which is unsubstituted or substituted as phenyi, or R(15) is (C1-C6)-alkyl, which is unsubstituted or substituted by 1 - 3 OH;
R(16), R(17), R(18), R(19) and R(20) are hydrogen or (C1-C3)-alkyl;
R(3) is defined as R(1), or R(3) is (C1-C6)-alkyl or -X-R(22);
X is oxygen, S or NR(16);
R(16) is H or (C1-C3)-alkyl;
or R(22) and R(16) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(22) is defined as R(14);
and their pharmaceutically tolerable salts.

i) benzoylguanidines of the formula I

in which:
R(1) is hydrogen, F, Cl, Br, I, -NO2, -C~N, R(16)-CpH2p-Oq, R(4)-SOm or R(5)R(6)N-SO2-;
m is zero,1 or 2;

p is zero or 1;
q is zero, 1, 2 or 3;
R(16) is CrF2r+1;
r is 1, 2 or 3;
R(4) and R(5) are (C1-C8)-alkyl, (C3-C6)-alkenyl, -CnH2n-R(7) or CF3;
n is zero, 1, 2, 3 or 4;
R(7) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(8)R(9);
R(8) and R(9) are H or C1-C4-alkyl;
or R(5) is H;
R(6) is H or (C1-C4)-alkyl;
or R(5) and R(6) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl, R(2) is (C1-C9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(2) is -SR(10), -OR(10), -NR(10)R(11), -CR(10)R(11)R(12);
R(10) is-CaH2a-(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
a is zero, 1 or 2;
R(11) and R(12) independently of one another are defined as R(10) or are hydrogen or (C1-C4)-alkyl;
R(3) is defined as R(1), or is (C1-C6)-alkyl or-X-R(13);
X is oxygen, S, or NR(14);
R(14) is H or (C1-C3)-alkyl;
R(13) is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or-CbH2b-R(15);
b is zero, 1, 2, 3 or 4;
or R(13) and R(14) together are 4 or 5 methylene groups, of which [lacuna] CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(15) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(8)R(9);
R(8) and R(9) are H or (C1-C4)-alkyl;
and their pharmaceutically tolerable salts;

k) benzoylguanidines of the formula I

in which:
one of the substituents R(1), R(2), R(3) or R(4):
is an amino group ;

R(5) is hydrogen or C(1-6)-alkyl;
n is zero, 1, 2, 3 or 4;
R(6) is H or C(14)-alkyl;
in which one CH2 group can be replaced by 1 sulfur atom or a group NR(7);
R(7) is hydrogen, methyl or ethyl;
or R(6) is C(3-8)-cycloalkyl or phenyl, which is unsubstituted or carries 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, methyl, methoxy, -NR(8)R(9);
R(8) and R(9) are H, methyl or ethyl;
or R(5) and R(6) together with the nitrogen atom are a 5-, 6- or 7-membered ring, in which 1 carbon atom can be replaced by oxygen, S or NR(10);
R(10) is H, C(1-3)-alkyl or benzyl;
and the other substituents R(1), R(2), R(3), R(4) in each case are:
hydrogen, F, Cl, Br, I, CN, CF3, NO2, CF3-O-, CmF2m+1-CH2-O- or R(11)-CqH2q-Xp-;
m is 1, 2 or 3;
q is zero, 1, 2, 3 or 4;
p zero or 1;
X is oxygen or NR(12);
R(12) is H or C(1-3)-alkyl;
R(11) is hydrogen, C(1-6)-alkyl, C(3-8)-cycloalkyl or phenyl, which is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, CH3, CH3-O- and NR(13)R(14);
R(13), R(14) are H, methyl or ethyl;
and their pharmaceutically tolerable salts.

I) benzoylguanidines of the formula I

in which R(1) is R(4)R(5)N-C(X)-;
X is oxygen, S or N-R(6);
R(4) and R(5) identically or differently, are H, (C1-C8)-alkyl, (C3-C6)-alkenyl or -CnH2n-R(7);
n is zero, 1, 2, 3 or 4;
R(7) is (C5-C7)-cycloalkyl or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methoxy and (C1-C4)-alkyl;
or R(4) and R(5) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(6) is defined as R(4) or is amidine;
R(2) is H, F, Cl, Br, I, (C1-C8)-alkyl, 1-alkenyl or 1-alkynyl, (C3-C8)-cycloalkyl, (C3-C8)-cycloalkyl-(C1-C4)-alkyl, phenyl, C6H5-(C1-C4)-alkyl, naphthyl, biphenylyl, 1,1-diphenyl-(C1-C4)-alkyl, cyclopentadienyl, pyridyl, thiopyridyl, pyrrolyl, furanyl, thienyl, thiazolyl, oxazolyl, indenyl, quinolyl, indolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl or -W-R(8);
W is oxygen, S or NR(9);
R(8) is H, (C1-C6)-alkyl, (C5-C7)-cycloalkyl, cyclohexylmethyl, cyclopentylmethyl, -(CH2)mCpF2p+
or -CqH2q-R(10);
m is zero or 1;
p is 1, 2 or 3;
q is zero, 1, 2, 3 or 4;

R(10) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(11)R(12);
R(11) and R(12) are H or (C1-C4)-alkyl;
R(9) is H or (C1-C3)-alkyl;
or R(8) and R(9) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(3) is H, F, Cl, Br, I, (C1-C6)-alkyl or-W-R(8) as defined for R(2), and their pharmaceutically acceptable salts;

m) benzoylguanidines of the formula I

in which:
R(1), R(2), R(3) are hydrogen, F, Cl, Br, I or (C1-C12)-alkyl;
one of the substituents R(1), R(2) or R(3) is N3, CN, OH or (C1-C10)-alkyloxy, if at least one of the remaining substituents R(1), R(2) or R(3) is a sufficiently lipophilic alkyl radical having 3 to 12 carbon atoms;
or one of the substituents R(1), R(2) or R(3) is R(4)-CnH2n-Om-;

m is zero or 1;
n is zero, 1, 2 or 3;
R(4) is CpF2p+1;
p is 1, 2 or 3, if n is zero or 1;
or R(4) is (C3-C12)-cycloalkyl, phenyl, pyridyl, quinolyl or isoquinolyl, where the aromatic and heteroaromatic ring systems are unsubstituted or substituted by a substituent selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(5)R(6);
R(5) and R(6) are hydrogen or (C1-C4)-alkyl;
or one of the substituents R(1), R(2) or R(3) is -C~CR(5) or -C[R(6)] = CR(5);
R(5) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy, hydroxyl, amino, methylamino and dimethylamino, (C1 -C9)-heteroaryl, which is unsubstituted or substituted as phenyl, or R(5) is (C1-C6)-alkyl, which is unsubstituted or substituted by 1 - 3 OH;
or R(5) is (C3-C8)-cycloalkyl, R(6) is hydrogen or methyl;
and their pharmacologically acceptable salts;

o) benzoylguanidines of the formula I

in which:
R(1) is hydrogen, F, Cl, Br, I, -NO2, -C~N, Xo-(CH2)p-(CF2)q-CF3, R(5)-SOm, R(6)-CO- or R(6)R(7)N-SO2-, where X is oxygen, S or NR(14);
m is zero, 1 or 2;
o is zero or 1;
p is zero, 1 or 2;
q iszero, 1,2,3,4,5 or 6;
R(5) and R(6) are (C1-C8)-alkyl, (C3-C6)-alkenyl, -CnH2n-R(8) or CF3;
n is zero, 1, 2, 3 or 4;
R(8) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H or C1-C4-alkyl;
or R(6) is H;
R(7) is H or (C1-C4)-alkyl;
or R(6) and R(7) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;

or or Y is oxygen, -S- or-NR(12)-;
R(11) and R(12) are hydrogen or (C1-C3)-alkyl;
h is zero or 1;
i, j and k independently are zero, 1, 2, 3 or 4;
but where h, i and k are not simultaneously zero, R(3) is defined as R(1), or is (C1-C6)-alkyl or-X-R(13);
X is oxygen, S or NR(14);
R(14) is H or (C1-C3)-alkyl;
R(13) is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or -CbH2b-R(15);
b is zero, 1, 2, 3 or 4;
or R(13) and R(14) together are 4 or 5 methylene groups, where one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(15) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H or (C1-C4)-alkyl;
R(4) is hydrogen, -OR(16) or -NR(16)R(17);
R(16) and R(17) independently are hydrogen or (C1-C3)-alkyl;
and their pharmaceutically tolerable salts;

p) benzoylguanidines of the formula I

in which:
R(1) is R(6)-CO or R(7)R(8)N-CO;
R(6) is (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CnH2n-R(9);
n is zero, 1, 2, 3 or 4;
R(9) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(10)R(11);
R(10) and R(11) are H, (C1-C4)-alkyl or (C1-C4)-perfuoroalkyl;
R(7) is H, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CnH2n-R(12);
n is zero, 1, 2, 3 or 4;
R(12) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(13)R(14);

R(13) and R(14) are H, (C1-C4)-alkyl or (C1-C4)-perfuoroalkyl;
R(8) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(7) and R(8) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(2) is defined [lacuna] R(1), or is H, F, Cl, Br, I, CN, NO2, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CnH2nR(15);
n is zero 1,2,3,4;
R(15) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(16)R(17);
R(16) and R(17) are H, (C1-C4)-alkyl or (C1-C4)-perfuoroalkyl or R(2) is (C1-C9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(2) is SR(18), -OR(18), -NR(18)R(19), -CR(18)R(19)R(20);
R(18) is -CaH2a-(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
a is zero, 1 or 2;
R(19) and R(20) independently of one another are defined as R(18) or are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(2) is R(21)-SOm or R(22)R(23)N-SO2-;
m is 1 or 2;
R(21) is (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl, -CnH2n-R(24), n is zero,1,2,3 or 4;
R(24) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(27)R(28);
R(27) and R(28) are H, (C1-C4)-alkyl or (C1-C4)-perfuoroalkyl;
R(22) is H, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl, -CnH2n-R(29);
n is zero, 1, 2, 3 or 4;
R(29) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(30)R(31);
R(30) and R(31) are H, (C1-C4)-alkyl or (C1-C4)-perfuoroalkyl;
R(23) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(22) and R(23) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
or R(2) is R(33)X-;
X is oxygen, S, NR(34), (D=O)A-, NR(34)C=MN(*)R(35)-;
M is oxygen or S;
A is oxygen or NR(34);
D is C or SO;
R(33) is (C1-C8)-alkyl, (C3-C8)-alkenyl, (CH2)bCdF2d+1, -CnH2nR(36), b is zero or 1;
d is 1, 2, 3, 4, 5, 6 or 7;
n is zero,1,2,3 or 4;
R(36) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(37)R(38);
R(37) and R(38) are H, (C1-C4)-alkyl or (C1-C4)-perfuoroalkyl;
R(34) is H, (C1-C4)-alkyl or (C1-C4)-perfuoroalkyl;
R(35) is defined as R(33);
or R(33) and R(34) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
where A and N(*) are bonded to the phenyl nucleus of the benzoylguanidine parent structure;
or R(2) is -SR(40), -OR(40), -NHR(40), -NR(40)R(41), -CHR(40)R(42), -C[R(42)R(43)OH], -C~CR(45), -CR(46)=CHR(45), -[CR(47)R(48)]u-(CO)-[CR49)R(50)]v-R(44);
R(40), R(41) identically or differently are -(CH2)p-(CHOH)q-(CH2)r-(CHOH)t-R(51) or -(CH2)p-O-(CH2-CH2O)q-R(51);

R(51) is hydrogen or methyl;
u is 1,2,3 or 4;
v is zero, 1,2,3 or 4;
p, q, r identically or differently are zero, 1, 2, 3 or 4;
t is 1,2,3 or 4;
R(42) and R(43) identically or differently are hydrogen or (C1-C6)-alkyl;
or R(42) and R(43) together with the carbon atom carrying them form a (C3-C8)-cycloalkyl;
R(44) is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or -CeH2e-R(45);
e is zero, 1, 2, 3 or 4;
R(45) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(52)R(53) where R(52) and R(53) are H or (C1-C4)-alkyl, or R(45) is (C1-C9)-heteroaryl, which is unsubstituted or substituted as phenyl;
or R(45) is (C1-C6)-alkyl, which is unsubstituted or substituted by 1 - 3 OH;
R(46), R(47), R(48), R(49) and R(50) are hydrogen or methyl;
or R(2) is R(55)-NH-SO2-;
R(55) is R(56)R(57)N-(C=Y)-;
Y is oxygen, S or N-R(58);
R(56) and R(57) identically or differently are H, (C1-C8)-alkyl, (C3-C6)-alkenyl or-CfH2fR(59);
f is zero, 1, 2, 3 or 4;

R(59) is (C5-C7)-cycloalkyl or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methoxy and (C1-C4)-alkyl;
or R(56) and R(57) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(58) is defined as R(56) or is amidine;
R(3), R(4) and R(5) independently of one another are defined as R(1) or R(2);
and their pharmaceutically tolerable salts;

q) benzoylguanidines of the formula I

in which:
R(1) is hydrogen, F, Cl, Br, I, -NO2, -C-N, -Xo-(CH2)p-(CF2)q-CF3, R(5)-SOm-, R(6)-CO-, R(6)R(7)N-CO- or R(6)R(7)N-SO2-;
X is oxygen, -S- or NR(14);
m is zero, 1 or 2;
o is zero or 1;
p is zero, 1 or 2;
q is zero, 1, 2, 3, 4, 5 or 6;
R(5) and R(6) are (C1-C8)-alkyl, (C3-C6)-alkenyl. -CnH2n-R(3) or CF3;
n is zero, 1, 2, 3 or 4;
R(8) is (C3-C7)-cycloalkyl, phenyl, which is not substituted or is substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H or (C1-C4)-alkyl;
or R(6) is hydrogen;
R(7) is hydrogen or (C1-C4)-alkyl;
or R(6) and R(7) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(2) is , or R(11) is (C1-C9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino, dimethylamino and benzyl;
Y is oxygen, -S- or NR(12);
R(12) is H or (C1-C4)-alkyl;
R(3) is defined as R(1);
or R(3) is (C1-C6)-alkyl or -X-R(13);
X is oxygen, -S- or NR(14);
R(14) is H or (C1-C3)-alkyl;
R(13) is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or-CbH2b-R(15);

b is zero, 1,2,3 or 4;
or R(13) and R(14) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(15) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H or (C1-C4)-alkyl;
R(4) is hydrogen, -OR(16), -NR(16)R(17) or CrF2r+1;
R(16) and R(17) independently are hydrogen or (C1-C3)-alkyl;
r is 1,2,3 or 4;
and their pharmaceutically tolerable salts;

r) benzo-fused 5-membered ring heterocycles of the formula I

in which:
X is N or CR(6);
Y is oxygen, S or NR(7);
A, B together are a bond or A, B are both hydrogen, if X is simultaneously CR(6) and Y is NR(7);
one of the substituents R(1) to R(6) is a -CO-N=C(NH2)2 group;
the other substituents R(1) to R(6) in each case are hydrogen, F, Cl, Br, I or (C1-C6)-alkyl;
up to two of the other substituents R(1) to R(6) are CN, NO2, N3, (C1-C4)-alkyloxy or CF3;
up to one of the other substituents is R(8)-CnH2n-Z-;
n is zero to 10;
where the alkylene chain -CnH2n- is straight-chain or branched and where one carbon atom can be replaced by an oxygen or sulfur atom or by a nitrogen atom;
R(8) is hydrogen, (C2-C6)-alkenyl or (C3-C10)-cycloalkyl, which is unsubstituted or substituted by 1 to 4 methyl groups or an OH group, or can contain an ethylene group -CH=CH-, and in which one methylene group can be replaced by an oxygen or sulfur atom or by a nitrogen atom;
or R(8) is phenyl, which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, CF3, CH3-S(O)s- or R(9)-Wy-;
s is zero, 1 or 2;
R(9) is H, methyl, ethyl, W is oxygen or NR(10);
R(10) is H or methyl;
y is zero or 1;
or R(8) is CmF2m+1;
m is 1 to 3;
or R(8) is 1- or 2-naphthyl, pyridyl, quinolyl or isoquinolyl;
Z is -CO-, -CH2- or-[CR(11)(OH)]q-;
q is 1, 2 or 3;
R(11 ) is H or methyl;
or Z is oxygen or -NR(12)-;
R(12) is H or methyl;
or Z is -S(O)s-;
s is zero, 1 or 2;
or Z is -SO2-NR(13)-;
R(13) is H or (C1-C4)-alkyl;
R(7) is hydrogen, (C1-C10)-alkyl, (C2-C10)-alkenyl or R(8)-CnH2n-;
and their pharmaceutically tolerable salts;

s) benzoylguanidines of the formula I

in which:
R(1), R(3) or R(4) is -NR(6) C=X NR(7)R(8);
X is oxygen or S;
R(6) is hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CnH2n-R(9);
n is zero, 1, 2, 3 or 4;
R(9) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(10)R(11);
R(10) and R(11) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;

R(7) is hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or-COH20-R(12);
o is zero, 1,2,3 or 4;
R(12) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(13)R(14);
R(13) and R(14) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(8) is defined as R(7);
or R(7) and R(8) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
the remaining substituents R(2), R(3), R(4), R(5) or R(1), R(2), R(4), R(5) or R(1), R(2), R(3), R(5) in each case independently of one another are hydrogen, F, Cl, Br, I, -Ota(C1-C8)-alkyl,-Otb(C3-C8)-alkenyl, -Otc(CH2)bCdF2d+1, -OtdCpH2pR(18), or up to 2 groups CN, NO2, NR(16)R(17), b is zero or 1;
d is 1 , 2, 3, 4, 5, 6 or 7;
ta is zero or 1;
tb is zero or 1;
tc is zero or 1;
td is zero or 1;
p is zero, 1, 2, 3 or 4;
R(18) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(19)R(20);
R(19) and R(20) are hydrogen or (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(16) is hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl, -CqH2q-R(21), q is zero, 1, 2, 3 or 4;
R(21) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents from the group F, Cl, CF3, methyl, methoxy or NR(22)R(23), R(22) and R(23) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(17) is hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl, -CrH2r-R(24);
r is zero, 1, 2, 3 or 4;
R(24) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(25)R(26);
R(25) and R(26) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(16) and R(17) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
and their pharmaceutically tolerable salts;

t) diacyl-substituted guanidines of the formula I

in which:
X(1) and X(2) are T1 is zero, 1, 2, 3 or 4;
R(A) and R(B) independently of one another are hydrogen, F, Cl, Br, I, CN, OR(106), (C1-C8)-alkyl, (C3-C8)-cycloalkyl, Ozk(CH2)zlCzmF2zm+1, NR(107)R(108), phenyl or benzyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(109)R(110);
R(109) and R(110) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
zl is zero, 1, 2, 3 or 4;
zk is zero or 1;
zm is 1, 2, 3, 4, 5, 6, 7 or 8;
R(106) is hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(111)R(112);
R(111) and R(112) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;

R(107) and R(108) independently of one another are defined as R(106), or R(107) and R(108) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
or X(1) and X(2) are T2a and T2b independently of one another are zero, 1 or 2;
where the double bond can have the (E)- or (Z)-configuration;
or X(1) and X(2) are T3 is zero, 1 or 2;
U, YY and Z
independently of one another are C or N, where U, YY, Z can carry the following number of substituents:

U, YY or Z Bonder in the ring to Number of permitted a double bond C yes 1 C no 2 N yes 0 N no 1 R(D) is hydrogen, (C1-C8)-alkyl or (C1-C8)-perfluoroalkyl, R(U1), R(U2), R(Y1), R(Y2), R(Z1), R(Z2) independently of one another are hydrogen, F, Cl, Br, I, CN, OR(114), (C1-C8)-alkyl, (C3-C8)-cycloalkyl, Ozka(CH2)zlaCzmaF2zma+1, NR(115)R(116), phenyl or benzyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy, NR(117)R(118), R(117) and R(118) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl, zka is zero or 1;
zla is zero, 1, 2, 3 or 4;
zma is 1,2,3,4,5,6,7 or 8;
R(114) is hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(119)R(120);
R(119) and R(120) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(115) and R(116) independently of one another are defined as R(114);
or R(115) and R(116) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
but where the constitution of U is nitrogen (N), W is nitrogen (N) and Z is carbon (C) is excluded, R(101), R(102), R(103), R(104) and R(105) independently of one another are hydrogen, F, Cl, Br, I, -C-N, Xzoa-(CH2)zpa-(CzqaF2zqa+1), R(110a)-SOzbm, R(110b)R(110c)N-CO, R(111a)-CO- or R(112a)R(113a)N-SO2-, where the perfluoroalkyl group is straight-chain or branched, X is oxygen, S or NR(114a);
R(114a) is H or (C1-C3)-alkyl;
zoa is zero or 1;
zbm is zero, 1 or 2;
zpa is zero, 1, 2, 3 or 4;
zqa is 1,2,3,4,5,6,7 or 8;
R(110a), R(110b), R(111a) and R(112a) independently of one another are (C1-C8)-alkyl, (C3-C8)-alkenyl, -CznH2zn-R(115a) or (C1-C8)-perfluoroalkyl;
zn is zero, 1, 2, 3 or 4;
R(115a) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(116a)R(117a);
R(116a) and R(117a) are hydrogen, (C1-C4)-perfluoroalkyl or (C1-C4)-alkyl;
or R(110b), R(111a) and R(112a) are hydrogen;
R(110c) and R(113a) independently are hydrogen, (C1-C4)-perfluoroalkyl or (C1-C4)-alkyl;
or R(110b) and R(110c) and R(112a) and R(113a) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
or R(101), R(102), R(103), R(104), R(105) independently of one another are (C1-C8)-alkyl, -CzalH2zalR(118a) or (C3-C8)-alkenyl, zal is zero, 1, 2, 3 or 4;
R(118a) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy or NR(119a)R(119b);
R(119a) and R(119b) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(101), R(102), R(103), R(104), R(105) independently of one another are (C1-C8)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(101), R(102), R(103), R(104), R(105) independently of one another are -C~C-R(193);
R(193) is phenyl which is not substituted or is substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy or NR(194)R(195);
R(194) and R(195) are hydrogen or CH3;
or R(101), R(102), R(103), R(104), R(105) independently of one another are -Y-para-C6H4-(CO)zh-(CHOH)zj-(CH2)zj-(CHOH)zk-R(123), -y-meta-C6H4-(CO)zad-(CHOH)zae-(CH2)zaf(CHoH)za9-R(124) or Y-ortho-C6H4-(CO)zah-(CHOH)zao-(CH2)zap-(CHOH)zak-R(125);
Y is oxygen, -S- or -NR(122d)-;
zh, zad, zah independently are zero or 1;
zi, zj, zk, zae, zaf, zag, zao, zap and zak independently are zero, 1, 2, 3 or 4;
but where in each case zh, zi and zk are not simultaneously zero, zad, zae and zag are not simultaneously zero, and zah, zao and zak are not simultaneously zero, R(123), R(124) R(125) and R(122d) independently are hydrogen or (C1-C3)-alkyl;
or R(101), R(102), R(103), R(104) and R(105) independently of one another are SR(129), -OR(130), -NR(131)R(132) or -CR(133)R(134)R(135);
R(129), R(130), R(131) and R(133) independently are -CzabH2zab-(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
zab is zero, 1 or 2;
R(132), R(134) and R(135) independently of one another are defined as R(129) or are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(101), R(102), R(103), R(104) and R(105) independently of one another are -W-para-(C6H4)-R(196), -W-meta-(C6H4)-R(197) or -W-ortho-(C6H4)-R(198);
R(196), R(197) and R(198) independently are (C1-C9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 to 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino, dimethylamino and benzyl;
W is oxygen, S or NR(136)-;
R(136) is hydrogen or (C1-C4)-alkyl;
or R(101), R(102), R(103), R(104) and R(105) independently of one another are R(146)X(1a)-;
X(1a) is oxygen, S, NR(147), (D=O)A-, NR(148)C=MN(*)R(149)-;
M is oxygen or sulfur;
A is oxygen or NR(150);
D is C or SO;
R(146) is (C1-C8)-alkyl, (C3-C8)-alkenyl, (CH2)zbzCzdzF2zdz+1 or -CzxaH2zxa-R(151);
zbz is zero or 1;
zdz is 1, 2, 3, 4, 5, 6 or 7;
zxa is zero, 1, 2, 3 or 4;
R(151) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(152)R(153);

R(152) and R(153) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(147), R(148) and R(150) independently are hydrogen, (C1-C4)-alkyl, (C1-C4)-perfluoroalkyl;
R(149) is defined as R(146), or R(146) and R(147), or R(146) and R(148) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
where A and N(*) are bonded to the phenyl nucleus of the alkanoyl parent structure;
or R(101), R(102), R(103), R(104) and R(105) independently of one another are -SR(164), -OR(165), -NHR(166), -NR(167)R(168), -CHR(169)R(170), -CR(154)R(155)OH, -C~CR(156), -CR(158)=CR(157) or -[CR(159)R(160)]Zu-(C=O)-[CR(161)R(162)]zv-R(163);
R(164), R(165), R(166), R(167), R(169) identically or differently are -(CH2)zy-(CHOH)zz-(CH2)zaa-(CHOH)zt-R(171) or -(CH2)zab-O-(CH2-CH2O)zac-R(172);
R(171) and R(172) are hydrogen or methyl;
zu is 1, 2, 3 or 4;
zv is zero, 1, 2, 3 or 4;
zy, zz, zaa, zab, zac identically or differently are zero, 1, 2, 3 or 4;
zt is 1, 2, 3 or 4;
R(168), R(170), R(154), R(155) identically or differently are hydrogen or (C1-C6)-alkyl, or R(169) and R(170), or R(154) and R(155) together with the carbon atom carrying them are a (C3-C8)-cycloalkyl;
(163) is hydrogen, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or -CzebH2zeb-R(173);
zeb is zero, 1, 2, 3 or 4;
R(156), R(157) and R(173) independently are phenyl which is unsubstituted or is substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(174)R(175);
R(174) and R(175) are hydrogen or (C1-C4)-alkyl;
or R(156), R(157) and R(173) independently are (C1-C9)-heteroaryl, which is unsubstituted or substituted as phenyl;
R(158), R(159), R(160), R(161) and R(162) are hydrogen or methyl, or R(101), R(102), R(103), R(104), R(105) independently of one another are R(176)-NH-SO2-;
R(176) is R(177)R(178)N-(C=Y')-;
Y' is oxygen, S or N-R(179);
R(177) and R(178) identically or differently are hydrogen, (C1-C8)-alkyl, (C3-C6)-alkenyl or-CzfaH2zfa-R(180);
zfa is zero, 1, 2, 3 or 4;
R(180) is (C5-C7)-cycloalkyl or phenyl, which [lacuna] unsubstituted [lacuna] by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methoxy or (C1-C4)-alkyl;
or R(177) and R(178) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;

R(179) is defined as R(177) or is amidine, or R(101), R(102), R(103), R(104), R(105) independently of one another are NR(184a)R(185), OR(184b), SR(184c) or -CznxH2znx-R(184d);
znx is zero, 1, 2, 3 or 4;
R(184d) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(116k)R(117k);
R(116k) and R(117k) are hydrogen or C1-C4-alkyl;
R(184a), R(184b), R(184c), R(185) independently of one another are hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl or (CH2)zao-R(184g);
zao is zero, 1, 2, 3 or 4;
184g is (C3-C7)-cycloalkyl or phenyl, which is not substituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(184u)R(184v);
R(184u) and R(184v) are hydrogen or C1-C4-alkyl;
or R(184a) and R(185) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
and their pharmaceutically tolerable salts;

u) benzoylguanidines of the formula I

in which:
R(1) is H, F, Cl, Br, I, CN, NO2, (C1-C8)-alkyl, (C3-C8)-cycloalkyl or Xa-(CH2)b-(CF2)c-CF3;
X is oxygen, S or NR(5);
a is zero or 1;
b is zero, 1 or 2;
c is zero, 1, 2 or 3;
R(5) is H, (C1-C4)-alkyl or -CdH2dR(6);
d is zero, 1, 2, 3 or 4;
R(6) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(7)R(8);
R(7) and R(8) independently are H or (C1-C4)-alkyl;
or R(1) is -SR(10), -OR(10) or -CR(10)R(11)R(12);
R(10) is -CfH2f(C3-C8)-cycloalkyl,-(C11-C9)-heteroaryl or phenyl, where the aromatic systems are unsubstituted or substituted by one to 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
f is zero, 1 or 2;
R(11) and R(12) independently of one another are defined as R(10) or are hydrogen or (C1-C4)-alkyl;
or R(1) is phenyl, naphthyl, biphenylyl or (C1-C9)-heteroaryl, the latter linked via C or N, and which are unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(1) is -SR(13), -OR(13), -NHR(13), -NR(13)R(14), -CHR(13)R(15), -C[R(15)R(16)]OH, -C~CR(18), -C[R(19)]=CR(18), -[CR(20)R(21)]k-(CO)-[CR(22)R(23)R(24)]1 R(13) and R(14) identically or differently are -(CH2)g-(CHOH)h-(CH2)j-(CHOH)j-R(17).
R(17) is hydrogen or methyl;
-(CH2)g-O-(CH2-CH2O)h-R(24), g, h, i identically or differently are zero, 1, 2, 3 or 4;
j is 1, 2, 3 or 4;
R(15) and R(16) identically or differently are hydrogen, (C1-C6)-alkyl or together with the carbon atom carrying them are a (C3-C8)-cycloalkyl;
R(18) is phenyl, which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(25)R(26);
R(25) and R(26) are H or (C1-C4)-alkyl;
or R(18) is (C1-C9)-heteroaryl, which is unsubstituted or substituted as phenyl;
or R(18) is (C1-C6)-alkyl, which is unsubstituted or substituted by 1 to 3 OH;
or R(18) is (C3-C8)-cycloalkyl;
R(19), R(20), R(21), R(22) and R(23) are hydrogen or methyl;
k is zero, 1,2,3 or 4;
is zero, 1, 2, 3 or 4;
R(24) is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or-CmH2m-R(18);
m is 1,2,3 or 4;
R(2) and R(3) independently of one another are defined as R(1);
R(4) is (C1-C3)-alkyl, F, Cl, Br, I, CN or -(CH2)n-(CF2)o-CF3;
n is zero or 1;
o is zero, 1 or 2;
and their pharmaceutically tolerable salts;

v) acylguanidines of the formula I

in which:
X is carbonyl, sulfonyl, R(1) is H, (C1 -C8)-alkyl, unsubstituted or substituted by hydroxyl, (C3-C8)-cycloalkyl, phenyl, which is unsubstituted or substituted by 1 - 3 substituents from the group F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino or dimethylamino, R(2) is H, (C1-C4)-alkyl, and their pharmaceutically tolerable salts;
w) phenyl-substituted alkycarboxylic acid guanidides, carrying perfluoroalkyl groups, of the formula I

in which:
R(A) is hydrogen, F, Cl, Br, I, CN, OR(6), (C1-C8)-alkyl, (C3-C8)-cycloalkyl, Or(CH2)aCcbF2b+1 or NR(7)R(8);
r is zero or 1;
a is zero, 1, 2, 3 or 4;
b is 1,2,3,4,5,6,7 or 8;
R(6) is hydrogen, (C1-C8)-alkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(7) and R(8) independently of one another are defined as R(6);
R(B) independently is defined as R(A);
X is 1, 2 or 3;
R(1) is hydrogen, (C1-C8)-alkyl, (C3-C8)-cycloalkyl, -Ot(CH2)dCeF2e+1,F, Cl, Br, I or CN;
t is zero or 1;
d is zero, 1, 2, 3 or 4;
e is 1, 2, 3, 4, 5, 6, 7 or 8;
R(2), R(3), R(4) and R(5) independently of one another are defined as R(1);
but with the condition that at least one of the substituents R(1), R(2), R(3), R(4), R(5), R(A) and R(B) is an -Ot(CH2)dCeF2e+1 or an Or(CH2)aCbF2b+1 group, and their pharmaceutically tolerable salts;

x) heteroaroylguanidines of the formua I

in which:
HA is SOm, O or NR(5);
m is zero, 1 or 2;
R(5) is hydrogen, (C1-C8)-alkyl or -CamH2amR(81);
am is zero, 1 or 2;
R(81) is (C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(82)R(83);
R(82) and R(83) is H or CH3;
or R(81) is (C1-C9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

one of the two substituents R(1) and R(2) is -CO-N=C(NH2)2;
and the other in each case is hydrogen, F, Cl, Br, I, (C1-C3)-alkyl, -OR(6), CrF2r+1, -CO-N=C(NH2)2 or -NR(6)R(7);
R(6) and R(7) independently are hydrogen or (C1-C3)-alkyl;
r is 1,2,3 or 4;
R(3) and R(4) independently of one another are hydrogen, F, Cl, Br, I, -C-N, X-(CH2)p-(Cq-F2q+1), R(8)-SObm, R(9)R(10)N-CO, R(11)-CO- or R(12)R(13)N-SO2-, where the perfluoroalkyl group is straight-chain or branched, X is oxygen, S or NR(14);
R(14) is H or (C1-C3)-alkyl;
bm is zero, 1 or 2;
p is zero, 1 or 2;
q is zero, 1,2,3,4,5 or 6;
R(8), R(9), R(11) and R(12) independently are (C1-C8)-alkyl, (C3-C6)-alkenyl, CnH2n-R(15), CF3;
n is zero, 1, 2, 3 or 4;
R(15) is (C3-C7)-cycloalkyl or phenyl;
which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy or NR(16)R(17);
R(16) and R(17) are H or C1-C4-alkyl;
or R(9), R(11) and R(12) are H;
R(10) and R(13) independently are H or (C1-C4)-alkyl;
or R(9) and R(10), and R(12) and R(13) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl, or R(3) and R(4) independently of one another are (C1-C8)-alkyl or -CalH2alR(18);
al is zero, 1 or 2;
R(18) is (C3-C8)-cycloalkyl or phenyl;
which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(19)R(20);
R(19) and R(20) are H or CH3;
or R(3) and R(4) independently of one another are (C1-C9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(3) and R(4) independently of one another are or or Y is oxygen, -S- or -NR(22)-;
h, ad, ah independently are zero or 1;
i, j, k, ae, af, ag, ao, ap and ak independently are zero,1, 2, 3, 4, but where in each case h, i and k are not simultaneously zero, ad, ae and ag are not simultaneously zero, ah, ao and ak are not simultaneously zero, R(23), R(24) R(25) and R(22) independently are hydrogen or (C1-C3)-alkyl;
or R(3) and R(4) independently of one another are hydrogen, F, Cl, Br, I, CN, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or-CgH2gR(26);
g is zero,1,2,3 or 4;
R(26) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(27)R(28);
R(27) and R(28) are H, (C1-C4)-alkyl or (C1-C4)-pefluoroalkyl;
or R(3) and R(4) independently of one another are SR(29), -OR(30), -NR(31)R(32) or -CR(33)R(34)R(35);
R(29), R(30), R(31) and R(33) independently are -CaH2a-(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
a is zero,1 or 2;
R(32), R(34) and R(35) independently of one another are defined as R(29) or are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(3) and R(4) independently of one another are , or R(96), R(97) and R(98) independently are (C1-C9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino, dimethylamino or benzyl;
W is oxygen, S or NR(36)-;
R(36) is H or (C1-C4)-alkyl;
or R(3) and R(4) independently of one another are R(37)-SOcm or R(38)R(39)N-SO2-;
cm is 1 or 2;
R(37) is (C1-C8)-alkyl,(C1-C8)-perfluoroalkyl,(C3-C8)-alkenyl or -CsH2sR(40);
s is zero, 1, 2, 3 or 4;
R(40) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and N R(41)R(42);
R(41) and R(42) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(38) is H, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CwH2w-R(43);

w is zero, 1, 2, 3 or 4;
R(43) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(44)R(45);
R(44) and R(45) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(39) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(38) and R(39) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
or R(3) and R(4) independently of one another are R(46)X(1)-;
X(1) is oxygen, S, NR(47), (D=O)A-, NR(48)C=MN(*)R(49)-, M is oxygen or S;
A is oxygen or NR(50);
D is C or SO;
R(46) is (C1-C8)-alkyl, (C3-C8)-alkenyl, (CH2)bCdF2d+1 or -CxH2x-R(51);
b is zero or 1;
d is 1, 2, 3, 4, 5, 6 or 7;
x is zero,1, 2, 3 or 4;
R(51) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(52)R(53);
R(52) and R(53) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;

R(47), R(48) and R(50) independently are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(49) is defined as R(46);
or R(46) and R(47), or R(46) and R(48) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl, where A and N(*) are bonded to the phenyl nucleus of the benzoylguanidine parent structure;
or R(3) and R(4) independently of one another are -SR(64), -OR(65), -NHR(66), -NR(67)R(68), -CHR(69)R(70), -C(OH)R(54)R(55), -C~CR(56), -CR(58)=CHR(57), -[CR(59)R(60)]u-(CO)-[CR(61)R(62)]v-R(63);
R(64), R(65), R(66), R(67) and R(69) identically or differently are -(CH2)y-(CHOH)z-(CH2)aa -(CH2OH)t-R(71) or -(CH2)ab-O-(CH2-CH2O)ac-R(72), R(71) and R(72) are hydrogen or methyl;
u is 1,2,3 or 4;
v is zero,1,2,3 or 4;
y, z, aa identically or differently are zero, 1, 2, 3 or 4;
t is 1,2,3 or 4;
R(68), R(70), R(54) and R(55) identically or differently are hydrogen, (C1-C6)-alkyl;
or R(69) and R(70), or R(54) and R(55) together with the carbon atom carrying them are a (C3-C8)-cycloalkyl;
R(63) is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or -CeH2e-R(73);

e is zero, 1, 2, 3 or 4;
R(56), R(57) and R(73) independently are phenyl, which are unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(74)R(75);
R(74) and R(75) are H or (C1-C4)-alkyl;
or R(56), R(57) and R(73) independently are (C1-C9)-heteroaryl, which is unsubstituted or substitued as phenyl;
R(58), R(59), R(60), R(61) and R(62) are hydrogen or methyl, or R(3) and R(4) independently of one another are R(76)-NH-SO2-;
R(76) is R(77)R(78)N-(C=Y')-;
Y' is oxygen, S or N-R(79);
R(77) and R(78) identically or differently are H, (C1-C8)-alkyl, (C3-C6)-alkenyl, -CfH2f-R(80);
f is zero, 1,2,3 or 4;
R(80) is (C5-C7)-cycloalkyl or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methoxy and (C1-C4)-alkyl;
or R(77) and R(78) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl, R(79) is defined as R(77) or is amidine;
or R(3) and R(4) independently of one another are NR(84)R(85);
R(84) and R(85) independently of one another are H, (C1-C4)-alkyl, or together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl; or of which one or two CH2 groups can be replaced by CH-CdmH2dm+1, and their pharmaceutically tolerable salts;

y) bicyclic heteroaroylguanidines of the formula I

in which:
T, U, V, W, X, Y and Z
independently of one another are nitrogen or carbon;
but with the restriction that X and Z are not simultaneously nitrogen, and that T, U, V, W, X, Y and Z carry no substituents if they are nitrogen, and that no more than four of them are simultaneously nitrogen, R(1) and R(2) independently of one another are hydrogen, F, Cl, Br, I, (C1-C3)-alkyl, (C1-C3)-perfluoroalkyl, OR(8), NR(8)R(9) or C(=O)N=C(NH2)2;
R(8) and R(9) independently of one another are hydrogen or (C1-C3)-alkyl, or R(8) and R(9) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(3), R(4), R(5), R(6) and R(7) independently of one another are hydrogen, F, Cl, Br, I, -C~N, Xk-(CH2)p-(CqF2q+1), R(10a)-SObm, R(10b)R(10c)N-CO, R(11)-CO- or R(12)R(13)N-SO2-, where the perfluoroalkyl group is straight-chain or branched;
X is oxygen, S or NR(14);
R(14) is H or C1-C3)-alkyl;
bm is zero,1 or 2;
p is zero,1 or 2;
k is zero or 1;
q 1,2,3,4,5 or 6;
R(10a), R(10b), R(11) and R(12) independently of one another are (C1-C8)-alkyl, (C3-C6)-alkenyl, -CnH2n-R(15) or (C1-C8)-perfluoroalkyl;
n is zero,1,2,3 or 4;
R(15) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(16)R(17);
R(16) and R(17) are H or C1-C4-alkyl;
or R(10b), R(11) and R(12) are hydrogen;
R(10c) and R(13) independently are hydrogen or (C1-C4)-alkyl;
or R(10b) and R(10c) and R(12) and R(13) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are (C1-C8)-alkyl, -CalH2alR(18) or (C3-C8)-alkenyl;
al is zero, 1 or 2;
R(18) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(19a)R(19b);
R(19a) and R(19b) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are (C1-C9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino or dimethylamino;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are or o r Y is oxygen, -S- or-NR(22)-;
h, ad, ah independently of one another are zero or 1;

i,j,k,ae,af,ag,ao,ap and ak independently of one another are zero, 1, 2, 3 or 4;
but where in each case h, i and k are not simultaneously zero, ad, ae and ag are not simultaneously zero, and ah, ao and ak are not simultaneously zero, R(23), R(24) R(25) and R(22) independently of one another are hydrogen or (C1-C3)-alkyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are SR(29), -OR(30), -NR(31)R(32) or -CR(33)R(34)R(35);
R(29), R(30), R(31) and R(33) independently of one another are -CaH2a-(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
a is zero, 1 or 2;
R(32), R(34) and R(35) independently of one another are defined as R(29) or are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are , o r R(96), R(97) and R(98) independently of one another are (C1-C9)-heteroaryl, which is linked via C or N and which is unsubstitued or substituted by 1 to 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino, dimethylamino or benzyl;

W is oxygen, S or NR(36);
R(36) is H or (C1-C4)-alkyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are R(46)X(1)-;
X(1) is oxygen, S, NR(47), (D=O)A- or NR(48)C=MN(*)R(49)-;
M is oxygen or sulfur;
A is oxygen or NR(50);
D is C or SO;
R(46) is (C1-C8)-alkyl, (C3-C8)-alkenyl, (CH2)bCdF2d+1 or-CxH2x-R(51);
b is zero or 1;
d is 1,2,3,4,5,6 or 7;
x is zero,1,2,3 or 4;
R(51) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(52)R(53);
R(52) and R(53) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(47), R(48) and R(50) independently are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(49) is defined as R(46);
or R(46) and R(47), or R(46) and R(48) together are 4 or 5 methylene groups, of which one CH2 groups can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
where A and N(*) are bonded to the phenyl nucleus of the heteroaroylguanidine parent structure;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are -SR(64), -OR(65), -NHR(66), -NR(67)R(68), -CHR(69)R(70) or -CR(54)R(55)OH, -C-CR(56),-CR(58)=CR(57) or -[CR(59)R(60)]u-CO-[CR(61)R(62)]v-R(63);
R(64), R(65), R(66), R(67) and R(69) identically or differently are -(CH2)y-(CHOH)z-(CH2)aa-(CHOH)t-R(71) or -(CH2)ab-O-(CH2-CH2O)ac-R(72);
R(71), and R(72) independently of one another are hydrogen or methyl;
u is 1, 2, 3 or 4;
v is zero,1, 2, 3 or 4;
y, z, aa identically or differently are zero, 1,2,3 or 4;
t is 1,2,3 or 4;
R(68), R(70), R(54) and R(55) identically or differently are hydrogen or (C1-C6)-alkyl;
or R(69) and R(70), or R(54) and R(55) together with the carbon atom carrying them are (C3-C8)-cycloalkyl;
R(63) is hydrogen, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or -CeH2e-R(73);
e is zero, 1,2,3 or 4;
R(56), R(57) and R(73) independently are phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(74)R(75);
R(74) and R(75) are hydrogen or (C1-C4)-alkyl;
or R(56), R(57) and R(73) independently are (C1-C9)-heteroaryl, which is unsubstituted or substituted as phenyl;

R(58), R(59), R(60), R(61) and R(62) are hydrogen or methyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are R(76)-NH-SO2-;
R(76) is R(77)R(78)N-(C=Y')-;
Y' is oxygen, S or N-R(79);
R(77) and R(78) identically or differently are hydrogen, (C1-C8)-alkyl, (C3-C6)-alkenyl or-CfH2fR(80);
f is zero, 1, 2, 3 or 4;
R(80) is (C5-C7)-cycloalkyl or phenyl, which [lacuna]
unsubstituted [lacuna] by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methoxy and (C1-C4)-alkyl;
or R(77) and R(78) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
R(79) is defined as R(77) or is amidine;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are NR(84a)R(85), OR(84b), SR(84c) or -CnH2n-R(84d);
n is zero, 1, 2, 3 or 4;
R(84d) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(16)R(17);
R(16) and R(17) are hydrogen, or C1-C4-alkyl;
R(84a), R(84b), R(84c) and R(85) independently of one another are hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl or (CH2)ax-R(84g);
ax is zero, 1,2,3 or 4;
R(84g) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(84u)R(84v);
R(84u) and R(84v) are hydrogen or C1-C4-alkyl;
or R(84a) and R(85) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl, and their pharmaceutically tolerable salts;

z) benzoylguanidines of the formula I

in which:
R(1) is R(6)-SOm;
m is zero, 1 or 2;
R(6) is perfluoroalkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, which is straight-chain or branched;
R(2) and R(3) independently of one another are hydrogen, F, Cl, Br, I, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms or phenoxy, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, methyl and methoxy;
or R(2) and R(3) independently of one another are pyrrol-1-yl, pyrrol-2-yl- or pyrrol-3-yl, which is not substituted or is substituted by 1 to 4 substituents selected from the group consisting of F, Cl, Br, I, CN, alkanoyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxycarbonyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, formyl, carboxyl, CF3, methyl and methoxy;
R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2 or 3 carbon atoms, F, Cl, Br, I, CN, OR(7), NR(8)R(9) or -(CH2)n-(CF2)o-CF3;
R(7), R(8) and R(9) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
n is zero or 1;
o is zero, 1 or 2;
and their pharmacologically acceptable salts;

ab)phenyl-substituted alkenylcarboxylic acid guanidides, carrying perfluoroalkyl groups, of the formula I

in which:

R(A) is hydrogen, F, Cl, Br, I, CN, OH, OR(6), (C1-C8)-alkyl, Or(CH2)aCbF2b+1, (C3-C8)-cycloalkyl or NR(7)R(8);
r is zero or 1;
a is zero, 1, 2, 3 or 4;
b is 1, 2, 3, 4, 5, 6, 7 or 8;
R(6) is (C1-C8)-alkyl, (C1-C4)-perfluoroalkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl;
where the aromatics are not substituted or are substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(7) and R(8) independently of one another are defined as R(6);
or R(7) and R(8) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
R(B) independently is defined as R(A);
X is zero, 1 or 2;
Y is zero, 1 or 2;
R(C) is hydrogen, F, Cl, Br, I, CN, OR(12), (C1-C8)-alkyl, Op(CH2)fCgF29+
or (C3-C8)-cycloalkyl;
p is zero or 1;
f is zero,1,2,3 or 4;
g is 1, 2, 3, 4, 5, 6, 7 or 8;
R(12) is (C1-C8)-alkyl, (C1-C4)-perfluoroalkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl;
where the aromatics phenyl or benzyl are not substituted or are substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(13)R(14);
R(13) and R(14) independently of one another are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(D) independently is defined as R(C), R(1) is hydrogen, (C1-C8)-alkyl, -Ot(CH2)dCeF2e+1, (C3-C8)-cycloalkyl, F, Cl, Br, I or CN;
t is zero or 1;
d is zero, 1,2,3 or 4;
e is 1,2,3,4,5,6,7 or 8;
R(2), R(3), R(4) and R(5) independently of one another are defined as R(1);
but with the condition that at least one of the substituents R(A), R(B), R(C), R(D), R(1), R(2), R(4) or R(5) is a Or(CH2)aCbF2b+1, Op(CH2)fCgF2g+1 or Ot(CH2)dCeF2e+1 group and R(3) is not a Ot(CH2)dCeF2e+1 group;
and their pharmaceutically tolerable salts;

ac) ortho-amino-substituted benzoylguanidines of the formula I

in which:
R(1) is NR(50)R(6), R(50) and R(6) independently of one another are hydrogen, (C1-C8)-alkyl or (C1-C8)-perfluoroalkyl;
R(2), R(3), R(4) and R(5) independently of one another are R(10)-SOa-, R(11)R(12)N-CO-, R(13)-CO- or R(14)R(15)N-SO2-;
a is zero,1 or 2, R(10), R(11), R(12), R(13), R(14)and R(15) independently of one another are (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C6)-alkenyl or -CabH2ab-R(16);
ab is zero,1, 2, 3 or 4;
R(16) is (C3-C7)-cycloalkyl, phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy or NR(17)R(18);
R(17) and R(18) independently of one another are H, CF3 or (C1-C4)-alkyl;
or R(11), R(12), and also R(14) and R(15) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
or R(11), R(12), R(14) and R(15) independently of one another are hydrogen;
or R(2), R(3), R(4) and R(5) independently of one another are SR(21), -OR(22), -NR(23)R(24) or -CR(25)R(26)R(27);
R(21), R(22), R(23) and R(25) independently of one another are -CbH2b-(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
b is zero, 1 or 2;
R(24), R(26) and R(27) independently of one another are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(2), R(3), R(4) and R(5) independently of one another are hydrogen, F, Cl, Br, I, CN, -(Xa)dg-CdaH2da+1, -(Xb)dh-(CH2)db-CdeF2de+1, (C3-C8)-alkenyl or -CdfH2dfR(30);
(Xa) is O, S or NR(33);
R(33) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
dg is zero or 1;
(Xb) is O, S or NR(34);
R(34) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
dh is zero or 1;
da is zero, 1,2,3,4,5,6,7,8;
db is zero, 1, 2, 3, 4;
de is zero, 1,2,3,4,5,6,7;
df is zero, 1, 2, 3, 4;
R(30) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics phenyl, biphenylyl or naphthyl are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(31)R(32);
R(31) and R(32) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(2), R(3), R(4) and R(5) independently of one another are NR(40)R(41) or -(Xe)-(CH2)ebR(45);
R(40) and R(41) independently of one another are hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl or (CH2)e-R(42);
e is zero, 1,2,3 or 4;
R(42) is (C3-C7)-cycloalkyl, phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(43)R(44);
R(43) and R(44) independently of one another are H, CF3 or (C1-C4)-alkyl;
or R(40) and R(41) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
(Xe) is O, S or NR(47);
R(47) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
eb is zero,1, 2, 3 or 4;
R(45) is (C3-C7)-cycloalkyl, phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3,methyl, methoxy, NR(50)R(51) and --(Xfa)-(CH2)ed-(Xfb)R(46);
Xfa is CH2, O, S or NR(48);
Xfb is O, S or NR(49);
ed is 1, 2, 3 or 4;
R(46) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(48), R(49), R(50) and R(51) independently of one another are H or (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
where R(3) and R(4), however, cannot be hydrogen, and their pharmaceutically tolerable salts;

ad) benzoylguanidines of the formula I

in which:
one of the three substituents R(1), R(2) and R(3) is (C1-C9)-heteroaryl-N-oxide, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or one of the three substituents R(1), R(2) and R(3) is -SR(10), -OR(10), -NR(10)R(11) or -CR(10)R(11)R(12);
R(10) is -CaH2a-(C1-C9)-heteroaryl-N-oxide, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting [lacuna]F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
a is zero,1 or 2;
R(11) and R(12) independently of one another are defined as R(10), are hydrogen or (C1-C4)-alkyl;
and the other substituents R(1), R(2) and R(3) in each case independently of one another are (C1-C8)-alkyl, (C2-C8)-alkenyl or -CmH2mR(14);
m is zero,1 or 2;
R(14) is (C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(15)R(16), R(15) and R(16) are hydrogen or CH3;
or the other substituents R(1), R(2) and R(3) in each case independently of one another are hydrogen, F, Cl, Br, I, -C~N, X-(CH2)p-(CqF2q+1), R(22)-SOu, R(23)R(24)N-CO, R(25)-CO or R(26)R(27)N-SO2-where the perfluoroalkyl group is straight-chain or branched;
X is a bond, oxygen, S or NR(28);
u is zero,1 or 2;
p is zero,1 or 2;
q is zero,1,2,3,4,5 or 6;
R(22), R(23), R(25) and R(26) independently are (C1-C8)-alkyl, (C2-C6)-alkenyl, -CnH2n-R(29) or CF3;
n is zero,1, 2, 3 or 4;
R(28) is hydrogen or (C1-C3)-alkyl;
R(29) is (C3-C7)-cycloalkyl or phenyl;
which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(30)R(31);
R(30) and R(31) are hydrogen or C1-C4-alkyl, or R(23), R(25) and R(26) are also hydrogen;
R(24) and R(27) independently of one another are hydrogen or (C1-C4)-alkyl;
or R(23) and R(24), and also R(26) and R(27) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
or the other substituents R(1), R(2) and R(3) in each case independently of one another are OR(35) or NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or (C1-C6)-alkyl;

or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl, R(4) and R(5) independently of one another are hydrogen, (C1-C4)-alkyl, F, Cl, -OR(32), -NR(33)R(34) or CrF2r+1;
R(32), R(33) and R(34) independently of one another are hydrogen or (C1-C3)-alkyl;
r is 1, 2, 3 or 4;
and their pharmaceutically tolerable salts;

ad) benzoylguanidines of the formula I

in which:
R(1 ) is hydrogen, F, Cl, Br, I, CN, NO2, OH, (C1-C8)-alkyl, (C3-C8)-cycloalkyl, Oa-(CH2)b-(CF2)c-CF3;
a is zero or 1;
b is zero, 1 or 2;
c is zero, 1, 2 or 3;
or R(1 ) is R(5)-SOm or R(6)R(7)N-SO2-;
m is zero, 1 or 2;
R(5) and R(6) independently of one another are (C1-C8)-alkyl, (C3-C6)-alkenyl, CF3 or -CnH2n-R(8);
n is zero, 1, 2, 3 or 4;
R(7) is hydrogen or (C1-C4)-alkyl;
R(8) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) independently of one another are hydrogen or (C1-C4)-alkyl;
or R(6) is H;
or R(6) and R(7) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl, or R(1) is -SR(11), -OR(11 ) or -CR(11)R(12)R(13);
R(11) is-CpH2p-(C3-C8)-cycloalkyl,-(C1-C9)-heteroaryl or phenyl, where the aromatic systems are unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(12), R(13) independently of one another are defined as R(11) or are hydrogen or (C1-C4)-alkyl;
p is zero, 1 or 2;
or R(1) is phenyl, naphthyl, biphenylyl or (C1-C9)-heteroaryl, the latter linked via C or N, which are unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(2) is -CF2R(14),-CF[R(15)][R(16)],-CF[(CF2)q-CF3)][R(15)], -C[(CF2)r-CF3]=CR(15)R(16);
R(14) is (C1-C4)-alkyl or (C3-C6)-cycloalkyl;
R(15) and R(16) independently of one another are hydrogen or (C1-C4)-alkyl;

q is zero, 1 or 2;
r is zero, 1 or 2;
R(3) is defined as R(1);
R(4) is hydrogen, (C1-C3)-alkyl, F, Cl, Br, I, CN, -(CH2)s-(CF2)t-CF3;
s is zero or 1;
t is zero, 1 or 2;
and their pharmaceutically tolerable salts;

af) benzoylguanidines of the formula I

in which:
one of the three substituents R(1), R(2) and R(3) is -Y4-[(CH2)k-CHR(7)-(C=O)R(8)]-phenyl, -Y-3-(CH2)k-CHR(7)-(C=O)R(8)]-phenyl or -Y-2-[(CH2)k-CHR(7)-(C=O)R(8)]-phenyl, where the phenyl in each case is unsubstituted or substituted by 1 - 2 substituents from the group F, Cl, -CF3, methyl, hydroxyl, methoxy, or -NR(37)R(38);
R(37) and R(38) independently of one another are hydrogen or -CH3;
Y is a bond, oxygen, -S- or -NR(9);
R(9) is hydrogen or-(C1-C4)-alkyl;
R(7) is -OR(10) or-NR(10)R(11);
R(10) and R(11) independently of one another are hydrogen, -(C1-C8)-alkyl, -(C1 -C8)-alkanoyl, -(C1 -C8)-alkoxycarbonyl, benzyl, benzyloxycarbonyl;
or R(10) is trityl;
R(8) is -OR(12) or-NR(12)R(13);
R(12) and R(13) independently of one another are hydrogen, -(C1-C8)-alkyl or benzyl;
k is zero,1,2,3 or 4;
and the other radicals R(1), R(2) and R(3) in each case independently of one another are -(C1-C8)-alkyl, -(C2-C8)-alkenyl or -(CH2)mR(14);
m is zero, 1 or 2;
R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) are hydrogen or -CH3;
or the other radicals R(1), R(2) and R(3) in each case independently of one another are R(18)R(19)N-(C=Y')-NH-SO2-;
Y' is oxygen, -S- or -N-R(20);
R(18) and R(19) independently of one another are hydrogen, -(C1-C8)-alkyl, -(C3-C6)-alkenyl or -(CH2)t-R(21);
t is zero,1,2,3 or 4;
R(21) is -(C5-C7)-cycloalkyl or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the groups consisting of F, Cl, -CF3, methoxy and -(C1-C4)-alkyl;
or R(18) and R(19) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -N-CH3 or -N- benzyl;
R(20) is defined as R(18) or is amidine;
or the other radicals R(1), R(2) and R(3) in each case independently of one another are hydrogen, F, Cl, Br, I, -C- N, X-(CH2)p-(CqF2q+1), R(22)-SOu-, R(23)R(24)N-CO-, R(25)-CO- or R(26)R(27)N-SO2-, where the perfluoroalkyl group is straight-chain or branched;
X is a bond, oxygen, -S- or -NR(28);
u is zero, 1 or 2;
p is zero, 1 or 2;
q is 1,2,3,4,5 or 6;
R(22), R(23), R(25) and R(26) independently of one another are -(C1-C8)-alkyl, -(C3-C6)-alkenyl, -(CH2)n-R(29) or -CF3;
n is zero, 1,2,3 or 4;
R(28) is hydrogen or -(C1-C3)-alkyl;
R(29) is -(C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl, methoxy and -NR(30)R(31);
R(30) and R(31) are hydrogen or -(C1-C4)-alkyl;
or R(23), R(25) and R(26) are hydrogen;
R(24) and R(27) independently of one another are hydrogen or -(C1-C4)-alkyl;
or R(23) and R(24), and also R(26) and R(27) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, - N-CH3 or -N-benzyl;
or the other radicals R(1), R(2) and R(3) in each case independently of one another are -OR(35) or -NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or -(C1-C6)-alkyl;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -N-CH3 or -N-benzyl;

R(4) and R(5) independently of one another are hydrogen, -(C1-C4)-alkyl, F, Cl, -OR(32), -NR(33)R(34) or -CrF2r+1;
R(32), R(33) and R(34) independently of one another are hydrogen or -(C1-C3)-alkyl;
r is 1, 2, 3 or 4;
and their pharmaceutically tolerable salts;

ag) benzoylguanidines of the formula I

in which:
R(1) is R(6)-CO or R(7)R(8)N-CO;
R(6) is (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CnH2n-R(9), n is zero, 1, 2, 3 or 4;
R(9) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(10)R(11), R(10) and R(11) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(7) is H, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CnH2n-R(12);
n is zero,1,2,3 or 4;
R(12) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(13)R(14);
R(13) and R(14) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(8) is H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(7) and R(8) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(2) is defined as R(1), or is H, OH, F, Cl, Br, I, CN, NO2, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CnH2nR(15);
n is zero, 1, 2, 3 or 4;
R(15) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(16)R(17);
R(16) and R(17) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(2) is (C1-C9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(2) is SR(18), -OR(18), -NR(18)R(19) or -CR(18)R(19)R(20);
R(18) -is CaH2a-(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino, dimethylamino;
a is zero, 1 or 2;
R(19) and R(20) independently of one another are defined as R(18) or are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(2) is R(21)-SOm or R(22)R(23)N-SO2-;
m is 1 or 2;
R(21) is (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CnH2n-R(24);
n is zero,1, 2, 3 or 4;
R(24) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(27)R(28);
R(27) and R(28) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(22) is H, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl, (C3-C8)-alkenyl or -CnH2n-R(29);
n is zero, 1, 2, 3 or 4;
R(29) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(30)R(31);
R(30) and R(31) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(23) is hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(22) and R(23) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
or R(2) is R(33)X-;
X is oxygen, S, NR(34), (D=O)A- or NR(34)C=MN(*)R(35)-;
M is oxygen or S;
A is oxygen or NR(34);
D is C or SO;
R(33) is (C1-C8)-alkyl, (C3-C8)-alkenyl, (CH2)bCdF2d+1 or -CnH2n-R(36);
b is zero or 1;
d is 1, 2, 3, 4, 5, 6 or 7;
n is zero, 1, 2, 3, or 4;
R(36) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(37)R(38);
R(37) and R(38) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(34) is hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(35) is defined as R(33);
or R(33) and R(34) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
where A and N(*) are bonded to the phenyl nucleus of the benzoylguanidine parent structure;
or R(2) is -SR(40), -OR(40), -NHR(40), -NR(40)R(41), -CHR(40)R(42), -CR(42)R(43)OH, -C~CR(45), -CR(46)=CR(45) or -[CR(47)R(48)]u-CO-[C(R49)R(50)]v-R(44);
R(40) and R(41) independently of one another are -(CH2)p-(CHOH)q-(CH2)r-(CHOH)t-R(51) or -(CH2)p-O-(CH2-CH2O)q-R(51);
R(51) is hydrogen or methyl;
u is 1,2,3 or 4;
v is zero, 1,2,3 or 4;
p, q and r independently of one another are zero, 1, 2, 3 or 4;
t is 1,2,3 or 4;
R(42) and R(43) independently of one another are hydrogen or (C1-C6)-alkyl;
or R(42) and R(43) together with the carbon atom carrying them are a (C3-C8)-cycloalkyl;
R(44) is hydrogen, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, -CeH2e-R(45);
e is zero,1,2,3 or 4;
R(45) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(52)R(53);
R(52) and R(53) are H or (C1-C4)-alkyl;
or R(45) is (C1-C9)-heteroaryl, which is unsubstituted or substituted as phenyl;
or R(45) is (C1-C6)-alkyl, which is unsubstituted or substituted by 1 - 3 OH;
R(46), R(47), R(48), R(49) and R(50) independently of one another are hydrogen or methyl;
or R(2) is R(55)-NH-SO2-;
R(55) is R(56)R(57)N-(C=Y)-;
Y is oxygen, S or N-R(58);
R(56) and R(57) independently of one another are hydrogen, (C1-C8)-alkyl, (C3-C6)-alkenyl or -CfH2f-R(59);
f is zero, 1, 2, 3 or 4;
R(59) is (C5-C7)-cycloalkyl, phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methoxy and (C1-C4)-alkyl;
or R(56) and R(57) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(58) is defined as R(56) or is amidine;
R(3), R(4) and R(5) are independently of one another defined as R(1) or R(2), but where at least one of the substituents R(2), R(3), R(4) and R(5) must be OH;
and their pharmaceutically tolerable salts;

ah) benzoylguanidines of the formula I

in which:
one of the three substituents R(1), R(2) and R(3) is R(6)-A-B-D-;
R(6) is a basic protonatable radical, i.e. an amino group -NR(7)R(8), an amidino group R(7)R(8)N-C[=N-R(9)]- or a guanidino group R(7), R(8), R(9) and R(10) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(7) and R(8) together are CaH2a;
a is 4,5,6 or 7;
where if a = 5, 6 or 7 a methylene group of the group CaH2a can be replaced by a heteroatom group O, SOm or NR(11), or R(8) and R(9) or R(9) and R(10) or R(7) and R(10) are a group CaH2a;
a is 2,3,4 or 5;
where if a = 3, 4 or 5 a methylene group of the group CaH2a can be replaced by a heteroatom group O, SOm or NR(11);
m is zero, 1 or 2;
R(11) is hydrogen or methyl;
or R(6) is a basic heteroatomic ring system having 1 - 9 carbon atoms;
A is CbH2b:
b is 1, 2, 3, 4, 5 , 6, 7, 8, 9, 10:
where in the group CbH2b one or more methylene groups can be replaced by one of the groupings selected from the group consisting of -O-, -CO-, -CH[OR(20)]-, -SOm-, -NR(20)-, -NR(20)-CO-, -NR(20)-CO-NH-, -NR(20)-CO-NH-SO2- and -SOaa[NR(19)]bb';
and where in the group CbH2b a methylene group can be replaced by -CH-R(99), where R(99) together with R(7) forms a pyrrolidine or piperidine ring;
aa is 1 or 2;
bb is 0 or 1;
aa+bb=2;
R(19) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(20) is hydrogen or methyl;

B is a phenylene or naphthylene radical R(12) and R(13) independently of one another are hydrogen, methyl, F, Cl, Br, I, CF3 or -SOw-R(14);
R(14) is methyl or NR(15)R(16):
R(15) and R(16) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
w is zero, 1 or 2;
D is-CdH2d-X~;
d is zero, 1, 2, 3 or 4;
X is -O-, -CO-, -CH[OR(21)]-, -SOm- or -NR(21)-;
f is zero or 1;
R(21) is hydrogen or methyl;
m is zero, 1 or 2;
and the other substituents R(1) and R(2) and R(3) in each case independently of one another are hydrogen F, Cl, Br, I, -CN, -(C1-C8alkyl, -(C2-C8)-alkenyl, -NR(35)R(36) or R(17-CgH2g-Zh-;
g is zero, 1, 2, 3 or 4;
h is zero or 1;
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or-N-benzyl;
Z is -O-, -CO-, -SOv- ,-NR(18)-, -NR(18)-CO-, -NR(18)-CO-NH-or -NR(18)-SO2;
R(18) is hydrogen or methyl;
v is zero, 1 or 2;
R(17) is hydrogen, cycloalkyl having 3, 5 or 6 carbon atoms or CkF2k+1;
k is 1,2 or 3, or R(17) is pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not subsituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, I, CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl and methoxy;
or R(17) -is (C3-C8)-cycloalkl or phenyl, which ix not substituted or is substituted by 1 - 3 substituents selected from the group consisting of and Cl, -CF3, methyl, hydroxyl~ methoxy, -NR(37)R(38), CH3SO2- and H2NO2S-;
R(37) and R(38) are hydrogen or CH3;
R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms. F, Cl, -OR(32), -NR(33)R(34) or -CrF2r+1;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2 or 3 carbon atoms;
r is 1, 2, 3 or 4;
and their pharmacologically tolerable salts ai) indenoylguanadines of the formula I

in which:
R(1) and R(2) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7, 8, g or 10 carbon atoms. cycloalkyl having 3, 4, 5 or 6 carbon atoms. O-Alkyl having 1, 2, 3 or 4 carbon atoms, O-C(=O)-alkyl having 1, 2, 3 or 4 carbon atoms or CmH2m-NR(12)R(13);
R(12) and R(13) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
m is zero, [lacuna] 2, 3 or 4;
NH-C(-O)-NH2, C(=O)-O-alkyl having 1, 2, 3 or 4 carbon atoms, C(=O)-NH2, C(=O)-NH-alkyl having 1, 2, 3 or 4 carbon atoms, C(=O)-N(alkyl)2 having 1, 2, 3 or 4 carbon atoms in each alkyl group, alkenyl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, alkynyl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, alkylaryl having 1, 2, 3 or 4 carbon atoms in the alkyl group, alkenylaryl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms in the alkenyl group, alkynylaryl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms in the alkynyl group, C1-C4-alkyl-substituted aryl, C1-C4-alkylheteroaryl, C1-C4-alkenylheteroaryl, aminoalkylaryl having 1, 2, 3 or 4 carbon atoms in the alkyl group, substituted aryl, heteroaryl and substituted heteroaryl;
R(3), R(4), R(5) and R(6) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, O-alkyl having 1, 2, 3, 4, 5, 6. 7, 8, 9 or 10 carbon atoms, halogen. (such as F, Cl, Br, I), OH, aryl, substituted aryl, heteroaryl, substituted heteroaryl, O-lower alkyl, O-aryl, O-lower alkylaryl, O-substituted aryl, O-lower alkyl-substituted aryl, O-C(=O)-C1-C4-alkylaryl, O-C(=O)-NH-C1-C4-alkyl, O-C(=O)-N(C1-C4-alkyl)2, NO2, CN, CF3, NH2, NH-C(=O)-C1-C4-alkyl NH-C(=O)-NH2, COOH, C(=O)-O-C1-C4-alkyl, C(=O)-NH2, C(=O)-NH-C1-C4-alkyl, C(=O)-N(C1-C4-alkyl)2, C1-C4-COOH, C1-C4-alkyl-C(=O)-O-C1-C4-alkyl, SO3H, SO2-alkyl, SO2-alkylaryl, SO2-N-(alkyl)2, SO2-N(alkyl)(alkylaryl), C(=O)-R(11), C1-C10-alkyl-C(=O)-R
(11), C2-C10-alkenyl-C(=O)-R(11), C2-C10-alkynyl-C(=O)-R(11), NH-C(=O)-C1-C10-alkyl-C(=O)-R(11), O-C1-C11-alkyl-C(=O)-R(11);
R(11) is C1-C4-alkyl, C1-C4-alkynyl, aryl, substituted aryl, NH2, NH-C1-C4-alkyl, N-(C1-C4-alkyl)2, SO3H, SO2-alkyl, SO2-alkylaryl, SO2-N-(alkyl)2, SO2-N(alkyl)(alkylaryl);
X is O,S or NH;
R(7), R(8), R(9) and R(10) independently of one another are hydrogen, alkyl, cycloalkyl, aryl, alkylaryl;
or R(8) and R(9) together are part of a 5, 6 or 7-membered heterocyclic ring;
A is absent or is a nontoxic organic or inorganic acid.

ak) benzyloxycarbonylguanidines of the formula I

in which:
R(1), R(2) and R(3) independently of one another are -Y-[4-R(8)-phenyl], -Y-[3-R(8)-phenyl]
or-Y-[2-R(8)-phenyl], where the phenyl is in each case unsubstituted or substituted by 1 - 2 substituents from the group consisting of F, Cl, -CF3, methyl, hydroxyl, methoxy and -NR(96)R(97);
R(96) and R(97) independently of one another are hydrogen or -CH3;
Y is a bond, CH2, oxygen, -S- or -NR(9);
R(9) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(8) is SOa[NR(98)]bNR(99)R(10);
a is 1 or 2;
b is 0 or 1;
a + b = 2;
R(98), R(99) and R(10) independently of one another are hydrogen, -(C1-C8)-alkyl, benzyl,-(C2-C8)-alkylene-NR(11)R(12), (C2-C8)-alkylene-NR(13)-(C2-C8)-alkylene-NR(37)R(38) or (CO-C8)-alkylene-CR(39)R(40)CR(41)R(42)(C0-C8)-alkylene-NR(43)R(44);
R(11), R(12), R(13), R(37), R(38), R(43) and R(44) independently of one another are hydrogen, -(C1-C8)-alkyl or benzyl:
R(39), R(40), R(41) and R(42) independently of one another are hydrogen, -(C1-C8)-alkyl or -(C0-C3)-alkylenephenyl, where the phenyl is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl and methoxy;
or R(99) and R(10) together are 4 - 6 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -N-CH3 or -N-benzyl;
or R(8) is SOa[NR(98)]bNR(95)-C[=N-R(94)]-NR(93)R(92);
R(92), R(93), R(94) and R(95) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(1), R(2) and R(3) independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, I, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl, methoxy;
or R(1), R(2) and R(3) independently of one another are hydrogen, -(C1-C8)-alkyl, -(C2-C8)-alkenyl or -(CH2)mR(14);
m is zero, 1 or 2;
R(14) is-(C3-C8)-cycloalkylorphenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and -Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) are hydrogen or-CH3;
or R(1), R(2) and R(3) independently of one another are -Q4-[(CH2)k-CHR(17)-(C=O)R(20)]-phenyl, -Q-3-(CH2)k-CHR(17)-(C=O)R(20)]-phenyl or -Q-2-[(CH2)k-CHR(17)-(C=O)R(20)]-phenyl, where the phenyl in each case is unsubstituted or substituted by 1 - 2 substituents from the group F, Cl, -CF3, methyl, hydroxyl, methoxy and -NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or -CH3;
Q is a bond, oxygen, -S- or-NR(18);
R(18) is hydrogen or -(C1-C4)-alkyl;
R(17) is -OR(21) or -NR(21)R(22);

R(21) and R(22) independently of one another are hydrogen, -(C1-C8)-alkyl, -(C1-C8)-alkanoyl, -(C1-C8)-alkoxycarbonyl, benzyl, benzyloxycarbonyl;
or R(21) is trityl;
R(20) is -OR(23) or -NR(23)R(24);
R(23), R(24) independently of one another are hydrogen, -(C1-C8)-alkyl or benzyl;
k is zero, 1, 2, 3 or 4;
or R(1), R(2) and R(3) independently of one another are (C1-C9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents from the group F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(1), R(2) and R(3) are -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is -CfH2f(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents from the group F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
f is zero, 1 or 2;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or (C1-C4)-alkyl, or R(1), R(2) and R(3) independently of one another are (C1-C9)-heteroaryl-N-oxide, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(1), R(2) and R(3) independently of one another are -SR(28), -OR(28), -NR(28)R(29) or -CR(28)R(29)R(30);
R(28) is -CgH2g-(C1-C9)-heteroaryl-N-oxide, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
g is zero, 1 or 2;
R(29), R(30) independently of one another are defined as R(28), hydrogen or (C1-C4)-alkyl;
or R(1), R(2) and R(3) independently of one another are hydrogen, F, Cl, Br, I, -C-N, T-(CH2)h-(C~F2~+1), R(31)SOI-, R(32)R(33)N-CO-, R(34)-CO-or R(45)R(46)N-SO2, where the perfluoroalkyl group is straight-chain or branched;
T is a bond, oxygen, -S- or-NR(47);
is zero, 1 or 2;
h is zero, 1 or 2;
is 1, 2, 3,4, 5 or 6;
R(31), R(32), R(34) and R(45) independently of one another are -(C1-C8)-alkyl, -(C3-C6)-alkenyl, (CH2)nR(48) or-CF3;
n is zero, 1, 2, 3 or 4;
R(47) is hydrogen or alkyl with 1, 2 or 3 carbon atoms;
R(48) is -(C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl, methoxy and -NR(49)R(50);

R(49) and R(50) are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(32), R(34) and R(45) are hydrogen;
R(33) and R(46) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(32) and R(33), and R(45) and R(46) together are 5 or 6 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
or R(1), R(2) and R(3) independently of one another are R(51)-A-G-D-;
R(51) is a basic protonatable radical, i.e. an amino group -NR(52)R(53), an amidino group R(52)R(53)N-C[=N-R(54)]-or a guanidino group R(52)R(53)N-C[=N-R(54)]-NR(55)-;
R(52), R(53), R(54) and R(55) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(52) and R(53) are a group C.alpha.H2.alpha.;
.alpha. is 4,5,6 or 7;
where if .alpha. = 5, 6 or 7 a carbon atom of the group C.alpha.H2.alpha. can be replaced by a heteroatom group O, SOd or NR(56), or R(53) and R(54) or R(54) and R(55) or R(52) and R(55) are a group CyH2y;
y is 2,3,4 or 5;
where if y = 3, 4 or 5 a carbon atom of the group CyH2y can be replaced by a heteroatom group O, SOd or NR(56);
d is zero, 1 or 2;
R(56) is hydrogen or methyl;
or R(51) is a basic heteroaromatic ring system having 1 - 9 carbon atoms;
A is a group CeH2e;
e is zero, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
where in the group CeH2e a carbon atom can be replaced by one of the groupings -O-, -CO-, -CH[OR(57)]-, -SOr-, -NR(57)-, -NR(57)-CO-, -NR(57)-CO-NH-, -NR(57)-CO-NH-SO2- or -NR(57)-SO2-;
r is zero, 1 or 2;

G is a phenylene radical R(58) and R(59) independently of one another are hydrogen, methyl, methoxy, F, Cl, Br, I, CF3 or -SOS-R(60);
R(60) is methyl or NR(61)R(62);
R(61) and R(62) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
D is-CvH2v-Ew-;
v is zero, 1, 2, 3 or 4;
E is -O-, -CO-, -CH[OR(63)]-, -SOaa- or -NR(63)-;
w is zero or 1;
aa is zero, 1 or 2 R(63) is hydrogen or methyl, or R(1), R(2) and R(3) independently of one another are -CF2R(64), -CF[R(65)][R(66)], -CF[(CF2)q)-CF3)][R(65)], -C[(CF2)p-CF3]=CR(65)R(66);
R(64) is alkyl having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms;
R(65) and R(66) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
q is zero, 1 or 2;
p is zero, 1 or 2;
or R(1), R(2) and R(3) independently of one another are -OR(67) or -NR(67)R(68);
R(67) and R(68) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(67) and R(68) together are 4, 5, 6 or 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, SO2, -NH-, -NCH3 or -N-benzyl;
R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(69), -NR(70)R(71) or -CzF2z+1;
R(69), R(70) and R(71) independently of one another are hydrogen or alkyl having 1, 2 or 3 carbon atoms;
z is 1,2,3 or 4;
R(6) and R(7) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
X is oxygen or NR(72);
R(72) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;

al) alkenylcarboxylic acid guanidides, carrying fluorophenyl groups, of the formula I
in which:
R(6) is hydrogen, (C1-C8)-alkyl, (C3-C8)-cycloalkyl or phenyl, where the phenyl group is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(7) independently is defined as R(6);
R(1), R(2), R(3), R(4) and R(5) independently of one another are hydrogen or F;
where, however, at least one of the radicals R(1), R(2), R(3), R(4) and R(5) must be fluorine;
and their pharmaceutically tolerable salts;

am) benzoylguanidines of the formula I

in which:
R(1) is R(4)-SOm or R(5)R(6)N-SO2-;
m is 1 or 2;
R(4) and R(5) independently of one another are alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 3, 4, 5 or 6 carbon atoms, CF3 or -CnH2n-R(7);
n is zero, 1, 2, 3 or 4;
R(6) is H or alkyl having 1, 2, 3 or 4 carbon atoms;
R(7) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(8)R(9);
R(8) and R(9) are H or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(5) is also hydrogen;
or R(5) and R(6) together are 4 or 5 methylene groups, of which a CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
or R(1) is -Op-(CH2)q-(CF2)r-CF3;
p is zero or 1;
q is zero, 1 or 2;
r is zero, 1, 2 or 3;
or R(1) is -SR(10), -OR(10) or -CR(10)R(11)R(12);
R(10), R(11) and R(12) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, -CsH2s-(C3-C8)-cycloalkyl or an aromatic system selected from the group consisting of pyridyl, pyrrolyl, quinolyl, isoquinolyl, imidazolyl or phenyl;
s is zero, 1 or 2;
where the aromatic systems pyridyl, pyrrolyl, quinolyl, isoquinolyl, imidazolyl and phenyl are unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(2) is -(CH2)u-(CF2)t-CF3;
t is zero, 1, 2 or 3;
U is zero or 1;
R(3) is hydrogen or independently is defined as R(1);
and their pharmaceutically tolerable salts;

an) substituted cinnamic acid guanidides of the formula I
in which:
at least one of the substituents R(1), R(2), R(3), R(4) and R(5) is -Xa-Yb-Ln-U;
X is CR(16)R(17), O, S or NR(18);
R(16), R(17) and R(18) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
a is zero or 1;
Y is alkylene having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkylene-T having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group, T, T-alkylene having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group;
T is NR(20), O, S or phenylene, where the phenylene is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(21)R(22);

R(20), R(21) and R(22) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1,2, 3 or 4 carbon atoms;
b is zero or 1;
L is O, S, NR(23) or CkH2k;
k is 1, 2, 3,4, 5, 6, 7, 8;
n is zero or 1;
U is NR(24)R(25) or an N-containing heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms;
R(24) and R(25) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
or R(24) and R(25) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
where the N-containing heterocycles are N- or C-bridged and are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(27)R(28);
R(23), R(27) and R(28) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
and the other substituents R(1), R(2), R(3), R(4) and R(5) in each case independently of one another are H, F, Cl, Br, I, CN, -On-CmH2m+1, -Op-(CH2)s-CqF2q+1 or -CrH2rR(10);
n is zero or 1;
m is zero 1, 2, 3,4, 5, 6, 7 or 8;

p is zero or 1;
q is 1, 2, 3, 4, 5, 6, 7 or 8;
s is zero, 1, 2, 3 or 4;
r is zero, 1, 2, 3 or 4;
R(10) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, where the phenyl is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxyand NR(11)R(12);
R(11) and R(12) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
R(6) and R(7) independently of one another are hydrogen, F, Cl, Br, I, CN, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxyand NR(14)R(15);
R(14) and R(15) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;

ao) benzoylguanidines of the formula I

in which:
at least one of the substituents R(1), R(2) and R(3) is R(6)-C(OH)2-;
R(6) is perfluoroalkyl having 1, 2 or 3 carbon atoms, which is straight-chain or branched;
and the other substituents R(1), R(2) and R(3) independently of one another are hydrogen, OH, F, Cl, Br, I, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl with 3, 4, 5 or 6 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms or phenoxy, which is unsubstituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, methyl and methoxy;
or the other substituents R(1), R(2) and R(3) independently of one another are alkyl-SOx, -CR(7)=CR(8)R(9) or -C~CR(9);
x is zero, 1 or 2;
R(7) is hydrogen or methyl;
R(8) and R(9) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl and methoxy;
or the other substituents R(1), R(2) and R(3) independently of one another are phenyl, C6H5-(C1-C4)-alkyl, naphthyl, biphenylyl, quinolinyl, isoquinolinyl or imidazolyl, where quinolinyl, isoquinolinyl or imidazolyl are bonded via C
or N and where phenyl, C6H5-(C1-C4)-alkyl, naphthyl, biphenylyl, quinolinyl, isoquinolinyl and imidazolyl are unsubstituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or the other substituents R(1), R(2) and R(3) independentiy of one another are SR(10), -OR(10), -CR(10)R(11)R(12);
R(10) is -CfH2f-(C3-C8)-cycloalkyl, quinolinyl, isoquinolinyl, pyridinyl, imidazolyl or phenyl, where the aromatic systems quinolinyl, isoquinolinyl, pyridinyl, imidazolyl and phenyl are unsubstituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
f is zero,1 or 2;
R(11) and R(12) independently of one another are defined as R(10), hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2 or 3 carbon atoms, F, Cl, Br, I, CN, OR(13), NR(14)R(15), -(CH2)n-(CF2)o-CF3;
R(13), R(14) and R(15) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
n is zero or 1;
o is zero, 1 or 2;
and their pharmacologically acceptable salts;

ap) sulfonimidamides of the formula I

in which:

at least one of the three substituents R(1), R(2) and R(3) is a benzoylguanidine, which is unsubstituted or substituted in the phenyl moiety by 1 - 4 radicals selected from the group consisting of alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, -(CH2)m-R(14), F, Cl, Br, I, -C~N, CF3, R(22)SO2-, R(23)R(24)N-CO-, R(25)-CO-, R(26)R(27)N-SO2, -OR(35), -SR(35) or -NR(35)R(36);
m is zero,1 or 2;
R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or -CH3;
R(22), R(23), R(25) and R(26) independently of one another are alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, (CH2)nR(29) or -CF3;
n is zero, 1, 2, 3 or 4;
R(29) is -(C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl, methoxy and -NR(30)R(31);
R(30) and R(31) are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(23), R(25) and R(26) are hydrogen;
R(24) and R(27) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(23) and R(24), and also R(26) and R(27) together are 5 or 6 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or-N-benzyl;
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
or R(35) is phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl, methoxy, SO2R(5), SO2NR(6)R(7) and -NR(32)R(33);
R(5) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms R(6) and R(7) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;

R(32) and R(33) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(35) is C1-C9-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
and the other substituents R(1), R(2) and R(3) in each case independently of one another are alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, (CH2)pR(10) p is zero, 1, 2, 3 or 4;
R(10) is phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl, methoxy, -SO2NR(17)R(8) and -SO2R(9);
R(17) and R(8) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(9) is alkyl having 1, 2, 3 or 4 carbon atoms;
or the other radical R(1) and R(3) in each case are hydrogen, R(4) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;

aq) benzoylguanidines of the formula I

in which:
R(1) is alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or NR(7)R(8);
R(7) and R(8) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms R(2) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or -SO2R(9);
R(9) independently is defined as R(1);
R(3) is hydrogen, -SR(25), -OR(25), -NR(25)R(26) or -CR(25)R(26)R(27);
R(25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(25) is -(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
R(4) is hydrogen, F, Cl, Br, I, OH, -C~N, CF3, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or-(CH2)mR(14);
m is zero, 1 or 2;
R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or -CH3;
R(5) and R(6) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(32), -NR(33)R(34) or CF3;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;

ar) benzenedicarboxylic acid diguanidides of the formula I
in which:
one of the radicals R(1), R(2), R(3) and R(4) is -CO-N=C(NH2)2;
and the other radicals R(1), R(2), R(3) and R(4) in each case are:
R(1) is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, -OR(32), -NR(33)R(34) or CF3;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;

R(2) and R(4) independently of one another are hydrogen, F, Cl, Br, I, OH, -CN, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or -(CH2)mR(14);
m is zero,1 or 2;
R(14) is-(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) are hydrogen or-CH3;
or R(2) and R(4) independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, each of which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, I, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl, methoxy;
or R(2) and R(4) independently of one another are R(22)-SO2-, R(23)R(24)N-CO-, R(28)-CO- or R(29)R(30)N-SO2;
R(22) and R(28) independently of one another are methyl or -CF3;
R(23), R(24), R(29) and R(30) independently of one another are hydrogen or methyl;
or R(2) and R(4) independently of one another are -OR(35) or -NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;

or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or-N-benzyl;
R(3) is hydrogen, -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(25) is-(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
R(5) is alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, X-(CH2)y-CF3 or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F and Cl, -CF3, methyl, methoxy and -NR(6)R(7);
R(6) and R(7) independently of one another are hydrogen or -CH3;
X is a bond or oxygen;
y is zero, 1 or 2;
and their pharmaceutically tolerable salts;

as) benzenedicarboxylic acid diguanidides of the formula I

in which:
one of the radicals R(1), R(2), R(3) and R(5) is -CO-N=C(NH2)2;
and the other radicals R(1), R(2), R(3) and R(5) in each case are:
R(1) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(32), -NR(33)R(34) or CF3;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(2) is hydrogen, F, Cl, Br, I, OH, -C°N, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or -(CH2)mR(14);
m is zero, 1 or 2;
R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or -CH3;
or R(2) is R(22)-SO2-, R(23)R(24)N-CO-, R(28)-CO- or R(29)R(30)N-SO2;
R(22) and R(28) independently of one another are methyl or -CF3;
R(23), R(24), R(29) and R(30) independently of one another are hydrogen or methyl;
or R(2) is -OR(35) or-NR(35)R(36);

R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or-N-benzyl;
R(3) is hydrogen, -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(25) is -(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
R(4) is CF3, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, -(C3-C8)-cycloalkyl or -(CH2)mR(14);
m is 1 or 2;
R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or -CH3;

or R(4) is phenyl, which is substituted by 2, 3, 4 or five substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or CH3;
and their pharmaceutically tolerable salts;

at) diaryldicarboxylic acid diguanidides of the formula I

in which:
one of the radicals R(1), R(2), R(3), R(4) and R(5) is -CO-N=C(NH2)2;
the other radicals R(1) and R(5) in each case independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(32), -NR(33)R(34) or CF3;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
the other radicals R(2) and R(4) in each case independently of one another are hydrogen, F, Cl, Br, I, OH, -CN, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or -(CH2)mR(14);
m is zero, 1 or 2;
R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F

and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) are hydrogen or -CH3;
or the other radicals R(2) and R(4) in each case independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, I, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl, methoxy;
or the other radicals R(2) and R(4) in each case are R(22)-SO2-, R(23)R(24)N-CO-, R(28)-CO- or R(29)R(30)N-SO2;
R(22) and R(28) independently of one another are methyl or -CF3;
R(23), R(24), R(29) and R(30) independently of one another are hydrogen or methyl;
or the other radicals R(2) and R(4) in each case independently of one another are -OR(35) or -NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
the other radical R(3) in each case is hydrogen, -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(25) is -(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
one of the radicals R(6), R(7), R(8), R(9) and R(10) is -CO-N=C(N H2)2;
the other radicals R(6) and R(10) in each case independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(132), -NR(133)R(134) or CF3;
R(132), R(133) and R(134) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
the other radicals R(7) and R(9) in each case independently of one another are hydrogen, F, Cl, Br, I, OH, -CN, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or -(CH2)mmR(114);
mm is zero, 1 or 2;
R(114) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(115)R(116);
R(115) and R(116) are hydrogen or-CH3;
or the other radicals R(7) and R(9) in each case independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, I, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl and methoxy;
or the other radicals R(7) and R(9) in each case are R(122)-SO2-, R(123)R(124)N-CO-, R(128)-CO- or R(129)R(130)N-SO2;
R(122) and R(128) independently of one another are methyl or -CF3;
R(123), R(124), R(129) and R(130) independently of one another are hydrogen or methyl;
or the other radicals R(7) and R(9) in each case independently of one another are -OR(135) or -NR(135)R(136);
R(135) and R(136) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(135) and R(136) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
the other radical R(8) in each case is hydrogen, -SR(125), -OR(125), -NR(125)R(126) or -CR(125)R(126)R(127);
R(125) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(125) is -(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(126) and R(127) independently of one another are defined as R(125) or are hydrogen or alkyl having 1, 2, 3,4, 5, 6, 7 or 8 carbon atoms;
A is absent or is -NR(11)-CO-, -NR(12)-CO-NR(13)-, -NR(17)-CO-NR(18)-SO2-, -NR(19)-SO2-, -SO2-NR(19)-SO2-, -SO2-NR(19)-CO-, -O-CO-NR(19)-SO2- or -CR(20)=CR(21)-;
R(11), R(12), R(13), R(17), R(18), R(19), R(20)and R(21) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms and their pharmaceutically tolerable salts;

au) substituted thiophenylalkenylcarboxylic acid guanidides of the formula I

in which:
at least one of the substituents R(1), R(2) and R(3) is -Op-(CH2)s-CqF2q+1, R(40)CO or R(31)SOk-;
p is zero or 1;
s is zero,1, 2, 3 or 4;
q is 1, 2, 3, 4, 5, 6, 7 or 8;
k is zero,1 or 2;
R(40) is alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl and methoxy;
R(31) is alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl or methoxy;
or R(31) is NR(41)R(42);
R(41) and R(42) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, perfluoroalkyl having 1, 2, 3 or 4 carbon atoms, or R(41) and R(42) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
and the other substituents R(1), R(2) and R(3) in each case independently of one another are H, F, Cl, Br, I, CN, -Ona-CmaH2ma+1 or -OgaCraH2raR(10);
na is zero or 1;
ma is zero, 1, 2, 3, 4, 5, 6, 7 or 8;
ga is zero or 1;
ra is zero, 1, 2, 3 or 4;
R(10) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, where the phenyl is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl and methoxy;

R(4) and R(5) independently of one another are hydrogen, F, Cl, Br, I, CN, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(14)R(15);
R(14) and R(15) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;

av) ortho-substituted benzoylguanidines of the formula I

in which:
R(2) and R(3) independently of one another are hydrogen, Cl, Br, I, (C1-C8)-alkyl, (C3-C8)-cycloalkyl or-OR(5);
R(5) is (C1-C8)-alkyl or-CdH2d-(C3-C8)-cycloalkyl;
d is zero, 1 or 2;
where one of the two substituents R(2) and R(3) is always hydrogen but both substituents R(2) and R(3) are not simultaneously hydrogen, and their pharmaceutically tolerable salts;

ax) benzoylguanidines of the formula I

in which:
R(1 ) is H, F, Cl, Br, I, CN, NO2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxy having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkoxy having 3, 4, 5, 6, 7 or 8 carbon atoms or Xa-(CH2)b-(CF2)c-CF3;
X is oxygen, S, NR(5), a is zero or 1;
b is zero, 1 or 2;
c is zero, 1, 2 or 3;
R(5) is H, alkyl having 1, 2, 3 or 4 carbon atoms or -CdH2dR(6);
d is zero, 1, 2, 3 or 4;
R(6) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, phenyl, biphenylyl or naphthyl, where the aromatics phenyl, biphenylyl or naphthyl are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(7)R(8);
R(7) and R(8) independently are H or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(1) is -SR(10), -OR(10) or -CR(10)R(11 )R(12);
R(10) is -CfH2fcycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms in the cycloalkyl ring, or phenyl, where phenyl is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
f is zero,1 or 2;
R(11) and R(12) independently of one another are defined as R(10) or are hydrogen or alkyl having 1,2,3 or 4 carbon atoms;
or R(1) is phenyl, naphthyl, biphenylyl or heteroaryl having 1,2,3,4,5,6,7, 8 or 9 carbon atoms, with the latter being linked via a carbon atom or a nitrogen atom of the ring, which are in each case unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino, or R(1) is -SR(13), -OR(13), -NHR(13), -NR(13)R(14), -CHR(13)R(15), -C[R(15)R(16)OH], -C~CR(18), -C[R(19)]=CHR(18), -C[R(20)R(21)]k-(CO)-[CR(22)R(23)]l-R(24), k is zero,1,2,3 or 4;
l is zero,1,2,3 or 4;
R(13) and R(14) identically or differently are -(CH2)g-(CHOH)h-(CH2)i-(CHOH)j-R(17) or -(CH2)g-O-(CH2-CH2O)h-R(24);
R(17) is hydrogen or methyl, g, h and i identically or differently are zero,1,2,3 or 4;
j is 1,2,3 or 4;
R(15) and R(16) identically or differently are hydrogen, alkyl having 1,2,3,4, 5 or 6 carbon atoms or, together with the carbon atom carrying them, are cycloalkyl having 3,4,5,6,7 or 8 carbon atoms;
R(18) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(25)R(26);
R(25) and R(26) are H or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(18) is heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, which is unsubstituted or substituted as phenyl;
or R(18) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, which is unsubstituted or substituted by 1 - 3 OH;
or R(18) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms;
R(19), R(20), R(21), R(22) and R(23) identically or differently are hydrogen or methyl;
R(24) is H, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or -CmH2m-R(18) very wide with all R(18) m is 1, 2, 3 or 4;
R(2) and R(3) are defined as R(1);
R(4) is alkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;

ay) ortho-substituted benzoylguanidines of the formula I

in which:
R(1) is H, F, Cl, Br, l, CN, NO2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxy having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkoxy having 3, 4, 5, 6, 7 or 8 carbon atoms or Xa-(CH2)b-(CF2)C-CF3;
X is oxygen, S, NR(5), a is zero or 1;
b is zero, 1 or 2;
c iszero, 1,2 or 3;
R (5) is H, alkyl having 1, 2, 3 or 4 carbon atoms or -CdH2dR(6);
d is zero, 1, 2, 3 or 4;
R(6) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, phenyl, biphenylyl or naphthyl, where the aromatics phenyl, biphenylyl or naphthyl are unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(7)R(8);
R(7) and R(8) independently are H or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(1) is -SR(10), -OR(10) or-CR(10)R(11)R(12);
R(10) is -CfH2fcycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms in the cycloalkyl ring, or phenyl, where phenyl is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
f is zero, 1 or 2;
R(11 ) and R(12) independently of one another are defined as R(10), or are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(1 ) is phenyl, naphthyl, biphenylyl or heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, with the latter being linked via a carbon atom or a nitrogen atom of the ring, which are in each case unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino, or R(1) is -SR(13), -OR(13), -NHR(13), -NR(13)R(14), -CHR(13)R(15), -C[R(15)R(16)OH], -C-CR(18), -C[R(19)]=CHR(18), -C[R(20)R(21)]k-(CO)-[CR(22)R(23)]l-R(24), k is zero,1, 2, 3 or 4;
is zero,1, 2, 3 or 4;
R(13) and R(14) identically or differently are -(CH2)9-(CHOH)h-(CH2)j-(CHOH)j-R(17) or -(CH2)9-O-(CH2-CH20)h-R(24);
R(17) is hydrogen or methyl, g, h and i identically or differently are zero,1, 2, 3 or 4;
is 1, 2, 3 0r 4;
R(15) and R(16) identically or differently are hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or, together with the carbon atom carrying them, are cycloalkyl having 3,4, 5, 6, 7 or 8 carbon atoms;
R(18) is phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(25)R(26);
R(25) and R(26) are H or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(18) is heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, which is unsubstituted or substituted as phenyl;

or R(18) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, which is unsubstituted or substituted by 1 - 3 OH;
or R (18) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms;
R(19), R(20), R(21), R(22) and R(23) identically or differently are hydrogen or methyl;
R(24) is H, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or -CmH2m-R(18);
m is 1,2,3 or 4;
one of the two substituents R(2) and R(3) is hydroxyl;
and the other of the substituents R(2) and R(3) in each case is defined as R(1);
R(4) is alkyl having 1, 2, 3 or 4 carbon atoms; alkoxy having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I or-(CH2)n-(CF2)0-CF3;
n is zero or 1;
o is zero or 1;
and their pharmaceutically tolerable salts.

II. Compounds of the formula in which:
W, Y and Z
are a nitrogen atom or a carbon atom substituted by R(2) or R(3) or R(4);
R(1 ) is hydrogen, A, Hal, -CF3, -CH2F, -CHF2, -CH2CF3, -C2F5, -CN, -NO2, -ethynyl, or an X-R';

A is alkyl having 1 to 6 carbon atoms;
Hal is F, Cl, Br or I;
X is oxygen, S or NR";
R" is hydrogen, A or a cyclic methylene chain having 3 to 7 carbon atoms;
R' is H, A, HO-A-, HOOC-A-, (C3-C7)-cycloalkyl, (C6-C8)-cycloalkylalkyl, CF3, CH2F, CHF2, CH2-CF3, Ph, -CH2-Ph or Het;
Ph is phenyl, naphthyl or biphenylyl, which is unsubstituted or mono-, di- or trisubstituted by A, OA, NR'R", Hal, CF3;
Het is a mono- or binuclear saturated, unsaturated or aromatic heterocycle having 1 to 4 nitrogen, oxygen and/or sulfur atoms, which is unsubstituted or mono-, di- or trisubstituted by Hal, CF3, A, OH, OA, -X-R', -CN, -NO2, and/or carbonyl oxygen, where Het is bonded via N or an alkylene chain CmH2m where m = zero to 6;
or R' and R"
together are alkylene having 4 - 5 carbon atoms, in which one CH2 group can also be replaced by oxygen, S, NH, N-A, N-Ph and N-CH2-Ph;
R(2) and R(3) independently of one another are hydrogen, Hal, A, HO-A-, X-R', -C(=N-OH)-A, A-O-CO-(C1-C4)-alkyl-, CN, NO2, COOH, halogen-substituted A, in particular CF3, CH2F, CHF2, C2F5, CH2CF3, or S(O)nR'";
R"' is A, Ph or -Het;
n is zero, 1 or 2;
or R(2) and R(3) independently of one another are SO2NR'R", Ph or -O-Ph, -O-CH2-Ph,-CO-A, -CHO, -COOA, -CSNR'R", CONR'R", -CH=CH-COOH,-CH=CH-COOA, indenyl, indanyl, decahydronaphthyl, cyclopentenyl, dihydrothienyl, dihydrofuryl, heterobicyclyl, alkylthienyl, halothienyl, haloalkylthienyl, acylthienyl, halofuryl, haloalkylfuryl or pyrrolyl;
or R(2) and R(3) independently of one another are R(5)-O-;
R(5) is hydrogen, A, (C1-C6)-alkenyl or (C3-C7)-cycloalkyl;
R(4) is Ph, Het, -O-Het; CF3, S(O)nR"', -SO2NR'R", alk;

;

or two of the substituents R(1) to R(4) together are a group -O-CR(6)R(7)-CO-NR(8)-, or or where R(2) has the meaning indicated;
R(6), R(7), R(8) and R(9) independently of one another are H or A;
or R(8) is (C5-C7)-cycloalkyl;
or R(9) is cyano;
alk is straight-chain or branched (C1-C8)-alkyl or (C3-C8)-cycloalkyl, which is unsubstituted or mono-, di- or trisubstituted by A;
or alk is an ethenyl or ethynyl radical which is substituted by H, A, Ph or Het;

III. Compounds of the formula in which:
X is H, Hal, (Hal)3C-, (C1-C6)-alkyl, (C3-C6)-cycloalkyl, substituted phenyl, (C1-C5)-alkyl-S- or (C1-C5)-alkyl-SO2-;
Y is NH2 or substituted amino;
or X and Z
together are a -(CH2)4- or a 1,3-butadienylene chain;
or Z is H, Hal, OH, HS, (C1-C5)-alkyl, (C3-C6)-cycloalkyl, substituted phenyl;
or Z is an amino group -NR(1 )R(2);
R(1 ) is H, straight- and branched-chain, optionally substituted (C1-C8)-alkyl, which can be interrupted by oxygen;
or R(1) is (C3-C8)-alkenyl, (C3-C8)-alkynyl, (C3-C7)-cycloalkyl or OH-substituted phenyl or OH-substituted phenyl-(C1-C4)-alkyl or OH-substituted (C3-C7)-cycloalkyl;
R(2) is 1-morpholino, hydrogen or a straight or branched (C1-C8)-alkyl chain, which can be interrupted by oxygen or an amino group, which straight or branched (C1-C8)-alkyl chain is unsubstituted or substituted by a substituted or unsubstituted mono- or polynuclear heterocycle which contains nitrogen, oxygen or sulfur atoms;
or which alkyl chain is substituted by phenyl, optionally mono- or polysubstituted by (C1-C4)alkoxy, optionally substituted by OH, alkylamino, alkyl or phenyl;
or by an aminocarbonyl group or by hydroxyl or (C1-C4)-alkoxy groups, or R(2) is phenyl, unsubstituted or substituted by alkyl, alkoxy, an amino group, which as substituents carries:
H, a mono- or polynuclear heterocycle which contains nitrogen, oxygen or sulfur atoms, which is unsubstituted or substituted by H, Hal or (C1-C4)-alkyl;
a phenyl radical, unsubstituted or substituted by a substituent selected from the group consisting of (C1-C4)-alkyl, (C1-C4)-alkoxy, Hal and OH;
or R(2) is 1 -piperidino, unsubstituted or substituted in the 4-position by an acyl radical of an aliphatic, alicyclic, aromatic or heteroaromatic carboxylic acid, (C1-C8) alkyl, which for its part can be substituted by OH or (C1-C4)-alkoxy or a (C1-C4)-alkoxy-substituted phenyl radical;
or R(2) is amidino, which is unsubstituted or substituted by phenyl, which is unsubstituted or substituted by Hal or alkyl;
or R(2) is an acyl radical of an aliphatic, alicyclic, aromatic or heteroaromatic carboxylic acid, or R(2) is a (C1-C8) alkyl chain, which can be substituted by a phenyl radical carrying OH, alkoxy or alkyl radicals.
or R(1) and R(2) together with the nitrogen atom to which they are bonded, are a piperazine ring, which is unsubstituted or via a (C1-C6)-methylene chain carries a mono- or polynuclear heterocycle, which contains nitrogen, oxygen or sulfurs (DE 41 27 026 and DE 43 37 609).
Hal is F, Cl, Br or l;

IV. Indoloylguanidine derivatives of the formula in which R(2) is hydrogen, unsubstituted or substituted (C1-C8)-alkyl, (C3-C7)-cycloalkyl, OH, (C1-C6)-alkyl-O-, an aromatic radical or a group -CH2-R(20);
R(20) is (c2-c6)-alkenyl or (C2-C6)-alkynyl;
R(1) is 1 to 5 identical or different substituents, which are:
hydrogen, unsubstituted or substituted (C1-C8)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C3-C7)-cycloalkyl, halogen, -NO2 (C2-C8)-alkanoyl, arylalkanoyl having up to 10 carbon atoms, aroyl having up to 11 carbon atoms, -COOH, (C2-C6)-alkoxycarbonyl, an aromatic group or one of the following mentioned groups: -OR(3), -NR(6)R(7) or -S(O)nR(40);
R(3) is hydrogen, (C1-C8)-alkyl, substituted (C1-C8)-alkyl, (C3-C7)-cycloalkyl, an aromatic radical or a group -CH2-R(30) R(30) is alkenyl or alkynyl;
R(6) and R(7) independently of one another are hydrogen, unsubstituted or substituted (C1-C8)-alkyl, (C3-C7)-cycloalkyl, (C2-C8)-alkanoyl, an arylalkanoyl group having up to 10 carbon atoms, an aroyl group having up to 11 carbon atoms, an aromatic group or -CH2-R(60);
R(60) is (c2-c6)-alkenyl or (C2-C6)-alkynyl;
or R(6) and R(7) together with the nitrogen atom are a 5 - 7-membered cyclic amine, which can additionally contain further heteroatoms in the ring;
n is zero, 1 or 2;
R(40) is unsubstituted or substituted (C1-C8)-alkyl, or an aromatic group, or a group A is oxygen, -S(O)n- or -N(R50)-;
R(50) is hydrogen or (C1-C8)-alkyl;
R' is hydrogen, unsubstituted or substituted (C1-C8)-alkyl, in which the ring represents a saturated 3 - 8 membered heterocycle having a nitrogen atom, said substituted alkyl carries one or more groups selected from the group consisting of halogen, -OH, (C1-C6)-alkoxy, -CN, -COOH, (C2-C6)-alkoxycarbonyl, (C2-C8)-alkanoyl, arylalkanoyl having up to 10 carbon atoms, aroyl having up to 11 carbon atoms, an aromatic group, -CONR(4)(R5), R(4) and R(5) identically or differently are hydrogen or (C1-C8)-alkyl;
or R(4) and R(5) are connected to one another and together form a 5 - 7-membered cyclic amine which can additionally contain further heteroatoms in the ring, or said substituted alkyl carries a group in which:
E is a nitrogen atom or a CH group;
R" is hydrogen, (C1-C8)-alkyl which is unsubstituted or substituted by OH or substituted (C1-C8)-alkyl, (C1-C6)-alkoxy,-CN,-COOH, (C2-C6)-alkoxycarbonyl, (C2-C8)-alkanoyl, aralkanoyl having up to 10 carbon atoms, aroyl having up to 11 carbon atoms, an aromatic group, -NR(6)R(7), -CONR(4)R(5);
R(4) and R(5) independently of one another are hydrogen or (C1-C8)-alkyl;
where the cyclic system of the formula is a 3 - 8 membered saturated aliphatic or heterocyclic ring system having a nitrogen atom, and where the aromatic groups mentioned are an aryl radical having up to 10 carbon atoms, a 5- or 6-membered heteroaryl radical having 1 - 4 nitrogen atoms, a 5- or 6-membered heteroaryl group containing 1 or 2 nitrogen atoms and a heteroatom which is oxygen or sulfur, or furyl, and where the aryl radicals mentioned can be unsubstituted or substituted by unsubstituted (C1-C8)-alkyl or substituted (C1-C8)-alkyl, halogen, -NO2, (C2-C6)-alkoxycarbonyl, COOH, -OR(3), NR(6)R(7), -CONR(4)R(5), -SO2NR(6)R(7) or S(O)nR(40), where R(1) and the guanidinocarbonyl radical can be in any desired position of the 5- or 6-membered ring of the indole system, and the appropriate pharmaceutically tolerable salts.

V. Heterocyclic guanidine derivatives of the formula in which:
X is -O-, -S-, -NH-, -N[(C1-C4)-alkyl]- or -N(phenyl)-;
R(1), R(2) and R(3) are hydrogen, halogen, (C1-C4)-alkyl, (C1-C4)-alkyl-O-, phenyl, benzyl;
or two of the substituents R(1), R(2) and R(3) together with one side of the benzo system are a 4 - 6-membered carbocyclic ring;
R(4) and R(5) independently of one another are hydrogen, (C1-C12)-alkyl, benzhydryl, aralkyl, which is unsubstituted or substituted by one or more substituents from the groups halogen, (C1-C4)-alkyl, (C1-C4)-alkyl-O- or-CF3, -(CH2)m-CH2-T, m is zero to 3;
T is -CO-O-T(1);
T(1) is hydrogen or (C1-C4)-alkyl;
Cy is a benzo-fused unsaturated or dihydro-5-membered ring heterocycle a pyrazole or imidazole ring of the formula or a naphthyl radical or a dihydro- or tetrahydronaphthyl radical a 2-, 3- or 4-pyridyl radical Z is N- or CH;
a thienyl radical R(6) is hydrogen, halogen, hydroxyl, (C1-C10)-alkyl, (C1-C10)-alkyl-O-, phenoxy, (C1-C10)-alkyloxymethyloxy- or -(O)nS-R(9);
R(9) is (C1-C10)-alkyl, thienyl, pyridyl-, thiazolyl, thiadiazolyl, imidazolyl, pyrazolyl or phenyl, each of which is unsubstituted or mono- or disubstituted by halogen, (C1-C4)-alkyl or (C1-C4)-alkyl-O-;
R(7) and R(8) is hydrogen, halogen, hydroxyl, (C1-C10)-alkyl, (C1-C10)-alkyl-O-, phenyl, phenoxy or (C1 -C10)-alkoxymethyloxy;
or Cy is phenyl, which is unsubstituted or mono- or disubstituted by halogen, (C1-C4)-alkyl or (C1-C4) alkyl-O-;
or Cy is-Gr-Am;
Gr is -R(13)-R(12)-(CH2)q-C[W][W(1)]-(CH2)q,-; R(13)R(14)- or -R(15)-;
R(12) is a single bond, -O-, -(O)nS-, -CO- or -CONH-;
R(13) is a single bond, phenyl, thienyl, pyridyl, thiazolyl, thiadiazolyl, imidazolyl or pyrazolyl;
R(14) is a single bond [lacuna] SO2-;
R(15) is (C2-C10)-alkenyl- or (C2-C10)-alkynyl;
W and W(1) independently of one another are hydrogen, (C1-C4)-alkyl;

or W and W(1) cyclically connected to one another are a (C3-C8)-hydrocarbon ring;
q and q' are zero to 9;
Am is -NR(10)R(11);
R(10) is hydrogen, (C1-C4)-alkyl or benzyl, R(11) is (C1-C4)-alkyl, phenyl or benzyl;
or R(10) and R(11) together are a (C3-C10)-alkylene group, which is unsubstituted or substituted by -COOH, (C1-C5)-alkoxycarbonyl, (C2-C4)-hydroxyl-alkylene or benzyl;
or Am is pyrrolyl, pyridyl, pyrazolyl, morpholinyl, dihydropyridyl, tetrahydropyridyl, quinuclidinyl, imidazolyl, 3-azabicyclo[3.2.1]octyl, which is unsubstituted or substituted by (C1-C4)-alkyl, or Am is azabicyclo[3.2.2]nonyl;
or Am is a piperazine group of the formula R(16) is hydrogen, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, phenyl, tolyl, methoxyphenyl, halophenyl, diphenylmethylene, benzyl or pyridyl;
or Am is an azido group -(O)t-(CH2)q-C[W][W(1)]-(CH2)q'-N3;
t is zero or 1;

where W and W(1) have the previously indicated meaning;
and the optical enantiomers and the pharmacologically tolerable salts.
3. The use as claimed in claim 1, which comprises using:
r) benzo-fused heterocycles, having a 5-membered ring, of the formula I

in which:
X is N or CR(6);
Y is oxygen, S or NR(7);
A, B together are a bond or A, B are both hydrogen, if X is CR(6) and Y is simultaneously NR(7);
one of the substituents R(1) to R(6) is a -CO-N=C(NH2)2 group;
the other substituents R(1) to R(6) in each case are hydrogen, F, Cl, Br, l or (C1-C6)-alkyl;
up to two of the other substituents R(1) to R(6) are CN, NO2, N3, (C1-C4)-alkyloxy or CF3;
up to one of the other substituents is R(8)-CnH2n-Z-;
n is zero to 10;
where the alkylene chain -CnH2n- is straight-chain or branched and where a carbon atom can be replaced by an oxygen or sulfur atom or by a nitrogen atom;
R(8) is hydrogen, (C2-C6)-alkenyl or (C3-C10)-cycloalkyl, which is unsubstituted or substituted by 1 to 4 methyl groups or an OH group, or can contain an ethylene group -CH=CH-, and where a methylene group can be replaced by an oxygen or sulfur atom or by a nitrogen atom;
or R(8) is phenyl, which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, CF3, CH3-S(O)s- or R(9)-Wy-;
s is zero, 1 or 2;
R(9) is H, methyl, ethyl, W is oxygen or NR(10);
R(10) is H or methyl;
y is zero or 1;
or R(8) is CmF2m+1;
m is 1 to 3;
or R(8) is 1- or 2-naphthyl, pyridyl, quinolyl or isoquinolyl;
Z is -CO-, -CH2- or -[CR(11)(OH)]q-;
q is 1,2 or 3;
R(11) is H or methyl;
or Z is oxygen or-NR(12)-;
R(12) is H or methyl;
or Z is-S(O)s-;
s is zero, 1 or 2;
or Z is-SO2-NR(13)-;
R(13) is H or (C1-C4)-alkyl;
R(7) is hydrogen, (C1-C10)-alkyl, (C2-C10)-alkenyl or R(8)-CnH2n-;
and their pharmaceutically tolerable salts;

v) acylguanidines of the formula I

in which:
X is carbonyl, sulfonyl, R(1) is H, (C1-C8)-alkyl, unsubstituted or substituted by hydroxyl, (C3-C8)-cycloalkyl, phenyl, which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino or dimethylamino, R(2) is H, (C1-C4)-alkyl, and their pharmaceutically tolerable salts;

w) phenyl-substituted alkylcarboxylic acid guanidides, carrying perfluoroalkyl groups, of the formula I

in which:
R(A) is hydrogen, F, Cl, Br, I, CN, OR(6), (C1-C8)-alkyl, (C3-C8)-cycloalkyl, Or(CH2)aCbF2b+1 or NR(7)R(8);
r is zero or 1;
a is zero, 1, 2, 3 or 4;
b is 1, 2, 3, 4, 5, 6, 7 or 8;
R(6) is hydrogen, (C1-C8)-alkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(7) and R(8) independently of one another are defined as R(6);
R(B) independently is defined as R(A);
X is1,2 or 3;
R(1) is hydrogen, (C1-C8)-alkyl, (C3-C8)-cycloalkyl, -Ot(CH2)dCeF2e+1, F, Cl, Br, I or CN;
t is zero or 1;
d is zero,1,2,3 or 4;
e is 1, 2, 3, 4, 5, 6, 7 or 8;
R(2), R(3), R(4) and R(5) independently of one another are defined as R(1);
but with the condition that at least one of the substituents R(1), R(2), R(3), R(4), R(5), R(A) and R(B) is an -Ot(CH2)dCeF2e+1 or an Or(CH2)aCbF2b+1- group, and their pharmaceutically tolerable salts;

y) bicyclic heteroaroylguanidines of the formula I

in which:
T, U, V, W, X, Y and Z
independently of one another are nitrogen or carbon;
but with the restriction that X and Z are not simultaneously nitrogen, and that T, U, V, W, X, Y and Z carry no substituents when they are nitrogen, and that no more than four of them are simultaneously nitrogen, R(1) and R(2) independently of one another are hydrogen, F, Cl, Br, I, (C1-C3)-alkyl, (C1-C3)-perfluoroalkyl, OR(8), NR(8)R(9) or C(=O)N=C(NH2)2;
R(8) and R(9) independently of one another are hydrogen or (C1-C3)-alkyl, or R(8) and R(9) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
R(3),R(4),R(5),R(6) and R(7) independently of one another are hydrogen, F, Cl, Br, I, -C~N, Xk-(CH2)p-(CqF2q+1), R(10a)-SObm, R(10b)R(10c)N-CO, R(11)-CO-or R(12)R(13)N-SO2-, where the perfluoroalkyl group is straight-chain or branched;
X is oxygen, S or NR(14);
R(14) is H or C1-C3)-alkyl;
bm is zero, 1 or 2;
p is zero,1 or 2;
k is zero or 1;
q is 1,2,3,4, 5 or 6;
R(10a), R(10b), R(11)and R(12) independently of one another are (C1-C8)-alkyl, (C3-C6)-alkenyl, -CnH2n-R(15) or (C1-C8)-perfluoroalkyl;
n is zero,1,2, 3 or 4;
R(15) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(16)R(17);
R(16) and R(17) are H or C1-C4-alkyl;
or R(10b), R(11) and R(12) are hydrogen;
R(10c) and R(13) independently are hydrogen or (C1-C4)-alkyl;
or R(10b) and R(10c) and also R(12) and R(13) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are (C1-C8)-alkyl, -CalH2alR(18) or (C3-C8)-alkenyl;
al is zero, 1 or 2;
R(18) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(19a)R(19b);
R(19a) and R(19b) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are (C1-C9)-heteroaryl which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino or dimethylamino;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are or or Y is oxygen, -S- or-NR(22)-;
h, ad, ah independently of one another are zero or 1;
i, j, k, ae, af, ag, ao, ap and ak independently of one another are zero, 1, 2, 3 or 4;
but where in each case h, i and k are not simultaneously zero, ad, ae and ag are not simultaneously zero, and ah, ao and ak are not simultaneously zero, R(23), R(24) R(25) and R(22) independently of one another are hydrogen or (C1-C3)-alkyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are SR(29), -OR(30), -NR(31)R(32) or -CR(33)R(34)R(35);
R(29), R(30), R(31) and R(33) independently of one another are -CaH2a-(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
a is zero, 1 or 2;
R(32), R(34) and R(35) independently of one another are defined as R(29) or hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;

or R(3), R(4), R(5), R(6) and R(7) independently of one another are , or R(96), R(97) and R(98) independently of one another are (C1-C9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 to 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino, dimethylamino or benzyl;
W is oxygen, S or NR(36)-;
R(36) is H or (C1-C4)-alkyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are R(46)X(1)-;
X(1) is oxygen, S, NR(47), (D=O)A- or NR(48)C=MN(*)R(49)-;
M is oxygen or sulfur;
A is oxygen or NR(50);
D is C or SO;
R(46) is (C1-C8)-alkyl, (C3-C8)-alkenyl, (CH2)bCdF2d+1 or -CXH2X-R(51);
b is zero or 1;
d is 1, 2, 3, 4, 5, 6 or 7;
x is zero,1, 2, 3 or 4;
R(51) is (C3-C8)-cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(52)R(53);
R(52) and R(53) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;R(47), R(48) and R(50) independently are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(49) is defined as R(46);
or R(46) and R(47), or R(46) and R(48) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
where A and N(*) are bonded to the phenyl nucleus of the heteroaroylguanidine parent structure;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are -SR(64), -OR(65), -NHR(66), -NR(67)R(68), -CHR(69)R(70) or-CR(54)R(55)OH, -C-CR(56), -CR(58)=CR(57) or -[CR(59)R(60)]u-CO-[CR(61)R(62)]v-R(63);
R(64), R(65), R(66), R(67) and R(69) identically or differently are -(CH2)y-(CHOH)z-(CH2)aa-(CHOH)t-R(71) or -(CH2)ab-O-(CH2-CH2O)ac-R(72);
R(71), and R(72) independently of one another are hydrogen or methyl;
u is 1, 2, 3 or 4;
v is zero, 1, 2, 3 or 4;
y, z, aa identically or differently are zero, 1, 2, 3 or 4;
t is 1, 2, 3 or 4;
R(68), R(70), R(54) and R(55) identically or differently are hydrogen or (C1-C6)-alkyl;
or R(69) and R(70), or R(54) and R(55), together with the carbon atom carrying them, are a (C3-C8)-cycloalkyl;

R(63) is hydrogen, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or -CeH2e-R(73);
e is zero, 1, 2, 3 or 4;
R(56), R(57) and R(73) independently are phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(74)R(75);
R(74) and R(75) are hydrogen or (C1-C4)-alkyl;
or R(56), R(57) and R(73) independently are (C1-C9)-heteroaryl, which is unsubstituted or substituted as phenyl;
R(58), R(59), R(60), R(61) and R(62) are hydrogen or methyl;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are R(76)-NH-SO2-;
R(76) is R(77)R(78)N-(C=Y')-;
Y' is oxygen, S or N-R(79);
R(77) and R(78) identically or differently are hydrogen, (C1-C8)-alkyl, (C3-C6)-alkenyl or -CfH2f-R(80);
f is zero, 1, 2, 3 or 4;
R(80) is (C5-C7)-cycloalkyl or phenyl, which [lacuna]
unsubstituted [lacuna] by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methoxy and (C1-C4)-alkyl;
or R(77) and R(78) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;

R(79) is defined as R(77) or is amidine;
or R(3), R(4), R(5), R(6) and R(7) independently of one another are NR(84a)R(85), OR(84b), SR(84c) or -CnH2n-R(84d);
n is zero, 1, 2, 3 or 4;
R(84d) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(16)R(17);
R(16) and R(17) are hydrogen, or C1-C4-alkyl;
R(84a), R(84b), R(84c) and R(85) independently of one another are hydrogen, (C1-C8)-alkyl, (C1-C8)-perfluoroalkyl or (CH2)aX-R(84g);
ax is zero, 1, 2, 3 or 4;
R(84g) is (C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(84u)R(84v);
R(84u) and R(84v) are hydrogen or C1-C4-alkyl;
or R(84a) and R(85) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl, and their pharmaceutically tolerable salts;

ab) phenyl-substituted alkenylcarboxylic acid guanidides, carrying perfluoroalkyl groups, of the formula I

in which:
R(A) is hydrogen, F, Cl, Br, I, CN, OH, OR(6), (C1-C8)-alkyl, Or(CH2)aCbF2b+1, (C3-C8)-cycloalkyl or NR(7)R(8);
r is zero or 1;
a is zero, 1, 2, 3 or 4;
b is 1, 2, 3, 4, 5, 6, 7 or 8;
R(6) is (C1-C8)-alkyl, (C1-C4)-perfluoroalkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl;
where the aromatics are not substituted or are substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(7) and R(8) independently of one another are defined as R(6);
or R(7) and R(8) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, sulfur, NH, N-CH3 or N-benzyl;
R(B) independently is defined as R(A);

X is zero, 1 or 2;
Y is zero, 1 or 2;
R(C) is hydrogen, F, Cl, Br, I, CN, ORt12), (C1-C8)-alkyl, Op(CH2)fCgF2g+1 or (C3-C8)-cycloalkyl;
p is zero or 1;
f is zero, 1, 2, 3 or 4;
g is 1 , 2, 3, 4, 5, 6, 7 or 8;
R(12) is (C1-C8)-alkyl, (C1-C4)-perfluoroalkyl, (C3-C8)-alkenyl, (C3-C8)-cycloalkyl, phenyl or benzyl;
where the aromatics phenyl or benzyl are not substituted or are substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, methyl, methoxy and NR(13)R(14);
R(13) and R(14) independently of one another are H, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(D) independently is defined as R(C), R(1) is hydrogen, (C1-C8)-alkyl, -Ot(CH2)dCeF2e+1, (C8-C8)-cycloalkyl, F, Cl, Br, I or CN;
t is zero or 1;
d is zero, 1, 2, 3 or 4;
e is 1, 2, 3, 4, 5, 6, 7 or 8;
R(2), R(3), R(4) and R(5) independently of one another are defined as R(1);
but with the condition that at least one of the substituents R(A), R(B), R(C), R(D), R(1), R(2), R(4) or R(5) is a Or(CH2)aCbF2b+1, Op(CH2)fCgF2g+1 or Ot(CH2)dCeF2e+1 group and R(3) is not a Ot(CH2)dCeF2e+1 group;
and their pharmaceutically tolerable salts;

ah) benzoylguanidines of the formula I

in which:
one of the three substituents R(1), R(2) and R(3) is R(6)-A-B-D-;
R(6) is a basic protonatable radical, i.e. an amino group -NR(7)R(8), an amidino group R(7)R(8)N-C[=N-R(9)]- or a guanidino group R(7), R(8), R(9) and R(10) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(7) and R(8) together are CaH2a;
a is 4, 5, 6 or 7;
where if a = 5, 6 or 7 a methylene group of the group CaH2a can be replaced by a heteroatom group O, SOm or NR(11), or R(8) and R(9) or R(9) and R(10) or R(7) and R(10) are a group CaH2a;
a is 2, 3, 4 or 5;
where if a = 3, 4 or 5 a methylene group of the group CaH2a can be replaced by a heteroatom group O, SOm or NR(11);

m is zero, 1 or 2;
R(11) is hydrogen or methyl;
or R(6) is a basic heteroaromatic ring system having 1 - 9 carbon atoms;
A is CbH2b;
b is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
where in the group CbH2b one or two methylene groups can be replaced by one of the groupings selected from the group consisting of -O-, -CO-, -CH[OR(20)]-, -SOm-, -NR(20)-, -NR(20)-CO-, -NR(20)-CO-NH-, -NR(20)-CO-NH-SO2- and -SOaa[NR(19)]bb-;
and where in the group CbH2b a methylene group can be replaced by -CH-R(99), where R(99) together with R(7) forms a pyrrolidine or piperidine ring;
aa is 1 or 2;
bb is 0 or 1;
aa + bb = 2;
R(19) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(20) is hydrogen or methyl;
B is a phenylene or naphthylene radical, R(12) and R(13) independently of one another are hydrogen, methyl, F, Cl, Br, I, CF3 or-SOw-R(14);
R(14) is methyl or NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
w is zero, 1 or 2;
D is -CdH2d-xf-;
d is zero, 1, 2, 3 or 4;
X is -O-, -CO-, -CH[OR(21)]-, -SOm- or-NR(21)-;
f is zero or 1;
R(21) is hydrogen or methyl;
m is zero, 1 or 2;
and the other substituents R(1) and R(2) and R(3) in each case independently of one another are hydrogen, F, Cl, Br, I, -CN, -(C1-C8)-alkyl, -(C2-C8)-alkenyl, -NR(35)R(36) or R(17)-CgH2g-Zh-;
g is zero, 1, 2, 3 or 4;
h is zero or 1;
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or-N-benzyl;
Z is -O-, -CO-, -SOv- ,-NR(18)-, -NR(18)-CO-, -NR(18)-CO-NH-or -NR(18)-SO2-;
R(18) is hydrogen or methyl;
v is zero, 1 or 2;
R(17) is hydrogen, cycloalkyl having 3, 5 or 6 carbon atoms or CkF2k+1-;
k is 1, 2 or 3, or R(17) is pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, I,-CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl and methoxy;
or R(17) is-(C3-C8)-cycloalkylorphenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, hydroxyl, methoxy, -NR(37)R(38), CH3SO2- and H2NO2S-;
R(37) and R(38) are hydrogen or-CH3;
R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(32), -NR(33)R(34) or -CrF2r+1;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2 or 3 carbon atoms;
r is 1, 2, 3 or 4;

and their pharmacologically tolerable salts;

ai) indenoylguanidines of the formula I

in which:
R(1) and R(2) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms. O-Alkyl having 1, 2, 3 or 4 carbon atoms, O-C(=O)-alkyl having 1, 2, 3 or4 carbon atoms orCmH2m-NR(12)R(13);
R(12) and R(13) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
m is zero, [lacuna] 2, 3 or 4;
NH-C(=O)-NH2, C(=O)-O-alkyl having 1, 2, 3 or 4 carbon atoms, C(=O)-NH2, C(=O)-NH-alkyl having 1, 2, 3 or 4 carbon atoms, C(=O)-N(alkyl)2 having 1, 2, 3 or 4 carbon atoms in each alkyl group, alkenyl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, alkynyl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, alkylaryl having 1, 2, 3 or 4 carbon atoms in the alkyl group, alkenylaryl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms in the alkenyl group, alkynylaryl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms in the alkynyl group, C1-C4-alkyl-substituted aryl, C1-C4-alkylheteroaryl, C1-C4-alkenylheteroaryl, aminoalkylaryl having 1, 2, 3 or 4 carbon atoms in the alkyl group, substituted aryl, heteroaryl and substituted heteroaryl;
R(3), R(4), R(5) and R(6) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, O-alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, halogen, (such as F, Cl, Br, I), OH, aryl, substituted aryl, heteroaryl, substituted heteroaryl, O-lower-alkyl, O-aryl, O-lower-alkylaryl, O-substituted aryl, O-lower-alkyl-substituted aryl, O-C(=O)-C1-C4-alkylaryl, O-C(=O)-NH-C1-C4-alkyl, O-C(=O)-N(C1-C4-alkyl)2, NO2, CN, CF3, NH2, NH-C(=O)-C1-C4 alkyl, NH-C(=O)-NH2, COOH, C(=O)-O-C1-C4-alkyl, C(=O)-NH2, C(=O)-NH-C1-C4-alkyl, C(=O)-N(C1-C4-alkyl)2, C1-C4-COOH, C1-C4-alkyl-C(=O)-O-C1-C4-alkyl, SO3H, SO2-alkyl, SO2-alkylaryl, SO2-N-(alkyl)2, SO2-N(alkyl)(alkylaryl), C(=O)-R(11), C1-C10-alkyl-C(=O)-R(11), C2-C10-alkenyl-C(=O)-R(11), C2-C10-alkynyl-C(=O)-R(11), NH-C(=O)-C1-C10-alkyl-C(=O)-R(11), O-C1-C11-alkyl-C(=O)-R(11);
R(11) is C1-C4-alkyl, C1-C4-alkynyl, aryl, substituted aryl, NH2, NH-C1-C4-alkyl, N-(C1-C4-alkyl)2, SO3H, SO2-alkyl, SO2-alkylaryl, SO2-N-(alkyl)2, SO2-N(alkyl)(alkylaryl);
X is O, S or NH;
R(7), R(8), R(9) and R(10) independently of one another are hydrogen, alkyl, cycloalkyl, aryl, alkylaryl;
or R(8) and R(9) together are part of a 5, 6 or 7-membered heterocyclic ring;
A is absent or is a nontoxic organic or inorganic acid.

ak) benzyloxycarbonylguanidines of the formula I

in which:
R(1), R(2) and R(3) independently of one another are -Y-[4-R(8)-phenyl], -Y-[3-R(8)-phenyl] or -Y-[2-R(8)-phenyl], where the phenyl in each case is unsubstituted or substituted by 1 - 2 substituents from the group consisting of F, Cl, -CF3, methyl, hydroxyl, methoxy and -NR(96)R(97);
R(96) and R(97) independently of one another are hydrogen or -CH3;
Y is a bond, CH2, oxygen, -S- or -NR(9);
R(9) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(8) is SOa[NR(98)]bNR(99)R(10);
a is 1 or 2;
b is 0 or 1;
a + b = 2;

R(98), R(99) and R(10) independently of one another are hydrogen, -(C1-C8)-alkyl, benzyl,-(C2-C8)-alkylene-NR(11)R(12), (C2-C8)-alkylene-NR(13)-(C2-C8)-alkylene-NR(37)R(38) or (C0-C8)-alkylene-CR(39)R(40)CR(41)R(42)(C0-C8)-alkylene-NR(43)R(44);
R(11), R(12), R(13), R(37), R(38), R(43)and R(44) independently of one another are hydrogen, -(C1-C8)-alkyl or benzyl:
R(39), R(40), R(41) and R(42) independently of one another are hydrogen, -(C1-C8)-alkyl or-(C0-C3)-alkylenephenyl, where the phenyl is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl and methoxy;
or R(99) and R(10) together are 4 - 6 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -N-CH3 or -N-benzyl;
or R(8) is SOa[NR(98)]bNR(95)-C[=N-R(94)]-NR(93)R(92);
R(92), R(93), R(94) and R(95) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(1), R(2) and R(3) independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, I, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl, methoxy;

or R(1), R(2) and R(3) independently of one another are hydrogen, -(C1-C8)-alkyl,-(C2-C8)-alkenyl or-(CH2)mR(14);
m is zero, 1 or 2;
R(14) is-(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) are hydrogen or-CH3;
or R(1), R(2) and R(3) independently of one another are -Q-4-[(CH2)k-CHR(17)-(C=O)R(20)]-phenyl, -Q-3-(CH2)k-CHR(17)-(C=O)R(20)]-phenyl or -Q-2-[(CH2)k-CHR(17)-(C=O)R(20)]-phenyl, where the phenyl in each case is unsubstituted or substituted by 1 - 2 substituents from the group consisting of F, Cl, -CF3, methyl, hydroxyl, methoxy and -NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or -CH3;
Q is a bond, oxygen, -S- or -NR(18);
R(18) is hydrogen or-(C1-C4)-alkyl;
R(17) is -OR(21) or -NR(21)R(22);
R(21) and R(22) independently of one another are hydrogen, -(C1-C8)-alkyl, -(C1-C8)-alkanoyl, -(C1-C8)-alkoxycarbonyl, benzyl, benzyloxycarbonyl;
or R(21) is trityl;
R(20) is -OR(23) or -NR(23)R(24);
R(23), R(24) independently of one another are hydrogen, -(C1-C8)-alkyl or benzyl;
k is zero, 1, 2, 3 or 4;

or R(1), R(2) and R(3) independently of one another are (C1-C9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(1), R(2) and R(3) are -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is -CfH2f(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
f is zero, 1 or 2;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or (C1-C4)-alkyl, or R(1), R(2) and R(3) independently of one another are (C1-C9)-heteroaryl-N-oxide, which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(1), R(2) and R(3) independently of one another are -SR(28), -OR(28), -NR(28)R(29) or -CR(28)R(29)R(30);
R(28) is-CgH2g-(C1-C9)-heteroaryl-N-oxide, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
g is zero, 1 or 2;
R(29), R(30) independently of one another are defined as R(28), or are hydrogen or (C1-C4)-alkyl;
or R(1), R(2) and R(3) independently of one another are hydrogen, F, Cl, Br, I, -C~N, T-(CH2)h-(CjF2j+1), R(31)SOl-, R(32)R(33)N-CO-, R(34)-CO- or R(45)R(46)N-SO2, where the perfluoroalkyl group is straight-chain or branched;
T is a bond, oxygen, -S- or -NR(47);
l is zero, 1 or 2;
h is zero, 1 or 2;
i is 1, 2, 3, 4, 5 or 6;
R(31), R(32), R(34) and R(45) independently of one another are -(C1-C8)-alkyl, -(C3-C6)-alkenyl, (CH2)nR(48) or -CF3;
n is zero, 1, 2, 3 or 4;
R(47) is hydrogen or alkyl having 1, 2 or 3 carbon atoms;
R(48) is -(C3-C7)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, -CF3, methyl, methoxy and -NR(49)R(50);
R(49) and R(50) are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(32), R(34) and R(45) are hydrogen;
R(33) and R(46) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(32) and R(33) and also R(45) and R(46) together are 5 or 6 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
or R(1), R(2) and R(3) independently of one another are R(51)-A-G-D-;
R(51) is a basic protonatable radical, i.e. an amino group -NR(52)R(53), an amidino group R(52)R(53)N-C[=N-R(54)]-or a guanidino group R(52)R(53)N-C[=N-R(54)]-NR(55)-;
R(52), R(53), R(54) and R(55) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
or R(52) and R(53) are a group C.alpha.H2.alpha.;
.alpha. is 4, 5, 6 or 7;
where if a = 5, 6 or 7 a carbon atom of the group C.alpha.H2.alpha. can be replaced by a heteroatom group O, SOd or NR(56), or R(53) and R(54) or R(54) and R(55) or R(52) and R(55) are a group CyH2y;
y is 2, 3, 4 or 5;
where if y = 3, 4 or 5 a carbon atom of the group CyH2y can be replaced by a heteroatom group O, SOd or NR(56);
d is zero, 1 or 2;
R(56) is hydrogen or methyl;
or R(51) is a basic heteroaromatic ring system having 1 - 9 carbon atoms;
A is a group CeH2e;
e is zero, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

where in the group CeH2e a carbon atom can be replaced by one of the groupings -O-, -CO-, -CH[OR(57)]-, -SOr-, -NR(57)-, -NR(57)-CO-, -NR(57)-CO-NH-, -NR(57)-CO-NH-SO2- or-NR(57)-SO2-;
r is zero,1 or 2;
G is a phenylene radical, R(58) and R(59) independently of one another are hydrogen, methyl, methoxy, F, Cl, Br, l, CF3 or-SOs-R(60);
R(60) is methyl or NR(61)R(62);
R(61) and R(62) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
D is-CvH2v-Ew-;
v is zero,1, 2, 3 or 4;
E is -O-, -CO-, -CH[OR(63)]-, -SOaa- or -NR(63)-;
w is zero or 1;
aa is zero, 1 or 2 R(63) is hydrogen or methyl, or R(1), R(2) and R(3) independently of one another are -CF2R(64), -CF[R(65)][R(66)], -CF[(CF2)q-CF3)][R(65)], -C[(CF2)p-CF3]=CR(65)R(66);
R(64) is alkyl having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms;
R(65) and R(66) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
q is zero, 1 or 2;

p is zero, 1 or 2;
or R(1), R(2) and R(3) independently of one another are -OR(67) or -NR(67)R(68);
R(67) and R(68) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(67) and R(68) together are 4, 5, 6 or 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, SO2, -NH-, -NCH3 or -N-benzyl;
R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(69), -NR(70)R(71) or -CzF2z+1;
R(69), R(70) and R(71) independently of one another are hydrogen or alkyl having 1, 2 or 3 carbon atoms;
z is 1, 2, 3 or 4;
R(6) and R(7) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
X is oxygen or NR(72);
R(72) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;

al) alkenylcarboxylic acid guanidides, carrying fluorophenyl groups, of the formula I

in which:
R(6) is hydrogen, (C1-C8)-alkyl, (C3-C8)-cycloalkyl or phenyl, where the phenyl group is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(9)R(10);
R(9) and R(10) are hydrogen, (C1-C4)-alkyl or (C1-C4)-perfluoroalkyl;
R(7) independently is defined as R(6);
R(1),R(2),R(3),R(4)and R(5) independently of one another are hydrogen or F;
where, however, at least one of the radicals R(1),R(2),R(3),R(4) and R(5) must be fluorine;
and their pharmaceutically tolerable salts;

an) substituted cinnamic acid guanidides of the formula I

in which:
at least one of the substituents R(1), R(2), R(3), R(4) and R(5) is -Xa-Yb-Ln-U;
X is CR(16)R(17), O, S or NR(18);
R(16), R(17) and R(18) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
a is zero or 1;
Y is alkylene having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkylene-T having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group, T, T-alkylene having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group;

T is NR(20), O, S or phenylene, where the phenylene is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(21)R(22);
R(20), R(21) and R(22) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
b is zero or 1;
L is O, S, NR(23) or CkH2k;
k is 1, 2, 3, 4, 5, 6, 7, 8;
n is zero or 1;
U is NR(24)R(25) or an N-containing heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms;
R(24) and R(25) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
or R(24) and R(25) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
where the N-containing heterocycles are N- or C-bridged and are not substituted or are substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(27)R(28);
R(23), R(27) and R(28) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

and the other substituents R(1), R(2), R(3), R(4) and R(5) in each case independently of one another are H, F, Cl, Br, I, CN, -On-CmH2m+1, -Op-(CH2)s-CqF2q+1 or -CrH2rR(10);
n is zero or 1;
m is zero 1, 2, 3, 4, 5, 6, 7 or 8;
p is zero or 1;
q is 1, 2, 3, 4, 5, 6, 7 or 8;
s is zero, 1, 2, 3 or 4;
r is zero, 1, 2, 3 or 4;
R(10) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, where the phenyl is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxyand NR(11)R(12);
R(11) and R(12) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
R(6) and R(7) independently of one another are hydrogen, F, Cl, Br, I, CN, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(14)R(15);
R(14) and R(15) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;

ar) benzenedicarboxylic acid diguanidides of the formula I

in which:
one of the radicals R(1), R(2), R(3) and R(4) is -CO-N=C(NH2)2;
and the other radicals R(1), R(2), R(3) and R(4) in each case are:
R(1) is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, -OR(32), -NR(33)R(34) or CF3;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(2) and R(4) independently of one another are hydrogen, F, Cl, Br, I, OH, -CN, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or -(CH2)mR(14);
m is zero, 1 or 2;
R(14) is-(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) are hydrogen or-CH3;
or R(2) and R(4) independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, each of which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, I, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl,-CF3, methyl, methoxy;
or R(2) and R(4) independently of one another are R(22)-SO2-, R(23)R(24)N-CO-, R(28)-CO- or R(29)R(30)N-SO2;
R(22) and R(28) independently of one another are methyl or -CF3;
R(23), R(24), R(29) and R(30) independently of one another are hydrogen or methyl;
or R(2) and R(4) independently of one another are -OR(35) or -NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
R(3) is hydrogen, -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(25) is-(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
R(5) is alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, X-(CH2)y-CF3 or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F and Cl, -CF3, methyl, methoxy and -NR(6)R(7);
R(6) and R(7) independently of one another are hydrogen or -CH3;
X is a bond or oxygen;
y is zero, 1 or 2;
and their pharmaceutically tolerable salts;

as) benzenedicarboxylic acid diguanidides of the formula I

in which:
one of the radicals R(1), R(2), R(3) and R(5) is -CO-N=C(NH2)2;
and the other radicals R(1), R(2), R(3) and R(5) in each case are:
R(1) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(32), -NR(33)R(34) or CF3;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
R(2) is hydrogen, F, Cl, Br, I, OH, -C°N, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or -(CH2)mR(14);
m is zero, 1 or 2;
R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or -CH3;
or R(2) is R(22)-SO2-, R(23)R(24)N-CO-, R(28)-CO- or R(29)R(30)N-SO2;
R(22) and R(28) independently of one another are methyl or -CF3;
R(23), R(24), R(29) and R(30) independently of one another are hydrogen or methyl;
or R(2) is -OR(35) or -NR(35)R(36);
R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or-N-benzyl;
R(3) is hydrogen, -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(25) is -(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
R(4) is CF3, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, -(C3-C8)-cycloalkyl or -(CH2)mR(14);
m is 1 or 2;
R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or -CH3;
or R(4) is phenyl, which is substituted by 2, 3, 4 or five substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) independently of one another are hydrogen or CH3;
and their pharmaceutically tolerable salts;

at) diaryldicarboxylic acid diguanidides of the formula I

in which:
one of the radicals R(1), R(2), R(3), R(4) and R(5) is -CO-N=C(NH2)2;
the other radicals R(1) and R(5) in each case independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(32), -NR(33)R(34) or CF3;
R(32), R(33) and R(34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
the other radicals R(2) and R(4) in each case independently of one another are hydrogen, F, Cl, Br, I, OH, -CN, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or -(CH2)mR(14);
m is zero, 1 or 2;
R(14) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(15)R(16);
R(15) and R(16) are hydrogen or-CH3;
or the other radicals R(2) and R(4) in each case independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, I, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl, methoxy;
or the other radicals R(2) and R(4) in each case are R(22)-SO2-, R(23)R(24)N-CO-, R(28)-CO- or R(29)R(30)N-SO2;
R(22) and R(28) independently of one another are methyl or -CF3;
R(23), R(24), R(29) and R(30) independently of one another are hydrogen or methyl;
or the other radicals R(2) and R(4) in each case independently of one another are -OR(35) or -NR(35)R(36);
R(35) and R(36) 1. independently of one another are hydrogen or alkyl having 1, 2, 3,4, 5 or 6 carbon atoms;
or R(35) and R(36) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
the other radical R(3) in each case is hydrogen, -SR(25), -OR(25), -NR(25)R(26), -CR(25)R(26)R(27);
R(25) is hydrogen, alkyl having 1, 2, 3,4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(25) is -(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
one of the radicals R(6), R(7), R(8), R(9) and R(10) is -CO-N=C(NH2)2;
the other radicals R(6) and R(10) in each case independently of one another are hydrogen, alkyl having 1,2, 3 or 4 carbon atoms, F, Cl, -OR(132), -NR(133)R(134) or CF3;
R(132), R(133) and R(134) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
the other radicals R(7) and R(9) in each case independently of one another are hydrogen, F, Cl, Br, I, OH, -CN, CF3, -CO-N=C(NH2)2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or -(CH2)mmR(114);
mm is zero, 1 or 2;
R(114) is -(C3-C8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F
and Cl, -CF3, methyl, methoxy and -NR(115)R(116);
R(115) and R(116) are hydrogen or -CH3;
or the other radicals R(7) and R(9) in each case independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1 - 4 substituents selected from the group consisting of F, Cl, Br, I, -CN, (C2-C8)-alkanoyl, (C2-C8)-alkoxycarbonyl, formyl, carboxyl, -CF3, methyl and methoxy;
or the other radicals R(7) and R(9) in each case are R(122)-SO2-, R(123)R(124)N-CO-, R(128)-CO- or R(129)R(130)N-SO2;
R(122) and R(128) independently of one another are methyl or -CF3;
R(123), R(124), R(129) and R(130) independently of one another are hydrogen or methyl;
or the other radicals R(7) and R(9) in each case independently of one another are -OR(135) or -NR(135)R(136);
R(135) and R(136) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;

or R(135) and R(136) together are 4 - 7 methylene groups, of which one CH2 group can be replaced by oxygen, -S-, -NH-, -NCH3 or -N-benzyl;
the other radical R(8) in each case is hydrogen, -SR(125), -OR(125), -NR(125)R(126) or -CR(125)R(126)R(127);
R(125) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
or R(125) is -(C1-C9)-heteroaryl, which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxyl, amino, methylamino and dimethylamino;
R(126) and R(127) independently of one another are defined as R(125) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
A is absent or is -NR(11)-CO-, -NR(12)-CO-NR(13)-, -NR(17)-CO-NR(18)-SO2-, -NR(19)-SO2-, -SO2-NR(19)-SO2-, -SO2-NR(19)-CO-, -O-CO-NR(19)-SO2- or -CR(20)=CR(21)-;
R(11), R(12), R(13), R(17), R(18), R(19), R(20) and R(21) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms and their pharmaceutically tolerable salts;

au) substituted thiophenylalkenylcarboxylic acid guanidides of the formula I

in which:
at least one of the substituents R(1), R(2) and R(3) is -Op-(CH2)s-CqF2q+1, R(40)CO- or R(31)SOk-;
p is zero or 1;
s is zero, 1, 2, 3 or 4;
q is 1,2,3,4,5,6,7 or 8;
k is zero, 1 or 2;
R(40) is alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl and methoxy;
R(31) is alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl or methoxy;
or R(31) is NR(41)R(42);
R(41) and R(42) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, perfluoroalkyl having 1, 2, 3 or 4 carbon atoms, or R(41) and R(42) together are 4 or 5 methylene groups, of which one CH2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl;
and the other substituents R(1), R(2) and R(3) in each case independently of one another are H, F, Cl, Br, I, CN, -Ona-CmaH2ma+1 or -OgaCraH2raR(10);
na is zero or 1;
ma is zero, 1, 2, 3, 4, 5, 6, 7 or 8;
ga is zero or 1;
ra is zero, 1, 2, 3 or 4;
R(10) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, where the phenyl is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl and methoxy;
R(4) and R(5) independently of one another are hydrogen, F, Cl, Br, I, CN, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, which is not substituted or is substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR(14)R(15);
R(14) and R(15) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;
and their pharmaceutically tolerable salts;
4. The use of an Na+/H+ exchange inhibitor as claimed in claim 1 to 3 for the production of a medicament for the treatment of muscle-related respiratory disorders.
5. The use of an Na+/H+ exchange inhibitor as claimed in claims 1-3 for the production of a medicament for the treatment of respiratory disorders after long-term ventilation.
6. The use of an Na+/H+ exchange inhibitor as claimed in claims 1-3 for the production of a medicament for the treatment of respiratory disorders during adaptation in a high mountain area.
7. The use of an Na+/H+ exchange inhibitor as claimed in claims 1-3 for the production of a medicament for the treatment of obstructive, central and mixed forms of sleep apnea.
8. The use of an Na+/H+ exchange inhibitor as claimed in claims 1-3 for the production of a medicament for the treatment of acute and chronic lung diseases with hypoxia and hypercapnia.
9. The use of an Na+/H+ exchange inhibitor as claimed in claims 1- 8 for the production of a medicament in combinations with an inhibitor of carboanhydratase.
10. The use of an Na+/H+ exchange inhibitor as claimed in claims 1- 9 for the production of a medicament in combinations with acetazolamide.

Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for respiratory stimulation The active compounds identified as NHE inhibitors are outstandingly suitable for the production of a medicament for respiratory stimulation.

They are particularly suitable for the treatment of sleep apnea or of other respiratory disorders.
CA002241531A 1995-12-27 1996-12-13 Use of inhibitors of the cellular na+/h+ exchanger (nhe) for the preparation of a drug for respiratory stimulation Abandoned CA2241531A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19548812A DE19548812A1 (en) 1995-12-27 1995-12-27 Use of inhibitors of the cellular Na · + · / H · + · exchanger (NHE) for the manufacture of a medicament for respiratory stimulation
DE19548812.1 1995-12-27

Publications (1)

Publication Number Publication Date
CA2241531A1 true CA2241531A1 (en) 1997-07-10

Family

ID=7781474

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002241531A Abandoned CA2241531A1 (en) 1995-12-27 1996-12-13 Use of inhibitors of the cellular na+/h+ exchanger (nhe) for the preparation of a drug for respiratory stimulation

Country Status (16)

Country Link
EP (1) EP0869779A1 (en)
KR (1) KR19990076802A (en)
CN (1) CN1207676A (en)
AU (1) AU717247B2 (en)
BR (1) BR9612287A (en)
CA (1) CA2241531A1 (en)
CZ (1) CZ202198DA3 (en)
DE (1) DE19548812A1 (en)
HU (1) HUP9900807A3 (en)
IL (1) IL125114A0 (en)
MX (1) MX9805141A (en)
NO (1) NO982989L (en)
PL (1) PL327693A1 (en)
SK (1) SK88398A3 (en)
TR (1) TR199801235T2 (en)
WO (1) WO1997024113A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686384B2 (en) 2000-12-05 2004-02-03 Aventis Pharma Deutschland Gmbh Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9932331B2 (en) 2014-07-25 2018-04-03 Taisho Pharmaceutical Co., Ltd. Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
WO2018129557A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129552A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
EP3351248A1 (en) 2008-12-31 2018-07-25 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2019060051A1 (en) 2017-08-04 2019-03-28 Ardelyx, Inc. Glycyrrhetinic acid derivatives for treating hyperkalemia
US10272079B2 (en) 2013-04-12 2019-04-30 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
WO2020163642A1 (en) 2019-02-07 2020-08-13 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9504537D0 (en) * 1995-12-19 1995-12-19 Jan Hedner Ways of treating and diagnosing respiratory disorders during sleep and means of performing the method
DE19945302A1 (en) * 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenyl derivatives as NHE-3 inhibitors
DE10163239A1 (en) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituted imidazolidines, process for their preparation, their use as medicaments or diagnostic agents, and medicaments containing them
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4325822A1 (en) * 1993-07-31 1995-02-02 Hoechst Ag Substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, and medicament containing them
EP0639573A1 (en) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzocondensed five membered heterocycles, process of their preparation, their use as drug, as diagnostic means and pharmaceuticals containing it
DE4337609A1 (en) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Novel pyrazinecarboxamide derivatives, their preparation and their use in medicines
DE4415873A1 (en) * 1994-05-05 1995-11-09 Hoechst Ag Substituted bicyclic heteroaroylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicament containing them

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958357B2 (en) 2000-12-05 2005-10-25 Aventis Pharma Deutschland Gmbh Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them
US6686384B2 (en) 2000-12-05 2004-02-03 Aventis Pharma Deutschland Gmbh Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them
EP3939964A1 (en) 2008-12-31 2022-01-19 Ardelyx, Inc. Combinations for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP3351248A1 (en) 2008-12-31 2018-07-25 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10272079B2 (en) 2013-04-12 2019-04-30 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
US10940146B2 (en) 2013-04-12 2021-03-09 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
EP3988120A1 (en) 2013-04-12 2022-04-27 Ardelyx, Inc. Nhe3-binding compounds and methods for inhibiting phosphate transport
EP3552630A1 (en) 2013-04-12 2019-10-16 Ardelyx, Inc. Nhe3-binding compounds for inhibiting phosphate transport
US9932331B2 (en) 2014-07-25 2018-04-03 Taisho Pharmaceutical Co., Ltd. Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
WO2018129552A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129557A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
WO2019060051A1 (en) 2017-08-04 2019-03-28 Ardelyx, Inc. Glycyrrhetinic acid derivatives for treating hyperkalemia
EP4397366A2 (en) 2017-08-04 2024-07-10 Ardelyx, Inc. Glycyrrhetinic acid derivatives for treating hyperkalemia
WO2020163642A1 (en) 2019-02-07 2020-08-13 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
EP4234016A2 (en) 2019-02-07 2023-08-30 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Also Published As

Publication number Publication date
AU1372097A (en) 1997-07-28
PL327693A1 (en) 1998-12-21
IL125114A0 (en) 1999-01-26
HUP9900807A2 (en) 1999-07-28
DE19548812A1 (en) 1997-07-03
WO1997024113A1 (en) 1997-07-10
NO982989L (en) 1998-08-06
SK88398A3 (en) 1999-03-12
CN1207676A (en) 1999-02-10
BR9612287A (en) 2005-05-24
KR19990076802A (en) 1999-10-15
TR199801235T2 (en) 1998-10-21
NO982989D0 (en) 1998-06-26
EP0869779A1 (en) 1998-10-14
AU717247B2 (en) 2000-03-23
MX9805141A (en) 1998-10-31
HUP9900807A3 (en) 2000-11-28
CZ202198DA3 (en) 1998-11-11

Similar Documents

Publication Publication Date Title
CA2241531A1 (en) Use of inhibitors of the cellular na+/h+ exchanger (nhe) for the preparation of a drug for respiratory stimulation
CA2257299A1 (en) Use of inhibitors of the cellular na+/h+ exchanger (nhe) for production of a medicament for the normalization of serum lipids
CA2245776A1 (en) Pharmaceutical combination preparation of an inhibitor of the sodium/hydrogen exchanger and a medicament for the treatment of cardiovascular diseases
DESANCTIS et al. Tachyarrhythmias in myocardial infarction
US9580398B2 (en) Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
US20120172449A1 (en) Polyamine transport inhibitors as novel therapeutics
IL106157A (en) 3,4,5-Substituted benzoylguanidines process for their preparation their use for the production of a medicament or diagnostic
Maiese et al. Nitric oxide: a downstream mediator of calcium toxicity in the ischemic cascade
RU2012135396A (en) METHODS FOR TREATING CANCER WITH THE USE OF AUTOFAGIA INHIBITOR BASED ON THIOXANTHON
WO2001076570A2 (en) Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses
MX2014002663A (en) Scheme for administering n-hydroxy-4-{2-[3-(n,n-dimethylaminometh yl)â­benzofuran-2-ylcarbonylamino]ethoxy}benzamide.
US20090143473A1 (en) Use of inhibitors of the cellular na+/h+ exchanger (nhe) for preparing a medicament for normalizing serum lipids
CA2357837A1 (en) The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life
US6242198B1 (en) Methods of treatment of eye trauma and disorders
NZ331566A (en) The use of inhibitors of the sodium-hydrogen exchanger such as a benzoylguanidine in the production of a pharmaceutical for the treatment of diseases caused by protozoa
CA2247733A1 (en) The use of an inhibitor of the na+/h+ exchanger for the production of a medicament for the treatment or prophylaxis of disturbances of the central nervous system
HRP980488A2 (en) The use of a sodium-hydrogen exchanger inhibitor in the production of a medicine for the prevention of undesirable effects of substances to a heart
JP2000500774A (en) Use of inhibitors of intracellular Na ++ / H ++ exchange agent (NHE) in the manufacture of a medicament for respiratory stimulation
Broadley et al. Functional antagonism as a means of determining dissociation constants and relative efficacies of sympathomimetic amines in guinea-pig isolated atria.
GB889317A (en) New phenyl-diazines and a process for their manufacture
WO2009069966A2 (en) Use of compounds for controlling the function of sphingosylphosphorylcholine
DE19750498A1 (en) Use of inhibitors of sodium-hydrogen ion exchangers for treating CNS conditions
CN114478579B (en) Small molecule compound with anti-influenza virus effect
Hashimoto et al. Coupling interval-related effects of class I antiarrhythmic drugs, mexiletine, cibenzoline and disopyramide, on ventricular activation in canine myocardial infarction
JPS60172919A (en) Antifungal agent

Legal Events

Date Code Title Description
FZDE Discontinued